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ABSTRACT 
Attention-deficit/hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental disorder which 
manifests as deficits in impulse control, excessive activity in home or school settings, and an inability to 
focus attention on relevant stimuli. While millions of individuals with ADHD lack this ability to effectively 
modulate behaviors and optimize societal, academic, or occupational performance, surprisingly little is 
known regarding its genetic etiology and few improvements in therapeutics have been accomplished 
over the past decades. This lack of progress is partly attributable to the dearth of genetic models of 
ADHD enabling unbiased exploration of the genetic architecture of hyperactive-impulsive behavior. The 
goal of my dissertation is to fill this critical need for a genetic model which may be used to meaningfully 
advance the field of ADHD research. Toward that end, I systemically evaluated the face, construct, and 
predictive validity of a genetically variable line mice selectively bred for increased home cage activity in 
order to determine whether it may faithfully recapitulate facets of ADHD symptomatology. In Chapter 1, 
the rodent models of ADHD currently used are reviewed in terms of their validity, advantages and 
limitations, and the extent to which these models have informed or obfuscated our understanding of 
ADHD. Chapter 2 summarizes promising results from our initial foray into assessing the predictive 
validity of the line; Generation 11 High-Active mice demonstrate home cage hyperactivity which is 
paradoxically ameliorated by chronic low-dose amphetamine. Furthermore in this chapter I establish a 
statistical procedure for estimating whether line differences are due to selection for hyperactivity versus 
genetic drift; results suggest the genetic underpinnings of home cage hyperactivity are unique and likely 
differ from those mediating other forms of increased physical activity. Chapter 3 vastly expounds on the 
face validity of the line by confirming the hyperactivity and motor impulsivity of the High-Active line in 
two different versions of the operant Go/No-go task and within adolescent males and adult females. 
Interestingly, the High-Active line shows little evidence of inattention as assessed by spontaneous 
alternation in the Y-maze, suggesting High-Active validity may be circumscribed to the Hyperactive-
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Impulsive subtype of ADHD. Furthermore the predictive validity of the line is reaffirmed in this chapter 
as the same low-dose amphetamine which reduces hyperactivity also paradoxically ameliorates motor 
impulsivity. Analysis of regional neural activation of High-Active versus Control mice at baseline and in 
response to low-dose amphetamine indicates dysregulated prefrontal cortex and cerebellum may partly 
modulate High-Active impulsive behavior. Chapter 4 addresses a fundamental question regarding the 
construct validity of the High-Active line. In this large-scale cross-fostering experiment I demonstrate 
that the significant deficits in the maternal competence of High-Active dams do not influence the 
hyperactivity of High-Active offspring; raw genetics mediate this transgenerational phenotype whose 
expression cannot be influenced even by the most stressful of perinatal environments. I further infer 
evidence of extreme dopaminergic dysregulation in the High-Active line, as only a genetic ablation of the 
dopamine transporter has produced dams which even somewhat approach the severity of High-Active 
deficits in maternal care. In Chapter 5 I propose high-yield uses of this now-validated model of ADHD, 
including strategies for uncovering relevant genetic etiological factors, identifying novel compounds to 
advance therapeutic approaches, and elucidating endophenotypes which may aid in the diagnosis of 
ADHD. Ultimately the efforts of this dissertation have culminated in a validated genetic model of 
Hyperactive-Impulsive ADHD which is poised to serve as a platform for significantly advancing our 
understanding of this ubiquitous, heritable behavioral disorder. 
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2 
 
Abstract 
Attention-deficit/hyperactivity disorder (ADHD) is a polygenic behavioral disorder that impairs impulse 
control, attention, and the regulation of physical activity in approximately 5% of people worldwide. 
Despite decades of genetic and genomic studies attempting to elucidate which gene networks underlie 
the disorder, little progress has been made in identifying variants relevant for improving diagnostic 
accuracy or developing novel therapeutics. In order to expand our understanding of ADHD and hence 
advance these important objectives, multiple rodent models of the disorder are evaluated. The 
spontaneously hypertensive rat (SHR), coloboma mouse, dopamine transporter knockout (DAT-KO) 
mouse, and the 6-hydroxydopamine lesion (6-OHDA) rat have all provided insight regarding the region-
specific influences of monoamines and glutamate in mediating the core deficits associated with ADHD. 
Furthermore, some models have enhanced our understanding of the specific contribution of certain 
genes (e.g. DAT and SNAP-25) in ADHD-like behavior and medication response. However, these models 
remain severely limited in construct and predictive validity. The abundance of work done on the SHR 
must be carefully re-evaluated in light of serious concerns regarding the control line choice. The DAT-KO 
and coloboma mice demonstrate the influence of only one gene on ADHD-like behavior and cannot 
provide novel insight into the etiology of this heterogeneous disorder. The 6-OHDA lesioned rat does not 
reflect clinical populations as ablation of dopaminergic projections is not observed. There is an urgent 
need for the development of a genetically variable model of ADHD and appropriate control line that may 
significantly advance our understanding of the genetics which mediate hyperactive-impulsive behavior 
and serve as a platform for testing novel drug interventions. 
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Attention-deficit/hyperactivity disorder (ADHD; OMIM #143465) is a highly prevalent behavioral 
disorder, both in the United States and worldwide. It is estimated that approximately 11-16% of 8-10 
year old children in the U.S. are affected by ADHD, as compared to 2-8% in low-prevalence countries 
such as Sweden and Australia, and 16-20% in higher-prevalence countries such as Ukraine and Germany 
(Faraone et al., 2003). From 2003-2007, the percentage of U.S. children diagnosed with ADHD increased 
from 8% to 10%, and as a majority of those children are medicated for ADHD, this means that 
approximately 5% of U.S. children aged 4-17 years old are on a long-term psychostimulant regimen 
(Polanczyk et al., 2014). Stimulants are the recommended first-line treatment for ADHD, despite the 
absence of clinical data on its long-term neurobiological or cardiovascular impact (Samuels et al., 2006, 
Fredriksen et al., 2013, Shin et al., 2016). Approximately 50% of children with ADHD continue to display 
symptoms of hyperactivity and/or inattention into adulthood (Kessler et al., 2010). If the diagnostic 
prevalence and predilection to medicate children are not alarming enough, it has also been shown that 
ADHD management incurs a substantial economic cost to the U.S. (as evaluated in terms of 
productivity/work loss and allocations for special medical and educational resources) to the tune of 143-
266 billion U.S. dollars annually (Doshi et al., 2012). Taken together, multiple societal, medical, and 
economic impetuses exist to better understand ADHD. 
According to the Diagnostic Statistical Manual (APA, 2013) ADHD is characterized by a 
combination of three main behavioral symptoms. Combinations of different levels of inattention, 
hyperactivity, and impulsivity result in one of three distinct diagnostic possibilities. Individuals exhibiting 
inattention symptoms alone, which remain present for at least 6 months to a point that is inappropriate 
for their developmental stage, results in a diagnosis of “Predominantly Inattentive Type ADHD”, while 
the presence of only hyperactive-impulsive behavior results in a diagnosis of “Predominantly 
Hyperactive-Impulsive Type ADHD”. Individuals displaying all three types of behavior representative of 
ADHD receive the diagnosis “Combined Type ADHD”. The diagnosis of this disorder is entirely subjective, 
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based on self-reports, parent or teacher reports, and clinician-administered assessments such as the 
Connor’s Comprehensive Rating Scale (APA, 2013, Hamed et al., 2015). In 2013, the fifth edition of the 
DSM (DSM-V) was released and included several critical changes to the diagnostic definition of ADHD. 
Previously, diagnosis required proof of onset of symptoms prior to age 7 but now the age of onset is 
raised to 12 years old, significantly broadening the number of individuals who may meet criteria for 
ADHD. Furthermore, fewer symptoms are now required to meet the diagnosis for adult ADHD (5 
symptoms per category, as opposed to 6 or more required by previous editions of the DSM). As a result 
of this relaxed criteria the prevalence of ADHD is expected to rise; in fact, one study discovered this new 
criteria increased rates of ADHD diagnosis by 65% in one sample population (Rigler et al., 2016). Clearly 
this broadening of diagnostic criteria has the potential to not only increase clinical heterogeneity and 
the number of individuals treated with psychostimulants, but it may also obscure relevant etiological 
findings in clinical studies attempting to identify the underpinnings of ADHD.  
Despite the worldwide prevalence of ADHD, little is known regarding the genetic etiology of this 
complex disorder. Multiple twin and adoption studies have demonstrated that ADHD is highly heritable; 
60-90% of the phenotypic variance associated with ADHD is attributable to genetic factors (Faraone et 
al., 2005, Elia et al., 2012, Larsson et al., 2014). The exact degree to which the three main symptoms 
share a genetic basis is debatable. While some studies find evidence for substantial genetic overlap 
between the hyperactive-impulsive and inattentive dimensions (McLoughlin et al., 2007), others suggest 
that the Combined Type has a different etiological basis as compared to the Predominantly Hyperactive-
Impulsive Type (Willcutt et al., 2000). While the genetic basis of ADHD has been repeatedly confirmed 
little is known regarding the exact genes and pathways underlying the disorder. The heterogeneous 
nature of ADHD implies that multiple genes with small effect sizes contribute to the phenotype, making 
it exceedingly difficult to pinpoint those variants which confer risk. Moreover, little progress has been 
made in identifying novel treatments to ameliorate the behavioral deficits associated with ADHD. In fact, 
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current forays into both the identification of ADHD-related genes and effective therapeutics are largely 
guided by an observation made nearly 80 years ago. In 1937, Charles Bradley administered Benzedrine-
sulfate (amphetamine) to 30 hyperkinetic school children and observed that this medication calmed 
activity while improving school performance (Bradley, 1937). For half a century, amphetamine (which 
largely influences dopamine (DA) and norepinephrine (NE) pathways) was exclusively used to treat 
hyperactive children, and as a result DA and NE became firmly engrained in the dogma of ADHD. 
Therefore, when candidate gene studies gained popularity in the 1990s, the obvious first targets for 
ADHD studies were DA/NE-related genes, such as the dopamine transporter (DAT), dopamine D4,5 
receptors (DRD4, DRD5), norepinephrine transporter (NET), dopamine beta hydroxylase (DβH), etc. 
(Gizer et al., 2009). However, genes associated with complex traits explain only a small proportion of the 
variance, often do not replicate (Munafò and Flint, 2014), and statistically speaking are likely to be false 
(Flint and Munafo, 2013, Li et al., 2014). GWAS studies of ADHD populations in the 2000s identify 
chromosomal regions with potential linkage (Romanos et al., 2008, Zhou et al., 2008) but meta-analyses 
do not find significant associations in ADHD populations (Neale et al., 2010).  
Due to our lack of understanding of the causal mechanism of ADHD, the most popular 
therapeutic interventions currently used to treat the disorder are still based on Bradley’s 20
th
 century 
observation. Currently used extended-release medications were approved by the FDA in the early 2000s, 
which includes the psychostimulants Adderall (amphetamine) and Ritalin (methylphenidate), and the 
non-psychostimulants Tenex (guanfacine) and Strattera (atomoxetine); these medications mimic or 
stimulate monoaminergic neurotransmission to varying degrees (Castle et al., 2007). Amphetamine has 
the capacity to increase both DA and NE signaling, but most emphasis is placed on its role in increasing 
intracellular and extracellular concentrations of DA. Cytoplasmic levels of DA are enhanced via the 
ability of amphetamine to decrease vesicular storage, inhibit monoamine oxidase activity to prevent 
degradation, and increase the activity and expression of tyrosine hydroxylase. Amphetamine also 
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functions to facilitate exchange diffusion at DAT on the plasma membrane, enabling reverse transport 
and effectively enhancing the release of DA into the synapse (Sulzer et al., 1995, Arnsten, 2006). 
Methylphenidate primarily works by blocking reuptake transporters such as DAT and NET, thereby 
increasing extracellular concentrations of DA and NE (Kuczenski and Segal, 1997). Guanfacine is a 
postsynaptic α2A-adrenoceptor agonist gaining popularity as an alternative treatment to stimulant 
ADHD medication (Sallee and Eaton, 2010, Alamo et al., 2016), while atomoxetine functions by 
selectively blocking NE reuptake via NET and therefore exerts its behavioral effects by manipulating the 
NE pathway (Christman et al., 2004).The continued use of these medications is standard of practice in 
the treatment of ADHD, as psychosocial interventions to date show inconsistent results in treating ADHD 
symptoms (Chan et al., 2016). However, there exists significant heterogeneity in clinical response to 
these drugs. Some studies indicate stimulants are more successful in correcting ADHD-associated 
deficits than non-stimulants (Faraone and Glatt, 2010), and further evidence suggests that amphetamine 
is more efficacious than methylphenidate (Faraone and Buitelaar, 2010). However efficacy alone does 
not predict medication use; these therapeutics cause variable, sometimes intolerable, side effects which 
influence an individuals’ treatment approach.  
The growing prevalence of ADHD diagnoses, coupled with the rapidly evolving field of brain 
imaging technology, has spurred research investigating how the disorder alters neuroanatomy. Clinical 
studies tend to focus on the prefrontal cortex (PFC) and its connections to the striatum and cerebellum 
(Middleton and Strick, 2000, Arnsten, 2011, Durston et al., 2011). The PFC has long been established as 
critical for executive function, decision-making, and impulse control. This region receives ascending 
dopaminergic projections and is highly sensitive to the influence of DA and NE; levels must be closely 
titrated to optimize performance on tasks of attentional and behavioral control (Arnsten, 2011). Many 
fMRI studies have demonstrated reduced activation in the PFC during attention tasks (also known as 
hypofrontality) as well as decreases in the volume of the PFC in patients with ADHD (Rubia et al., 1999, 
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Zang et al., 2005, Steinhausen, 2009). PFC projections also critically modulate DA release in the striatum 
(Karreman and Moghaddam, 1996). Within the striatum, DAT is highly expressed and regulates DA/NE 
synaptic concentrations, but the density of DAT expression in patients with ADHD is debated (Wang et 
al., 2013). Some studies observe elevated DAT in ADHD populations which can be modulated to control 
levels by methylphenidate (Krause et al., 2000) while others show decreased levels of DAT expression in 
ADHD subjects (Volkow et al., 2007). Furthermore, there is little consensus on the activation level of the 
striatum in ADHD patients; multiple studies hypothesized that striatal activation is decreased in ADHD 
populations (Dickstein et al., 2006, Rubia et al., 2009) but a recent meta-analysis did not associate 
decreased functionality of the striatum with ADHD (Cortese et al., 2012). The critical role of the 
cerebellum in the pathophysiology of ADHD is also emerging (Kucyi et al., 2015). In addition to 
coordinating motor function, the cerebellum also contributes to attention, executive control, and 
learning and memory via reciprocal connections with the PFC (Strick et al., 2009, Durston et al., 2011). 
Individuals with ADHD consistently show decreased cerebellar hemispheric volume, and decreased 
posterior vermis volume which may be normalized with chronic stimulant treatment (Castellanos et al., 
2002, Bledsoe et al., 2009, Durston et al., 2011). Taken together, abundant evidence suggests that 
dysregulation of monoamine concentrations in one region affects functionality of others. Yet the specific 
regional dysregulations mediating ADHD deficits remains elusive; as described above, many clinical 
studies produce conflicting results. In general this may be partly due to limited sample sizes under-
powering the detection of etiological factors with small effect; furthermore, the criteria used to identify 
patients with ADHD vary in accordance with the diagnostic scales employed in each study (Tripp et al., 
2006, Kieling et al., 2014). Coupled with the evolving definition of ADHD (Rigler et al., 2016), clinical 
findings are likely to rapidly increase in number and complexity. 
The underpinnings of complex traits are difficult to disentangle in clinical populations; therefore 
animal models serve as a critical tool in elucidating those causal factors which underlie heterogeneous 
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disorders. However, in order to obtain meaningful data from an animal model it must first prove to be a 
valid representation of the clinical disorder. The degree to which any animal model meets the following 
three criteria determines its validity, i.e. whether it is a “good” model of the disorder (McKinney and 
Bunney, 1969, Davids et al., 2003). That being said, it is important to emphasize that no animal model of 
a heterogeneous disorder has ever perfectly reflects its clinical condition. Nevertheless some models are 
able to reliably reflect facets of a clinical phenotype and are therefore useful in understanding those 
aspects of human disorders. The three established validity criteria are as follows: 
1) Face validity: the model must accurately reflect the basic behavioral characteristics of the 
disorder. In the case of ADHD, the animal should show hyperactivity and deficits in impulse control 
and/or attention capacity. Importantly, ADHD has three subtypes therefore an animal model should be 
specific enough to reflect one of those three clinical types (DSM-V). Furthermore, the hyperactive 
behavior exhibited by the animal must be present in a habituated environment, not only in a novel 
setting (Sleator and Ullmann, 1981). 
2) Construct (etiologic) validity: the model should be constructed in a way that is consistent 
with our clinical understanding of the basis of the disorder. As ADHD is a heritable, polygenic disorder, 
therefore an animal model of ADHD should ideally show significant genetic variability underlying 
hyperactive/impulsive/inattentive behavior. Furthermore, it would be useful to demonstrate 
dysregulation of DA/NE neurotransmission and/or differential activation of regions implicated in ADHD 
such as the PFC, striatum, or cerebellum. 
3) Predictive validity: the animal should model a clinical population’s response to established 
and/or new treatments, and should be able to demonstrate previously unknown aspects of the disorder. 
Animal models of ADHD should demonstrate the expected attenuation of locomotor 
activity/impulsivity/inattention in response to amphetamine or methylphenidate. In addition, the 
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development of new medications and identification of novel genetic underpinnings for ADHD should be 
feasible using an animal model with sufficient predictive validity. 
Rodent models of ADHD can be broadly classified into genetic models (e.g. those achieved by 
selective breeding, single-gene manipulation) and chemically-induced models (e.g. those achieved by 
lesioning). There are two main approaches for engineering genetic models, either using a “bottom-up” 
approach wherein theorized causal genetic factors are selectively manipulated and relevant phenotypes 
are assessed (e.g. mutant mouse models), or using a “top-down approach” wherein a behavior is 
selected for and the relevant genes underlying that behavior may be investigated (e.g. selectively bred 
models). The purpose of this introductory chapter is to therefore 1) evaluate the 
face/construct/predictive validity of the most widely-used animal models, 2) identify pertinent 
limitations in each model, 3) summarize the knowledge gained from use of these models, and 4) suggest 
a novel approach that would circumvent limitations and substantially advance the field of ADHD 
research.  
Arguably the most well-studied, validated ADHD model is the spontaneously hypertensive rat 
(SHR). This strain was selectively bred from Wistar Kyoto (WKY) progenitors in the 1960s in order to 
model the effects of high systolic blood pressure on cardiovascular physiology and stroke liability 
(Okamoto and Aoki, 1963). Nearly 20 years after the initial development of the SHR, a graduate student 
from the University of Oslo, Terje Sagvolden, conducted an experiment using SHRs wherein he positively 
correlated hypertension and increased levels of locomotor activity (Knardahl and Sagvolden, 1979). 
Following a decade of additional research on the hyperkinesis of the SHR, Dr. Sagvolden published the 
initial paper suggesting the SHR should serve as an animal model of ADHD (Wultz et al., 1990, Sagvolden 
et al., 1992). Abundant research regarding the validity of the SHR to model ADHD has occurred over the 
intervening 30 years, most of which was largely shaped by the continual efforts of Dr. Sagvolden and his 
colleagues. Multiple experiments have demonstrated the face validity of the SHR; this strain 
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demonstrates increased physical activity, as assessed by locomotion in open field tests and increased 
responding in operant tasks (Johansen et al., 2005, Sagvolden, 2011), impulsive lever-pressing behavior 
(Berger and Sagvolden, 1998, Sagvolden, 2000, Pardey et al., 2009), and impaired acquisition of operant 
task behavior indicating impaired learning and memory (Wyss et al., 1992). Some studies show modest 
evidence of inattention within the SHR (Sagvolden, 2000). Further supporting the face validity of the SHR 
is the evidence of significant inter-individual variability. There exists diversity in SHR impulsivity, which 
happens to co-vary with individual reductions in NE concentrations in the cingulate and frontal cortices, 
and reduced serotonin levels in the frontal cortex. The existence of diverse subpopulations of SHRs 
effectively mirrors clinical heterogeneity wherein patients exhibit varying degrees of impulsive, 
inattentive, or hyperactive behavior (Adriani et al., 2003). Evidence for the construct validity of the SHR 
has been well documented. Brain volume differences exist in SHRs versus controls; the SHR PFC volume 
and neuron number is reduced in young SHRs compared to WKY controls (Mignini et al., 2004). One 
proof-of-concept experiment indicated that dysregulated monoaminergic neurotransmission mediates 
SHR behaviors; a monoamine oxidase inhibitor (selegiline) effectively reversed behavioral deficits of the 
SHR (Boix et al., 1998). Further studies have more directly shown the role of DA/NE in the behavioral 
pathology associated with the SHR. A comparison between unmedicated SHR and control rats showed 
higher levels of tyrosine hydroxylase and DAT mRNA expression levels in the substantia nigra and ventral 
tegmental area (Roessner et al., 2010). This supports the construct validity of the SHR as it implies 
altered DA synthesis and reuptake. Additional studies have shown that DAT protein density is altered; 
SHRs have higher striatal DAT density across various developmental stages as compared to WKY/NCrl 
(Leo et al., 2003). The SHR also demonstrates predictive validity in that deficient behaviors are 
improved by chronic treatment with low dose amphetamine (Sagvolden, 2011) and methylphenidate 
(Sagvolden et al., 1992). The corrections in behavioral deficits are seen not only with administration of 
psychostimulant medication, but also from administration of non-stimulation medication. Specifically, 
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the α2A-adrenoceptor agonist guanfacine has been shown to improve behavioral deficits (Sagvolden, 
2006). It is hypothesized that the NE system is dysregulated in SHRs as a result of impaired α2A-
adrenoceptor regulation. Thus, the administration of the α2A-adrenoceptor agonist guanfacine 
ameliorated the impairments in SHR locomotor behavior, impulsivity, and attention (Sagvolden, 2006). 
Furthermore the importance of intact glutamatergic transmission in modulating ADHD-like deficits was 
identified in the SHR. Studies show increased glutamate release and dysfunctional reuptake in the SHR 
PFC compared to the WKY control strain (Russell, 2002, Miller et al., 2014). 
While the current consensus is that the SHR is the most valid model of ADHD, several critical 
concerns have been raised disputing its ultimate utility to the field. One issue is that hypertension is not 
a core feature of ADHD (Meyer et al., 2016) even though antihypertensive medications (e.g. guanfacine 
and clonidine) can be used off-label to treat ADHD symptoms. In the case of the SHR, severe 
hypertension could cause vascular/neural damage and obfuscate whether traits in the SHR are due to 
tissue damage or the genetics underlying the neural development. In an effort to further refine the 
model and evaluate how hypertension could impact hyperactive behavior and mediate the 
neurobiological changes seen in the SHR, one group selectively crossbred SHR with WKY rats to parse 
out a hyperactive/normotensive model (WKHA) from a hypertensive model (WKHT) in the late 1970s 
(Hendley and Fan, 1992, Hendley, 2000). While the WKHA rats showed similarities to the SHR 
(hyperactivity in a novel environment, sensitivity to stressors) they also differed significantly (habituate 
more quickly). Notably, hyperactivity in the WKHA was associated with greater DA uptake in the frontal 
cortex, while hypertension in the WKHT was associated with altered NE uptake in the cortex and 
cerebellum, indicating that hyperactivity primarily resulted from DA dysfunction (Hendley and Fan, 
1992). However, this interpretation is not fully supported, as administering the DA reuptake blocker 
methylphenidate to WKHA rats did not reduce hyperactivity but instead increased locomotion and 
impaired pre-pulse inhibition (PPI) in a dose-dependent manner (Drolet et al., 2002). The PPI test of the 
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acoustic startle reflex demonstrates the ability of an animal to habituate their response to a loud tone 
once primed with a lower, preceding tone. It effectively provides a model of abnormal sensorimotor 
gating, which appears to be irregular in some ADHD patients (Castellanos et al., 1996). Therefore, the 
modified WKHA model falls short in terms of its predictive validity since the hyperactivity and 
sensorimotor gating were not corrected through therapeutic administration of methylphenidate. In 
terms of face validity, locomotor activity of the SHR has been demonstrated in short-term exposure to 
open field fields, but not in habituated home cage environment which would be more reflective of 
clinical populations (Sleator and Ullmann, 1981). The predictive validity of the model has also been 
questioned. The reduced hyperactivity of SHRs in response therapeutic psychostimulant medication 
often fails to replicate (van den Bergh et al., 2006, Bizot et al., 2015), although it may be argued that it is 
unreasonable to expect consistent replication of behavioral response to a drug administered under 
varied experimental conditions in a genetically variable line. 
In addition to the aforementioned concerns regarding the construct and predictive validity of 
the SHR, the central limitation of the SHR ADHD model is its control strain (or lack thereof). Common 
controls used in SHR studies include WKY, Wistar, and Sprague-Dawley substrains, and most studies 
compare SHR traits to the traits of one or more control lines. Not only does varied control use limit 
comprehensive interpretation of SHR characteristics based on the literature, but accumulating evidence 
suggests that comparisons between SHRs and certain control strains are incorrect (Pare and Kluczynski, 
1997, Drolet et al., 2002, Ferguson et al., 2007). Many have argued that the WKY is an especially poor 
choice for control due to its documented stress reactivity (Grauer and Kapon, 1993) impaired learning 
(Bull et al., 2000), and depressive-like behaviors (Rittenhouse et al., 2002). Even Dr. Sagvolden, who 
tirelessly championed the value of SHR research, recognized and addressed the extensive confusion 
surrounding control strain comparisons. He concluded in 2009 that the SHR/NCrl from Charles River 
Germany is best suited to model Combined Type ADHD, and furthermore should exclusively be 
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compared to the WKY/NHsd strain from Harlan UK. He suggested that the use of other outbred strains 
as a control (e.g. Wistar, Sprague-Dawley, etc.) have likely led to erroneous conclusions in the field of 
ADHD research. He further suggests that a strain previously used as a control for SHR behavior, the 
WKY/NCrl rat from Charles River Germany, may itself be a model of Predominantly Inattentive Type 
ADHD (Sagvolden et al., 2009). Therefore it is prudent to very carefully evaluate the contribution of 
previous SHR studies using invalidated control strains. 
Another genetic model which recapitulates certain aspects of ADHD is the coloboma (Cm) 
mutation in mice. In 1966, neutron irradiation produced a coloboma mutant mouse which was initially 
used to study microphthalmia (Theiler and Varnum, 1981). This Cm mouse has a hemizygous deletion of 
a 1-2 centimorgan region of chromosome 2q which diminishes the endogenous expression of 
synaptosomal-associated protein of 25 kDa (SNAP-25) in addition to approximately 15 other genes 
(Wilson, 2000). In these mice SNAP-25 mRNA expression and protein levels are reduced by 
approximately 50% (Hess et al., 1994). SNAP-25 associates with the SNARE complex and mediates the 
vesicular release of neurotransmitters; it has also been shown to play a critical role in regulating NMDA 
receptor membrane insertion and therefore synaptic plasticity (Lau et al., 2010). Over many years, 
pioneering investigation of the validity of the coloboma mutant was driven by Dr. Ellen J. Hess. Her 
studies, among others, indicate that the coloboma mutant mice display strong face validity, in that they 
demonstrate significant spontaneous locomotor activity over a 24-hour session, impaired latent 
inhibition indicating inattention, and increased impulsivity in delayed reinforcement tasks (Hess et al., 
1992, Wilson, 2000, Bruno et al., 2007). An important follow-up study by Dr. Hess concluded that 
hyperactive behavior is caused by the SNAP-25 deletion and is not due to the absence of any other 
genes, as insertion of a transgene encoding SNAP-25 reduced hyperactivity (Hess et al., 1996). 
Interestingly, the model has significant construct validity as multiple gene association studies identify 
SNAP-25 polymorphisms in ADHD populations (Barr et al., 2000, Gizer et al., 2009, Elia et al., 2012). The 
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putative mechanism by which SNAP-25 alterations could induce ADHD symptoms is based on its 
association with the SNARE complex. An impaired SNARE mechanism might logically be expected to 
uniformly decrease neurotransmitter release across brain regions, but this is not the case in the 
coloboma mutant. The 50% reduction in SNAP-25 produces specific decreases in DA release in the dorsal 
(but not ventral) striatum, increases in NE concentrations and release in the striatum and nucleus 
accumbens, and no significant changes elsewhere in the brain (Wilson, 2000, Jones and Hess, 2003). 
Furthermore coloboma mice show reduced synaptosomal glutamate in the cortex and increased 
adrenergic α2A-adrenoceptor mRNA expression in the locus coeruleus (Raber et al., 1997, Jones et al., 
2001). Taken together these data suggested impaired neurotransmitter release and specifically 
dysfunctional DA/NE neurotransmission in the striatum underlie hyperactive behavior. The coloboma 
mutant shows predictive validity in terms of drug response, as amphetamine reduces hyperactivity 
(Wilson, 2000). Furthermore the coloboma has demonstrated true predictive validity by informing our 
understanding of the importance intact neurotransmission in clinical ADHD populations; this concept is 
significant because it helped advanced our conceptualization of ADHD beyond monoamine function. 
Furthermore, the extensive studies conducted by Dr. Hess using receptor-selective antagonists have 
demonstrated that the D2 dopamine receptor subtype (and not D1, D3, D4, or D5) primarily mediates 
the hyperactive phenotype and response to amphetamine in this SNAP-25-deficient background (Fan 
and Hess, 2007, Fan et al., 2010). 
Several limitations must be considered when evaluating the coloboma mouse as a model of 
ADHD. Firstly there is clear evidence that these mice are born with eye dysmorphia, delayed lens 
attachment, and microthalmia (Theiler and Varnum, 1981). These developmental abnormalities could 
affect vision and therefore performance on cognitive and motor tasks designed to evaluate ADHD-like 
symptoms. Another important consideration is whether the reduction of SNAP-25 is truly mediating the 
hyperactivity of the coloboma mouse. Although reinsertion of SNAP-25 reduced hyperactivity (Hess et 
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al., 1996), another group attempted to confirm the significance of this gene by selectively mutating a 
highly conserved domain of SNAP-25. Far from hyperactive, the resultant mice display ataxia (Jeans et 
al., 2007). Taken together, this evidence suggests that is more likely that downregulated SNAP-25 in the 
context of other altered genes on chromosome 2q produces ADHD-like behaviors. Furthermore the 
coloboma mouse shows an inconsistent response to administration of other psychostimulants typically 
used to treat ADHD. While amphetamine administration reduces hyperlocomotion, methylphenidate 
increased locomotor activity in both coloboma and control mice equally (Hess et al., 1996). 
As supported by clinical evidence and demonstrated in the SHR and coloboma models, altered 
synaptic monoamine levels appears to play a key role in the neuropathology underlying ADHD. As a 
result, any review of ADHD rodent models would be incomplete without an evaluation of the dopamine 
transporter knockout (DAT-KO) mouse model (Giros et al., 1996). DAT is an autoreceptor responsible for 
reabsorbing DA and NE into the presynaptic terminal, thereby directly regulating receptor stimulation. 
Knocking out DAT results in a mouse which clears synaptic DA 300 times slower than controls and 
remains in a persistently hyperdopaminergic state (Jones et al., 1998, Gainetdinov et al., 1999a). This KO 
model was selected for use in ADHD modeling as opposed to other DAT variants, such as the DAT-
knockdown (Zhuang et al., 2001, Salahpour et al., 2007) and DAT-overexpressing mice (Donovan et al., 
1999), which do not demonstrate home cage hyperactivity. Extensive work by Dr. Raul R. Gainetdinov 
has significantly advanced the validation of the DAT-KO model of ADHD. The DAT-KO exhibits face 
validity in that the mice displayed enhanced locomotion in novel settings, some form of impulsivity in 
cliff-avoidance tests, and impairments in learning and memory (Gainetdinov et al., 1999a, Trinh et al., 
2003, Yamashita et al., 2013). In terms of construct validity the DAT-KO model serves as an extreme 
proof-of-concept that aberrant synaptic monoamine concentrations produces hyperactive behavior. 
Even though it is unclear whether DAT expression is increased or decreased in clinical populations 
(Krause et al., 2000, Jucaite et al., 2005, Wang et al., 2013), certain mutations in the DAT gene which 
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may alter the functionality of the transporter are frequently associated with ADHD (Gizer et al., 2009, 
Elia et al., 2012).  
The DAT-KO model has also demonstrated extensive predictive validity. Administration of 
psychostimulants such as methylphenidate, cocaine, and amphetamine attenuate hyperlocomotion in 
DAT-KO mice (Gainetdinov et al., 1999b). This result is quite surprising as these stimulants largely exert 
their behavioral effects via interactions with DAT; the fact that these mice do not express DAT, yet the 
stimulants decrease hyperactivity while DA concentrations remain unchanged, suggests the 
compensatory involvement of other systems (Leo and Gainetdinov, 2013). An in-depth examination of 
exactly which regions are activated in response to stimulants (as measured by expression of the 
immediate early gene, c-Fos) indicate that while psychostimulants activate mesostriatal and mesolimbic 
DA pathways and increase locomotion as expected in wild-type mice, DAT-KO mice only show activation 
of limbic areas, which implies that non-dopaminergic transmitter systems partly mediate stimulant 
response (Trinh et al., 2003). This hypothesis is further supported by the finding that blocking the 
serotonin transporter (SERT) via fluoxetine or administering a non-selective 5-HT receptor 
agonist/antagonist decreases hyperactivity in the hyperdopaminergic DAT-KO mouse (Gainetdinov et al., 
1999b, Gainetdinov and Caron, 2000, Barr et al., 2004). In fact, SERT and serotonin receptor variants 
have also been identified in candidate gene studies (Elia et al., 2012). However, psychostimulants and 
serotonin agonists lose their ability to ameliorate hyperactivity when NMDA receptors are 
pharmacologically blocked, i.e. decreasing glutamate signaling further potentiates DAT-KO hyperactivity 
despite concurrent therapeutic intervention (Gainetdinov et al., 2001). Taken together, DAT-KO data 
suggest that hyperdopaminergia of the striatum causes hyperactive behavior, and that prefrontal DA/NE 
levels (largely regulated by NET which has affinity for both DA and NE) likely influences the 
hyperdopaminergic striatum via glutamatergic projections. The DAT-KO model also provided critical 
insight into which secondary signaling molecules may underlie hyperactivity. The baseline 
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hyperdopaminergic state of the DAT-KO striatum causes persistent changes to targets downstream of 
dopamine receptor signaling, namely DARPP-32, Akt, and ERK. However, Dr. Gainetdinov and colleagues 
made the discovery that inhibiting previously persistent ERK activation alone, via psychostimulant 
administration, is sufficient to significantly reduce DAT-KO hyperactivity (Beaulieu et al., 2006). This 
suggests that amphetamine may also directly target ERK to influence activity levels. Ultimately the DAT-
KO model comprehensively embodies predictive validity, as it identified novel molecular targets outside 
and downstream of monoaminergic systems in brain regions identified as relevant in the pathology of 
ADHD. 
While the DAT-KO undoubtedly provides a useful context for understanding the role of non-
DAT-mediated neurotransmission in hyperactivity, the model is partly limited in construct validity. Many 
researchers agree that the hyperdopaminergia of the DAT-KO is too extreme to accurately reflect clinical 
populations. This drastic reduction of DAT results in abnormalities such as dwarfism and severe 
hormonal dysregulation (Bosse et al., 1997). Moreover, in stark contrast to this KO model, some clinical 
studies identify increased DAT expression in the striatum of humans with ADHD (Krause et al., 2000). 
Ultimately, ADHD is a polygenic disorder and therefore examining the sole contribution of DAT cannot 
recapitulate the clinical condition nor ultimately advance our understanding of the etiology of ADHD. 
Nevertheless, the DAT-KO does provide proof-of-concept that aberrant DA signaling in the striatum 
produces ADHD-like behavior, and that psychostimulants act on multiple neurotransmitter systems to 
reduce hyperactivity.  
Thus far, this review has focused on genetically-manipulated rodent models to evaluate the 
symptoms of ADHD. However, lesion models are another tool used in evaluating the hypothesized 
system-level dysfunction of ADHD. Instead of altering the genetic architecture to modulate 
neurotransmission, the lesion approach produced hyperkinetic rats by chemically disrupting DA 
projections. 6-OHDA is a toxin that is administered at postnatal day 1 to dopaminergic neurons, taken up 
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by DAT, and effectively destroys susbtantia nigra (pars compacta) dopaminergic projections to the 
striatum. The resulting 6-hydroxydopamine (6-OHDA) lesioned rat model of ADHD has been studied for 
over 40 years. The model demonstrates some aspects of face validity, as the rats begin to display 
hyperactivity in novel environments at 4-5 weeks of age (Kostrzewa et al., 2008). The construct validity 
of the model is supported by observations of DA dysregulation, namely altered DA concentrations in the 
PFC and striatum, increased dopamine receptor D4 gene expression, and increased DAT expression in 
the midbrain (Masuo et al., 2002). These results are consistent with previous clinical evidence 
implicating increases in DAT density (Krause et al., 2000). The model also demonstrates predictive 
validity in that amphetamine and methylphenidate reduced hyperactivity and DA dysregulation 
(Shaywitz et al., 1978, Luthman et al., 1989), and atomoxetine also reduces hyperactive and inattentive 
behavior (Moran-Gates et al., 2005). Interestingly, the dopaminergic de-innervation of the striatum 
results in the compensatory hyper-innervation of the striatum by serotonergic projections from the 
raphe nucleus (Zhang et al., 2002, Kostrzewa et al., 2015). Relative to other animal models, however, 
there are significant concerns related to the validity of using 6-OHDA rats to model ADHD. Chiefly, the 
fact that the nigrostriatal tract is not abolished in patients with ADHD majorly undermines the construct 
validity for the 6-OHDA model. Furthermore, no studies to date have demonstrated impulsivity in the 6-
OHDA lesioned rat which limits its face validity. The ultimate usefulness of the 6-OHDA model to 
uncover novel etiological factors of ADHD or model potential therapeutic compounds is limited.  
While the SHR, coloboma mouse, DAT-KO mouse, and 6-OHDA lesioned rat are the most 
commonly studied models of ADHD, many others have been proposed. Other knockout models include 
the substance P-preferring tachykinin-1 receptors (NK1R) KO mice which are hyperactive, responsive to 
amphetamine, and show decreased DA in the PFC and striatum with increased NE in the PFC (Yan et al., 
2009, Yan et al., 2011). However further studies are required to determine whether these NK1R-KO mice 
are inattentive or impulsive. Other models of ADHD are generated based on suspected environmental 
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factors which are have been theorized to increase susceptibility to ADHD. Such hyperactive models 
include those generated by exposing inbred rodents to polychlorinated biphenyls (Sazonova et al., 
2011), prenatal nicotine (Thapar et al., 2003), and neonatal anoxia (Dell'anna et al., 1993). However, 
environmentally-induced models are of limited construct validity as ADHD is known to have genetic 
origins. Ultimately none of these rodent models have been widely embraced as ADHD animal models. 
Over the past several decades, these models have provided some insight into the 
neurobiological dysfunction associated with ADHD. Across all models discussed in this review, there is a 
consistent convergence on monoaminergic dysfunction (either up or down regulated) in the PFC and 
striatum underlying ADHD-like behaviors. Specifically, the SHR and DAT-KO models have proven useful in 
understanding dysregulated transmission beyond DA, emphasizing the role of NE and glutamate in 
ADHD (Gainetdinov and Caron, 2000, Gainetdinov et al., 2001, Russell, 2002, Miller et al., 2014). 
Additional evidence gained from these animal models corroborate the hypothesis that monoaminergic 
systems are not likely to be the primary defects in ADHD, but are rather part of broader dysfunction 
related to impaired excitatory tone in relevant regions. The coloboma mutant hints at this by 
demonstrating that a significant reduction in SNAP-25-mediated vesicular release differentially affects 
the functional neurotransmission in various regions and results in decreased availability of glutamate in 
the frontal cortex (Raber et al., 1997). The altered glutamate synthesis/storage may be a downstream 
effect of SNAP-25 reduction, as SNAP-25 has been shown to have a critical role in NDMA receptor 
insertion and effective glutamate signaling (Leo et al., 2003). The DAT-KO also underscores the 
importance of intact glutamate transmission in studies demonstrating that a blockade of NMDAR-
induced glutamate transmission further exacerbated hyperactivity (Gainetdinov et al., 2001). 
Concomitantly with baseline behavioral analyses, advances were made in understanding the molecular 
basis whereby therapeutics (psychostimulants, serotonin drugs, adrenoceptor drugs) ameliorate or 
exacerbate ADHD-like behaviors. Yet a majority of animal model literature is focused on whether models 
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reflect clinical data, and not on advancing our knowledge base regarding the causes of ADHD. This may 
be due the fact that these models are fundamentally limited in their predictive validity to varying 
degrees. There exists limited potential to uncover novel etiological factors associated with ADHD or 
predict novel medication response. In fact, a recent study evaluated the contribution of animal-based 
research to our contemporary understanding of ADHD. This citation-analysis discovered that only 57% of 
animal studies are cited in clinical literature, and furthermore only a scant 2.3% of published animal 
studies meaningfully contributed to medical advances. The vast majority of animal model studies only 
seem to inform other animal model studies (Carvalho et al., 2016). A continuation of this trend would 
validate the recent prediction made by the quantitative geneticist Peter M. Visscher, that within the 
next few decades “modeling human complex traits in experimental organisms will become obsolete” 
(Visscher, 2016). Indeed, more relevant models with strong predictive validity will be central to 
rejuvenating the field and advancing our understanding of and treatment for ADHD. 
In conclusion, many rodent models of ADHD exist which reflect facets of this heterogeneous 
disorder, yet each has limited potential to provide viable targets for future therapeutic research. The 
SHR lacks an appropriate control to make valid comparisons and interpretations. Other models lack 
construct validity, as ADHD is polygenic disorder which involves the dysregulation of several brain 
regions (partly invalidating coloboma, DAT-KO, 6-OHDA), and is not associated with hypertension (partly 
invalidating the SHR). Poor construct validity limits the usefulness of these models in predicting novel 
medication response in clinical populations. All models show some evidence of predictive validity in that 
hyperactivity is calmed by known therapeutics; yet the concept of predictive validity also encompasses 
prediction of novel treatment strategies that have not been observed in clinical populations. Thus far no 
animal models have shown this. There is a need for a genetically variable, hyperactive model along with 
an appropriate control line that would allow for the identification of novel genes underlying hyperactive 
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behavior and provide a platform for medication development that could more closely mimic clinical 
response. 
The goal of generating an ADHD model with strong construct and predictive validity may be 
achieved by employing a selective breeding approach. Selective breeding is a powerful tool which can be 
used to uncover novel genetic factors mediating the phenotype of highly heritable traits. Ongoing 
efforts from the Rhodes lab have resulted in the generation of a selectively bred model of home cage 
hyperactivity from the genetically variable Collaborative Cross mice. These High-Active mice show 
hyperactivity in the home cage that is not correlated with wheel running or open field behavior 
(Zombeck et al., 2011), suggesting that habituated home cage hyperactivity is a unique form of physical 
activity that may more closely reflect ADHD. Furthermore the High-Active line is extremely hyperactive 
(one aspect of face validity), comprised of sufficient genetic variability (construct validity), and may be 
used to identify the genes mediating hyperactive behavior in the home cage setting (potential predictive 
validity). Taken together these features indicate preliminary promise for the High-Active line to serve as 
a potential model of ADHD. Furthermore the line addresses certain major limitations confounding 
current models, in that 1) the co-bred Control line would allow for statistically valid comparisons of 
between-line differences in hyperactivity and related traits, 2) the variability of the genetic background 
underlying hyperactivity in the High-Active line would allow for the unbiased discovery of novel 
etiological (genetic) factors, and 3) the medication response of High-Active mice to novel therapeutics 
may more accurately predict medication response, thus providing the potential for comprehensive 
predictive validity. Future efforts should focus on evaluating the High-Active line for face, construct, and 
predictive validity in modeling ADHD, in order to ascertain whether this line may serve as a novel and 
sorely-needed platform for genetic research and medication discovery. 
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Abstract 
Daily levels of physical activity vary greatly across individuals and are strongly influenced by genetic 
background. While moderate levels of physical activity are associated with improved physical and 
mental health, extremely high levels of physical activity are associated with behavioral disorders such as 
Attention Deficit Hyperactivity Disorder (ADHD). However, the genetic and neurobiological mechanisms 
relating hyperactivity to ADHD or other behavioral disorders remain unclear. Therefore, we conducted a 
selective breeding experiment for increased home cage activity starting with a highly genetically variable 
population of house mice and evaluated the line for correlated responses in other relevant phenotypes. 
Here we report results through Generation 10. Relative to the Control line, the High-Active line traveled 
approximately 4 times as far in the home cage (on days 5 and 6 of a 6-day test), displayed reduced body 
mass at maturity, reduced reproductive success, increased wheel running and open field behavior, 
decreased performance on the rotarod, decreased performance on the Morris water maze that was not 
rescued by acute administration of d-amphetamine, reduced hyperactivity from chronically 
administered low clinical doses of d-amphetamine, and increased numbers of new cells and neuronal 
activation of the dentate gyrus. Standardized phenotypic differences between the lines were compared 
to estimates expected from genetic drift to evaluate whether the line differences could have resulted 
from random effects as opposed to correlated responses to selection. Results indicated line differences 
in body mass and locomotor responses to low doses of amphetamine were more likely due to selection 
than drift. The efficacy of low doses of d-amphetamine in ameliorating hyperactivity support the High-
Active line as a useful model for exploring the etiology of hyperactivity-associated comorbid behavioral 
disorders. 
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Introduction 
In human populations, individuals exhibit a wide variation in daily physical activity levels (e.g., 
distance traveled over the course of the day) (Trost et al., 2001). Significant deviations from healthy 
activity levels are associated with disease and behavioral disorders (Fox, 1999; Trost et al., 2001). 
Moreover, multiple studies show that levels of physical activity are heavily influenced by complex 
genetic factors that are inevitably entangled with other whole animal physiological and behavioral traits. 
For example, genetic predisposition for low levels of physical activity has been associated with increased 
adipose tissue mass (Choh et al., 2009; Demerath et al., 2013), while genetic predisposition for high 
levels of physical activity is associated with Attention Deficit Hyperactivity Disorder (ADHD) (Sharp et al., 
2009; Elia et al., 2012). In the context of ADHD, hyperactivity refers to abnormally high levels of physical 
activity in the home or school environment, and difficulty remaining still for extended periods of time. 
The increasing prevalence of complex genetic disorders associated with hyperactivity, such as ADHD, 
necessitates further elucidation of the underlying genetic and neurobiological mechanisms which 
contribute specifically to increased physical activity and further how genetic-hyperactivity mechanisms 
influence other relevant traits such as inattention, impulsivity, or behavioral responses to 
psychostimulant drugs (McLoughlin et al., 2007; Froehlich et al., 2010; Greven et al., 2011; Thapar et al., 
2013). 
Previous research from our laboratory has successfully used a genetically variable starting 
population of Collaborative Cross G2:F1 (CC) mice (intercross of 8 divergent mouse strains; (Chesler et 
al., 2008) to found two lines of mice, High-Active and Control (Zombeck et al., 2011). The High-Active 
line is selectively bred each generation for high levels of home cage activity as measured by continuous 
video tracking over 6 days, while the Control line is bred randomly with respect to cage activity. Our 
previous paper indicated a successful response to selection in the High-Active lines across 5 generations 
(Zombeck et al., 2011). At Generation 5, on days 5 and 6 of a six day test, the Control line traveled an 
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average of 0.35 km/day (± 0.026 SE), not statistically different from the level of activity in the starting 
population, whereas the High-Active line traveled an average of 1.0 km/day (± 0.076 SE), which was 
significantly different from the Control line and starting population. Further, the paper reported that 
selective breeding for home cage hyperactivity was not genetically correlated with other locomotor 
activity measures, including wheel running and open field behavior, suggesting specific genetic 
mechanisms for home cage activity. In a different study (Clark et al., 2011), we compared home cage 
activity in 9 standard inbred strains, 2 F1 hybrids, and one wild-derived mouse strain (CAST/EiJ) using the 
same 6-day video tracking procedure. Home cage activity ranged from approximately 0.1 km/day to 0.5 
km/day among these strains. Hence, our High-Active line is hyperactive not only relative to our Control 
line, but also relative to all other mouse strains that have been measured in our laboratory, and twice as 
active as CAST/EiJ, the highest active strain we measured.  
 As our High-Active mice continue to demonstrate increased hyperactivity following selective 
breeding, we hypothesize that they may be useful as a model for genetic hyperactivity disorders, such as 
ADHD. In order to characterize these High-Active mice, we first wanted to establish that they continue 
to display hyperactivity, a clinical facet of common ADHD subtypes. Enhanced locomotor activity in the 
home cage was clearly demonstrated in High-Active mice through Generation 5 (Zombeck et al., 2011), 
and this paper provides an update through Generation 10. The model is also evaluated for predictive 
validity, in that these High-Active mice should demonstrate the appropriate behavioral responsiveness 
to therapeutic, chronic doses of d-amphetamine. Previous studies have demonstrated that mice 
selectively bred for increased physical activity, as indicated by levels of wheel running activity, exhibit 
differential responsivity to dopamine agonists and antagonists relative to control lines. Importantly, 
mice selectively bred for increased wheel running behavior diminished running levels following exposure 
to methylphenidate, while control lines increased wheel running following exposure to methylphenidate 
(Rhodes et al., 2001; Rhodes and Garland, 2003; Garland et al., 2011b). Therefore, we expected low 
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doses of amphetamine to ameliorate hyperactivity in High-Active mice, whereas in the Control lines, we 
expected low doses of amphetamine to either have no effect or to stimulate activity (Gainetdinov, 2008; 
Napolitano et al., 2010).  
Our amphetamine administration paradigm was based on previous research from our lab (Dabe 
et al., 2013), which reported that at these specific doses, and over the same extended period of 
administration, amphetamine enhances neurogenesis in the dentate gyrus of C57BL6/J mice without 
inducing activation of the region (as indicated by expression of the immediate early gene, c-fos). The 
C57BL/6J inbred strain is one of the 8 strains represented in the 8-way cross (CC) G2:F1 starting 
population. Therefore, an additional goal was to determine whether administration of these 
amphetamine doses would reduce hyperactivity while simultaneously enhancing the number of new 
cells in the dentate gyrus. Further, we wished to determine the acute effect of the amphetamine doses 
on a hippocampal dependent task, the Morris water maze test of spatial learning. Mice were exposed to 
either saline or amphetamine, and tested on the water maze precisely 15 minutes after injection. While 
some evidence suggests that high levels of physical activity-induced neurogenesis does not improve 
Morris water maze performance, other studies in less active strains exposed to running wheels suggest 
increased neurogenesis due to enhanced physical activity may be correlated with enhanced 
performance on the water maze (Rhodes et al., 2003; Clark et al., 2008). We hypothesize that the 
therapeutic doses of d-amphetamine could acutely improve deficient performance in High-Active lines 
(Brown et al., 2000).  
Therefore, the purpose of the present paper is fourfold. The first goal is to characterize the 
progress of the selective breeding experiment to date and provide updated correlations with other 
physical activity, motor performance, and life history traits. Home cage activity levels collected during 
phenotyping are reported, in addition to a measure of reproductive success of the lines (number of 
successful pairs/generation) and body mass at the time of home cage activity phenotyping 
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(approximately postnatal day 60). The second goal is to begin to characterize whether the model may be 
relevant for exploring etiology of genetic hyperactivity disorders, such as ADHD, by evaluating locomotor 
responses to psychostimulant administration, our prediction being that low doses would ameliorate 
hyperactivity. The third is to determine how chronic amphetamine affects neuronal activation and 
growth of new cells in the granule layer of the hippocampus of High-Active and Control lines, since 
previous studies from our lab indicated that chronic amphetamine increases adult hippocampal 
neurogenesis in C57BL/6J mice. The fourth aim is to characterize acute effects of amphetamine 
treatment on spatial learning in the water maze, a hippocampus-dependent task, in the High-Active 
versus Control lines. 
Materials and Methods 
Animals 
Mice from Generations 10 and 11 of a selective breeding experiment for increased distance 
traveled in the home cage were used (Zombeck et al., 2011). Our lab continues to maintain two lines of 
genetically variable (outbred) mice: a randomly bred, unselected (Control) line and a line selectively 
bred for increased distance traveled in the home cage (High-Active). Each line consists of 10-14 pairs of 
mice, and within-family selection is applied to minimize inbreeding. The starting population for each line 
was generated from a mix of 8 inbred strains that were specifically chosen to maximize genetic variation 
(collaborative cross mice G2:F1; Chesler et al. (2008). Each generation at weaning (21 days old), mice are 
housed in groups of 4 by sex. At approximately postnatal day 60, they are phenotyped individually for 
home cage activity. Mice are placed in custom-made acrylic home cages (18.5 cm x 33.5 cm x 16 cm) 
with clear plastic lids that allow continuous ceiling-mounted video tracking by TopScan (CleverSystems, 
Reston, VA, USA). Each cage individually houses 4 mice, with an interaction zone constructed of wire 
mesh that allows for limited physical contact and interaction. The video coverage allows for continuous 
tracking of 64 individual mice over the span of 6 days. Well after an extended habituation period of 4 
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days, the average distance traveled during days 5 and 6 is used as the selection criterion. This criterion 
was chosen to represent behavioral patterns established in an acclimated, home cage environment, 
without any confounding effects of novelty. Moreover, this criterion of average activity over days 5 and 
6 has been successfully implemented in other selective breeding experiments for heightened physical 
activity (Swallow et al., 1998).  
General husbandry 
Rooms are kept controlled for temperature (21 ± 1°C) and photo-period (12:12 L:D; lights on at 
10:00 PM and off at 10:00 AM). Food (Harlan Teklad, 7012) and water are provided ad libitum at all 
times. Corncob bedding (7097 Harlan Teklad, Madison, Wisconsin, USA) was provided in all cages. The 
Beckman Institute Animal Facility is AAALAC approved. All procedures were approved by the University 
of Illinois Institutional Animal Care and Use Committee and adhered to NIH guidelines. 
Experiment 1: Genetic differences in wheel running and distance traveled in the open field between High-
Active and Control lines in Generation 10. 
  High-Active mice (n=10 males and n=10 females) and Control mice (n=9 males and n=10 
females) were randomly chosen from Generation 10 after excluding breeders for Generation 11. The 
mice were chosen from 10 different families per line, i.e., 1 male and 1 female was randomly selected 
per family. Mice were tested in the following order, first home cage activity as routinely performed 
starting at age 60 (± 2 days), then left undisturbed for 20 days, followed by 2 days of open field, 5 days 
of wheel running, and 3 days of rotarod testing. 
Open Field 
Testing occurred at approximately 11:00 AM during the animal’s normal dark cycle under diffuse 
white light. Mice were individually placed in a 67 cm x 67 cm x 30 cm (L x W x H) open field box for 5 
minutes. The procedure was repeated the following day, and the distance traveled was averaged 
between the two days. TopScan was used to track distance traveled.  
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Wheel running 
Mice were placed individually into cages with a running wheel for 5 days. Dimensions of running 
wheel cages were 36 cm × 20 cm × 14 cm (L × W × H) with a 23 cm diameter wheel mounted in the cage 
top (Respironics, Bend, OR). Wheel rotations were monitored continuously in 1 min increments.  
Rotarod 
Testing occurred at approximately 11:00 AM under red light during the animal’s normal dark 
cycle. Mice were placed on a stationary rotarod (AccuRotor Rota Rod Tall Unit, 63-cm fall height, 30-mm 
diameter rotating dowel; Accuscan, Columbus, OH). The dowel was then accelerated at 60 rpm/min, and 
the latency to fall (in seconds) was recorded. The procedure was repeated for 4 consecutive trials, which 
were averaged to give the daily latency to fall for each mouse. If an animal fell off the rotarod rapidly 
(e.g., due to inattention or slips), they were placed back on the rotarod for an additional trial, and the 
latency was not included in the average for the day. The entire procedure was repeated the following 2 
days for a total of 3 days. In addition to the average latency across the 4 trials per day, the maximum 
latency to fall per day was also analyzed. 
Experiment 2: Genetic differences in amphetamine-induced locomotor activity and hippocampal 
plasticity between High-Active and Control lines. 
Mice from Generation 11 were used [n= 5 per sex (Male or Female)/line (High-Active or 
Control)/treatment (saline, 0.25, 0.5, or 2 mg/kg d-amphetamine) = 80 total]. Generation 10 breeders 
were allowed to produce an additional litter for continuing the lines (i.e., for selecting Generation 11 
breeders). The litters used for this experiment were all born within 4 days of each other, which allowed 
all animals to be measured at the same time and at a similar age (Fig. 2.1). Mice from within a family 
were distributed across the 4 treatment groups to prevent possible family effects from confounding 
treatment differences. Mice were weaned into cages in groups of 4 until they were approximately 40 
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days old and underwent video tracking session 1, after which they were individually housed for the 
duration of the experiment. 
Amphetamine injections 
Beginning the second day after weaning at an age of 23 days old, all mice received twice daily 
intraperitoneal (i.p.) injections of saline, 0.25 mg/kg d-amphetamine, 0.5 mg/kg d-amphetamine, or 2 
mg/kg d-amphetamine, approximately 3 hours apart (at 10:00 AM and 1:00 PM). These twice daily 
treatment injections continued throughout the entirety of the experiment until sacrifice, including all 
days of behavioral testing. 
BrdU injections 
Throughout the first 10 days, when mice were 23 through 32 days old, they received daily i.p. 
injections of 50 mg/kg 5’bromo-5’-deoxyuridine (BrdU) to label dividing cells. These injections occurred 
at approximately 12:00 PM. 
Locomotor activity 
A random sample of 64 mice (n=4/sex/line/treatment) of the 80 total were used to measure 
distance traveled in the home cage in response to d-amphetamine administration. The sample size of 64 
was chosen because that is the limit for simultaneous video tracking in our laboratory. When the mice 
were 40-42 days old (video tracking session 1), 62-64 days old (video tracking session 2), and between 
71-73 days old (video tracking session 3), they were placed individually in the custom cages with the 
clear lids for continuous 24 hour video tracking. The d-amphetamine/saline injections continued 
throughout the video tracking sessions. While TopScan continued to record activity for a 24 hour period, 
the analysis of locomotor response to amphetamine was restricted to only 90 minutes following the 
injection because after 90 min, brain concentrations of amphetamine would be expected to wane 
(Zombeck et al., 2010). In addition, locomotor responses to amphetamine at the doses that were given 
are known to last for approximately 90 min in mice (Dabe et al., 2013). Data are shown only for the 
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second and third day of video tracking sessions 1 and 2, to allow for one day of habituation which was 
not analyzed. Locomotor response in video tracking session 3 represents only the 90 minutes between 
an animal’s final injection and sacrifice, after 1 to 2 days of habituation.  
Morris Water Maze 
A sample of 40 mice of the 80 total was tested on the Morris water maze. This sample included 
randomly selected: n=5 High-Active mice per amphetamine dose (3 males and 2 females), n=5 Control 
per dose (2 males and 3 females) times 4 doses equals 40 animals. Water maze training occurred exactly 
15 minutes after their daily afternoon injection of amphetamine. The sample of 40 mice rather than all 
80 were tested for feasibility and to keep the timing between amphetamine injections relatively 
constant. The maze consisted of a circular tub, 70 cm diameter and 30 cm deep. Extra-maze cues of 
varying geometric patterns, colors, and numbers were placed on the walls around the tub in order to 
provide spatial markers of location for the mice. A platform, made of a white plastic mesh measuring 8.5 
cm x 8.5 cm, was placed in the middle of one maze quadrant and submerged 1 cm below the surface of 
the water. Crayola white tempera paint was added to make the water sufficiently opaque, thereby 
hiding the platform from sight. The whitened water provided contrast against the dark mice, so TopScan 
could clearly track the animal as it navigated the maze. Water temperature was maintained at 21–23°C. 
A trial lasted either 60 seconds or until the mouse reached the platform and remained on the platform 
for 10 seconds. If a mouse did not reach the platform in 60 seconds, it was gently guided there by hand. 
Mice were placed back in their cage and allowed to rest for approximately 10 minutes between trials. 24 
hours after training Day 5, the platform was removed and mice were tested with a probe trial lasting 60 
seconds. TopScan video tracking software was used to measure path length (mm) to platform, and time 
(seconds) spent in the target quadrant of the maze during probe trial. 
Immunohistochemistry 
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Following Clark et al. (2008), animals were anesthetized with 100 mg/kg sodium pentobarbital 
via intraperitoneal injection, and then perfused transcardially with 4% paraformaldehyde in phosphate 
buffer solution (PBS). Brains were sectioned using a cryostat into 40 µm coronal sections and stored in 
tissue cryoprotectant at -20°C. 
Fos-DAB  
Following previous protocols from our lab (Zombeck et al., 2008),a 1-in-6 series of free-floating 
sections were pretreated with 0.6% hydrogen peroxide in PBS for 20 min at room temperature, then 
washed in PBS containing 0.2% Triton X-100 (PBS-X) and blocked with 6% goat serum for 1 h at room 
temperature. Sections were then incubated in monoclonal primary antibody against mouse Fos made in 
rabbit (Calbiochem, San Diego, CA) at a dilution of 1:20,000 in PBS-X containing 3% NGS for 48 h at 4 °C. 
Sections were subsequently washed in PBS-X and incubated in secondary biotinylated antibody against 
rabbit immunoglobulin made in goat (Vector Labs, Burlingame, CA) at a dilution of 1:200 in PBS-X with 
3% NGS for 90 minutes at room temperature. Sections were then treated using the Vectastain Elite ABC 
Kit (Vector Laboratories, Burlingame, CA, USA) with diaminobenzidine (DAB), enhanced with 0.008% 
nickel chloride (Sigma, St. Louis, MO).  
BrdU-DAB 
A 1-in-6 series of these sections (i.e., series of sections throughout the extent of the 
hippocampus with 240 µm increments separating each section) was stained to visualize BrdU to detect 
newly divided cells in the dentate gyrus. Free-ﬂoating sections were washed in tissue buffering solution 
(TBS) and then treated with 0.6% hydrogen peroxide. To denature DNA, sections were treated with 50% 
deionized formamide, 10% 20xSSC buffer, 2N hydrochloric acid, and 0.1M boric acid. Sections were then 
treated with a solution of 0.1% Triton-X and 3% goat serum in TBS (TBS-X plus), and then incubated in 
primary antibody against BrdU made in rat (Accurate, Westbury, NY, USA) at a dilution of 1:200 in TBS-X 
plus for 72 h at 4°C. Sections were then washed in TBS, treated with TBS-X plus for 30 min, and then 
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incubated in secondary antibody against rat made in goat at 1:250 in TBS-X plus for 100 min at room 
temperature. Sections were treated using the Vectastain Elite ABC Kit with DAB, enhanced with 0.008% 
nickel chloride. 
Image analysis 
Fos-DAB and BrdU-DAB 
The entire bilateral granule layer, represented in the 1-in-6 series, was photographed by 
systematically advancing the ﬁeld of view of the Zeiss brightﬁeld light microscope, and taking multiple 
photographs, via AxioCam interfaced to computer, under 10x (total 100x) magniﬁcation. These 
photographs were then analyzed using ImageJ software (NIH, Bethesda, MD, USA) to generate unbiased 
estimates of total number of BrdU- and Fos-positive cells. Specifically, in each image, the granule layer 
was traced and BrdU- or Fos-positive nuclei were counted within the traced region automatically by 
setting a fixed threshold to remove background. Following previous protocols from our lab (Clark et al., 
2011), to obtain unbiased estimates of cell numbers, total counts were multiplied by 0.85, under the 
assumption that 15% of the nuclei counted would intersect with the plane of the section. This was 
estimated based on the observation that the average size of granule neuron nuclei was 6 μm, which is 
15% of 40 μm, the thickness of the section.  
Statistical analysis 
Data were analyzed with SAS (version 9.2) and R (3.0.2) statistical software. In all analyses, 
P≤0.05 was considered to be statistically significant. Two different statistical tests were performed to 
compare phenotypic differences between the lines. The first was a simple test using standard analysis of 
variance (ANOVA) methods and the Fisher exact test for the reproductive success count data. Home 
cage locomotor activity and body mass were analyzed per generation by 2-way ANOVA, with sex and 
line (High-Active and Control) as factors. To compare reproductive success between the lines, the total 
number of successful first litters out of the total number of pairs was compared between High-Active 
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and Control lines using a Fisher exact test. Wheel running and Rotarod data were analyzed using a 
repeated-measure ANOVA, with line and sex as between-subjects factors and day as the within-subjects 
factor. Data were log transformed to improve homogeneity of variance between groups for Home cage 
activity and Rotarod. In Experiment 2, cumulative distance traveled 1.5 h after amphetamine or saline 
injections was analyzed by repeated-measures ANOVA with dose (saline, 0.25, 0.5, 2 mg/kg 
amphetamine), sex, and line as the between-subjects factors, and test day (Test 1-5) as the within-
subjects factor. Two animals were removed (one from the female/Control/saline group, and the other 
from the female/High-Active/2 mg/kg amphetamine group) due to erroneous video tracking. The 
locomotor activity data were also analyzed collapsed across test day (i.e., the average over the 5 tests), 
which is presented in Table 2. In addition, the collapsed data from the amphetamine groups were 
expressed as a difference relative to the saline-treated controls (by line and sex), and analyzed a similar 
way with line, sex, and dose (3 levels, 0.25, 0.5 and 2 mg/kg) as factors. Distance to the hidden platform 
in the water maze was analyzed by repeated measures ANOVA with dose and line as the between-
subjects factors, and day (1-5) as the within-subjects factor. Distance to the platform on days 2 and 3 
were collapsed and further analyzed by post-hoc Tukey tests. Duration spent in the target quadrant for 
the probe trial was analyzed by 2-way ANOVA with dose and line as factors. To establish whether the 
average duration in the target quadrant was greater than expected by chance, the average was 
compared to 25% (for the 4 quadrants) using a t-test. Total numbers of BrdU+ and c-Fos+ cells were 
analyzed by ANOVAs using dose, sex, and line as factors; c-Fos data were log transformed in this analysis 
to improve homogeneity of variance. Pair-wise Pearson’s correlations were evaluated between distance 
traveled, total number of c-Fos cells, and number of new neurons. Total numbers of BrdU+ cells and c-
Fos+ cells were also analyzed using a linear model that included distance traveled, line, dose, and sex in 
the model. Statistical power was estimated for the ANOVA analyses by simulating 10,000 data sets using 
the observed means and variances, and calculating the percentage of these data sets displaying 
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statistically significant results for the main and interaction effects. For data sets with repeated 
measures, the measures were averaged to obtain one measurement for statistical power analysis. 
The second analysis was conducted to determine whether the observed phenotypic differences 
between the two lines (High-Active versus Control) were likely correlated responses to selection for 
home cage activity (e.g., pleiotropy or linkage disequilibrium) as opposed to a result of genetic drift or 
founder effects unrelated to selection. We acknowledge that it is preferable to include replicate selected 
and control lines to establish evidence for genetic correlations between primary traits under selection 
and secondary traits. However, in absence of replication, we followed the guidelines suggested 
previously (Henderson, 1989, 1997; Konarzewski et al., 2005). First, we calculated standardized 
estimates of phenotypic differences between the lines (Dy), as mean value of the trait in High-Active 
minus mean value of Control divided by the pooled estimate of the standard deviation of the trait within 
lines. We then used the following equation (Equation 1) to estimate the standard deviation for Dy as 
expected from genetic drift (σ(dy)):  
 
	Equation	1:													() ≅ 2ℎ + 1/ 
 
Here h
2 
refers to heritability and was estimated from the literature, F refers to the inbreeding coefficient 
which was estimated in our lines by entering the pedigree from Generations 1-10 in ASReml-R version 
2.0 following Konarzewski et al. (2005). “n” refers to the number of families represented for the specific 
phenotypic trait that was analyzed. The 95% confidence interval for Dy was then calculated by 
multiplying σ(dy) by 1.96 (from standard normal distribution). If the absolute value of Dy was greater than 
the 95% confidence interval value, then Dy was considered unlikely due to drift and more likely a 
correlated response to selection. 
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Results 
Response to selection, reproductive success, and body mass 
The High-Active line of mice continues to respond to selection through 10 generations with 
some exceptions at Generations 6 and 9 (Fig. 2.2.A). No clear indication of a selection limit has been 
reached. Selection differentials (S), realized heritability estimates (h
2
realized) and responses to selection (R) 
for Generations 1-9 are shown in Table 2.1. At Generation 10, on days 5 and 6 of the six day test, the 
High-Active mice traveled an average of 1.51 ± 0.08 SE km/day whereas mice from the Control line 
traveled 0.36 ± 0.03 SE km/day (F1,171 = 101.5, P < 0.0001) in their cages, which is approximately a 4-fold 
increase. In the High-Active line, males traveled approximately 65% as far than females (F1,125 = 21.7, P < 
0.0001). In the Control line, the sex difference was smaller and not significant, resulting in a significant 
interaction between sex and line (F1,171 = 6.2, P = 0.0135). 
The High-Active line displayed significantly reduced fertility relative to the Control line as 
indicated by fewer successful pairs out of the 140 total (14 pairs per generation x 10 generations) that 
contributed progeny to the 2 lineages over the 10 generations (Fig. 2.2.B). In the Control line, 130 pairs 
out of 140 total pairs successfully contributed offspring to the subsequent generation, while in the High-
Active line only 95 pairs out of 140 successfully contributed (Fisher Exact test, P < 0.0001). The reason 
pairs failed to produce offspring included failure of the female to become pregnant, cannibalization of 
the pups, or death from poor mothering. 
The High-Active mice display significantly reduced body mass as compared to Controls at the 
time of phenotyping (age approximately 60 days) (Fig. 2.2.C). The difference was apparent starting at 
Generation 5 and continues through Generation 10. At Generation 10, High-Active mice were 
approximately 84% as heavy as Controls (F1,171 = 48.3, P < 0.0001) and Females were 80% as heavy as 
males (F1,171 = 81.2, P < 0.0001). No interaction between line and sex was detected. The difference in 
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body mass between the lines in Generation 10 was more likely a correlated response to selection than a 
consequence of genetic drift (Table 2.2). 
Experiment 1: Genetic differences in wheel running and distance traveled in the open field between High-
Active and Control lines in Generation 10.  
Home cage activity 
A sample of animals from Generation 10 (n=39 total) were used to examine wheel running and 
open field behavior in High-Active and Control Lines. Distance traveled in the home cage on days 5 and 6 
during the routine screening in this sample, ranged from 0.153 km/day (Control male) up to 3.53 km/day 
(High-Active female). Within this sample, a significant effect of line (F1,35 = 40.3, P < 0.0001) and sex (F1,35 
= 4.5, P = 0.041) was observed. No interaction between line and sex was detected (Fig. 2.3.A). 
Wheel running 
Average distance traveled across a 5 day test was 7.2 km/day (± 0.73 S.E.) for Control mice, and 
9.06 km/day (± 0.79 S.E.) for High-Active mice. Wheel running behavior showed main effects of line (F1,33 
= 4.4, P = 0.044) and sex (F1,33 = 9.7, P = 0.0038), and a trend for an interaction between line and sex 
(F1,33 =2.5, P = 0.12; Fig. 2.3.B). Statistical power was estimated to be 26% for detecting the interaction. 
The difference in wheel running between the lines is within the range expected by genetic drift and 
therefore we cannot conclude that it is necessarily a correlated response to selection (Table 2.2). 
Open field 
Average distance traveled in the open field over 5 minutes was significantly greater in the High-
Active line as compared to Control (F1,35 = 14.6, P = 0.0005; Fig. 2.3.C). No main effect of sex was 
detected, but a trend for an interaction between sex and line was observed (F1,35 = 2.0, P = 0.16). 
Statistical power was estimated to be 29% for detecting the interaction. The difference in open field 
activity between the lines is within the range expected by genetic drift and therefore we cannot 
conclude that it is necessarily a correlated response to selection (Table 2.2). 
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Rotarod 
All mice learned the rotarod task as indicated by increased latency to fall from the rotating 
beam from Day 1 to Days 2 and 3 (for average latency across 4 trials per day, F2,70 = 21.4, P < 0.0001; for 
max latency across 4 trials, F2,70 = 12.1, P < 0.0001). High-Active mice performed significantly worse on 
the rotarod as indicated by reduced latency to fall across days (for average latency, F1,35 = 5.0, P = 0.032; 
for maximum latency, F1,35 = 5.2, P = 0.029). No significant effect of sex was detected. However, a trend 
for an interaction between sex and line was observed (for average latency, F1,35 = 2.7, P = 0.10; for max 
latency, F1,35 = 3.9, P = 0.056; see Fig. 2.3.D & E). Statistical power to detect the interaction was 
estimated to be 31% for average latency to fall collapsed across the 3 days. The difference in rotarod 
performance between the lines is within the range expected by genetic drift and therefore we cannot 
conclude that it is necessarily a correlated response to selection (Table 2.2). 
Experiment 2: Genetic differences in amphetamine-induced locomotor activity and hippocampal 
plasticity between High-Active and Control lines. 
Locomotor activity (Fig. 2.4.A-D, Fig. 2.5) 
The overall ANOVA of distance traveled within the 90 min period after an injection of saline, 
0.25, 0.5, or 2 mg/kg amphetamine in High-Active versus Control mice over the 5 testing days indicated 
a significant effect of day (F4,183 = 14.4, P<0.0001), line (F1,46 = 85.7, P<0.0001), dose (F3,46 = 5.4, P=0.003), 
sex (F1,46 = 22.8, P<0.0001), line*dose (F3,46 = 3.2, P=0.03), line*day (F4,183 = 7.3, P<0.0001), dose*day 
(F12,183 = 1.9, P=0.04), sex*day (F4,183 = 5.2, P=0.0005), line*sex (F1,46 = 24.4, P<0.0001), and line*sex*day 
(F4,183 = 2.4, P<0.05). Figure 2.4.A-D shows the data separately by sex, line, day and dose.   
When the locomotor data were analyzed collapsed across the test days, results showed a 
significant effect of line (F1,46 = 83.2, P<0.0001), dose (F3,46 = 5.3, P=003), sex (F1,46 = 23.5, P<0.0001), 
line*sex (F1,46 = 26.0, P<0.0001), and line*dose (F3,46 = 3.3, P=0.03) (Table 2.2). When the locomotor 
activity data for the amphetamine groups were expressed as a difference score relative to their 
47 
 
respective saline controls (i.e., within each sex and line), results of the overall ANOVA showed a 
significant effect of line (F1,25 = 11.7, P=0.0016), dose (F2,35 = 9.1, P=0.0007), and line*dose (F2,35 = 4.4, 
P=0.02; Fig. 2.5). No other main effects or interactions were significant. The interaction between line 
and dose in these analyses is due to the low dose of amphetamine reducing locomotor activity in the 
High-Active line while increasing activity in the Control line (Fig. 2.5). This was indicated by a significant 
post-hoc Tukey test comparing the response to amphetamine at 0.25 mg/kg between Control and High-
Active mice (P=0.0024). Tukey tests between High-Active and Control mice for 0.5 mg/kg and 2 mg/kg 
were not significant. The differential responses to low, clinically relevant doses of d-amphetamine 
between the lines in both sexes are likely correlated responses to selection as opposed to consequences 
of genetic drift (Table 2.2). 
Morris Water Maze  
Acquisition (Fig. 2.6. A-D): On average, animals learned the Morris water maze as indicated by 
decreased path length with day (F4,128 = 34.7, P < 0.0001). In addition to a main effect of day, the overall 
analysis of variance indicated a significant effect of line (F1,32 = 5.6, P = 0.02), and interaction between 
day and line (F4,128 = 4.2, P = 0.003). No main effects or interactions with dose were detected. However, 
Figure 2.6 indicates that the learning curves for High-Active and Control mice were very similar following 
saline injections, but that the High-Active mice show impairment after amphetamine treatment, 
particularly on days 2 and 3. In an analysis that considered only days 2 and 3 (the days when most of the 
learning occurred), a trend for a significant interaction between line and dose was observed (F3,32 = 2.7, 
P = 0.06). Post-hoc Tukey tests indicated significant differences between High-Active and Control lines at 
the 0.5 mg/kg (P = 0.013) and 2 mg/kg (P = 0.008) doses of amphetamine. The impaired performance on 
the water maze in the High-Active line is likely a correlated response to selection as opposed to a 
consequence of genetic drift (see results for day 2; Table 2.2). 
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Probe test: On average, animals remembered the spatial location of the platform as indicated by 
significantly greater duration spent in the target quadrant than would be expected by chance (t38 = 2.8, P 
= 0.008). The average duration spent in the target quadrant across all animals was 28.3% ± 1.19 SE. No 
significant effects of line, dose or interaction were detected (data not shown).  
Immunohistochemistry 
c-Fos-DAB (Fig. 2.7.A): The 3-way ANOVA indicated a significant main effect of line (F1,64 = 24.3, P 
< 0.0001) and sex (F1,64 = 11.5, P = 0.001). No main effect of dose or any interactions were detected. 
Control mice displayed approximately 50% the number of c-Fos cells as compared to High-Active mice 
and males displayed approximately 55% the number as females.  
BrdU-DAB (Fig. 2.7.B): The 3-way ANOVA indicated a significant main effect of line (F1,61 = 5.3, P 
= 0.025) and sex (F1,61 = 8.7, P = 0.004). No main effect of dose or any interactions were detected. 
Control mice displayed approximately 77% the number of BrdU positive cells as compared to High-Active 
mice and males displayed approximately 71% the number as females.  
Correlation between locomotor activity, BrdU-DAB, and c-Fos-DAB 
The distance traveled within 90 min preceding euthanasia (Test 5) was strongly correlated with 
total number of c-Fos positive cells in the granule layer of the dentate gyrus (Pearson’s r = 0.67; F1,62 = 
51.7, P < 0.0001) (Fig. 2.8.A). After including distance traveled as a covariate in a 3-way ANOVA with 
factors line, sex and dose, no other factor or interaction was significant, indicating that the differences in 
number of c-Fos cells shown in Fig. 2.7.A can be explained by differences in locomotor activity.  
The distance traveled within 90 min preceding euthanasia (Test 5) was also correlated with total 
number of BrdU-positive cells in the granule layer (Pearson’s r = 0.40; F1,59 = 11.6, P = 0.001) (Fig. 2.8.B). 
After including distance traveled as a covariate in the 3-way ANOVA, no other factor or interaction was 
significant except for dose (F3,44 = 3.3, P = 0.03). Comparison of least square means indicated that the 
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0.25 mg/kg dose increased BrdU-positive cells to 111% of saline levels, whereas 0.5 mg/kg reduced 
BrdU-positive cells to 87% of saline levels, and 2 mg/kg reduced BrdU-positive cells 65% of saline levels. 
Numbers of c-Fos-positive cells were correlated with numbers of BrdU-positive cells in the 
granule layer of the dentate gyrus (Fig. 2.8.C). The correlation without 2 outliers (with c-Fos numbers 
above 10,000) shown in Figure 2.8.C was 0.67 (F1,73 = 58.6, P < 0.0001), and with the outliers present, the 
correlation was 0.51 (F1,75 = 26.8, P < 0.0001).  
 Table 2.2 indicates that the difference in BrdU cells between the lines is within the range 
expected by genetic drift. However, the phenotypic correlation between distance traveled and number 
of BrdU cells (Fig. 2.8.B) supports the conclusion that the line difference is probably a correlated 
response to selection via the intermediate phenotype of physical activity. 
Discussion 
Here we report an update on the progress of a selective breeding experiment for increased 
distance traveled in the home cage through Generation 10, and initial evidence that the hyperactivity 
demonstrated by High-Active mice is ameliorated by the low (0.25 mg/kg) dose of d-amphetamine. The 
differential responses to the low doses of amphetamine were likely a correlated response to selection 
rather than a consequence of genetic drift, providing support for the suitability of the High-Active line to 
model genetic hyperactivity disorders. Importantly, the High-Active line continues to respond to 
selection without reaching a clear selection limit (Fig. 2.2.A). Body mass at maturity significantly 
decreased in the High-Active line as compared to the Control line. The line difference is likely a 
correlated response to selection for home cage activity, and unlikely caused by random factors such as 
genetic drift (Fig. 2.2.C, Table 2.2). Small differences between the lines were detected in wheel running, 
open field, rotarod performance, and water maze performance, but these differences may not be 
definitely ascribed to the effects of selection, and could have resulted from genetic drift rather than 
correlated responses to selection (Table 2.2). The increased number of BrdU cells in the in the dentate 
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gyrus observed in High-Active mice is likely attributable to the neuronal activation (as measured by 
number of c-Fos positive cells) of the dentate gyrus associated acutely with increased levels or intensity 
of physical activity. Further work, including replicating the High-Active lines, will be necessary for greater 
statistical power to detect genetic correlations for these and other relevant traits.  
The reduction in number of successful pairings of High-Active parents relative to unselected 
Controls potentially indicates less viable offspring or impaired maternal competence in High-Active mice 
(Fig. 2.2.B). Future studies will determine whether instinctual maternal care is compromised by selection 
for hyperactivity, or whether pups are simply less viable. Some evidence suggests that maternal neglect 
has been linked to altered dopamine neurotransmission in key reward regions of the brain (Gammie et 
al., 2008), and selection for physical activity in other lines has itself been shown to alter those reward 
pathways (Rhodes et al., 2005; Garland et al., 2011b). Therefore, it is possible that over ten generations 
of selective breeding for hyperactivity has altered dopamine neurotransmission, which then produced 
secondary deficits in maternal care. Alternatively, as the High-Active mice exhibit lower body weights 
overall (Fig. 2.2.C) and during weaning (unpublished observations) it is possible High-Active pups are less 
viable. Interestingly, clinical studies have associated lower body weight at birth with the development of 
ADHD later in life (Mick et al., 2002; Lahti et al., 2006; Strang-Karlsson et al., 2008). Regardless of the 
cause of reduced reproductive success, this phenomenon may become a significant contributor to the 
continued divergence of our High-Active populations. For example, diminished reproductive success at 
Generations 5 and 8 reduced the selection differential and response to selection in generations 6 and 9 
(Fig. 2.2.A and B; Table 2.1).  
In addition to reduced reproductive success, the High-Active mice also display reduced body 
mass at maturity (Fig. 2.2.C). The difference in body mass between the lines survives the test of whether 
these results could be due to genetic drift represented in Table 2.2, suggesting the differences in body 
mass between the lines are probably not caused by genetic drift alone, and that selection likely 
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contributed to this effect. In a replicated selective breeding experiment for increased voluntary wheel 
running, a negative genetic correlation between levels of physical activity and body mass was also 
observed (Swallow et al., 1999). Taken together, these data provide strong support for the hypothesis 
that body mass at maturity and levels of physical activity in a habituated environment broadly speaking 
(e.g., as measured in cages without wheels or with wheels) are negatively genetically correlated. Further 
experiments are needed to determine whether the reduced body mass in our High-Active line results 
from a combination of reduced body fat and reduced skeletal length similar to mice selectively bred for 
increased voluntary wheel running behavior (Swallow et al., 1999, 2001; Houle-Leroy et al., 2003).  
Another interesting comparison to clinical populations arises from the enhanced activity of 
females in our High-Active strain (Figs. 2.2.A and 2.3.A). While many other studies across different 
strains of mice and within other populations selectively bred for physical activity corroborate our 
observation of increased female activity relative to males (Clark et al., 2011; Garland et al., 2011a), our 
High-Active female hyperactivity contrasts clinical ADHD populations in which males tend to be 
diagnosed more frequently with ADHD Hyperactive Type, while females more frequently present as 
ADHD Inattentive Type (Gaub and Carlson, 1997; Gershon, 2002). Despite the preponderance of 
Hyperactive Type males in clinical literature, some females also exhibit a hyperactivity component to 
their ADHD diagnosis. The lack of clinical data on female children with ADHD Hyperactive Type 
contribute to an especially poor understanding of the neurobiological underpinnings in hyperactive 
female populations (Rucklidge, 2010), and our selectively bred population may be useful in elucidating 
these characteristics. 
Our characterization of a subset of mice from Generation 10 (whose activity levels approximate 
the entirety of Generation 10, as shown in Fig. 2.3.A) shows differences in wheel running and open field 
locomotor activity between the lines (Fig. 2.3.B & C). However, Table 2.2 indicates that we cannot rule 
out the possibility that these differences are a result of genetic drift, rather than selection. Data from 
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the original report in Zombeck et al. (2010) favor the drift hypothesis rather than selection because in 
that study we observed no significant genetic correlation between wheel running or open field activity 
and home cage physical activity, but significant heritability of wheel running and open field in the 
starting population. Although wheel running might be hypothesized to be correlated with home cage 
activity, open field is expected to have different genetic underpinnings. Behavior in the open field test is 
thought to indicate exploratory behavior, or anxiety in a novel environment (Choleris et al., 2001), as 
distinct from behavior in a habituated home environment.  
The differential performance on the rotarod between the High-Active versus Control line did not 
survive the test for possible role of genetic drift (Figs. 2.3.D & E, Table 2.2). Therefore the small 
reduction in performance (Fig. 2.3.E) may not be related to selection, and could be caused by genetic 
drift. Replication of the lines would help resolve the selection versus drift issue. If the difference is 
related to selection, reduced rotarod performance in High-Active mice could have clinical relevance. 
Rotarod performance is generally considered to reflect cerebellar-mediated coordination (Goddyn et al., 
2006), and the current data demonstrate impaired performance. The reason for the impairment could 
be one of two possibilities - that High-Active mice are less coordinated than Controls, or that they lack 
the attentional control necessary to successfully focus on the task. Regardless of the source of the 
impairment, it will be interesting to further characterize the High-Active model by directly correlating 
total cerebellar and vermis volume with rotarod performance, as this could corroborate mounting 
clinical evidence which implicates the cerebellum in the neuropathology underlying hyperactivity 
disorders such as ADHD. While some studies indicate cerebellar volume does not vary between mice 
selectively bred for increased wheel running behavior and control lines (Kolb et al., 2013), it may be that 
selection for home cage hyperactivity will produce different effects on brain volume measurements. 
Studies suggest that the cerebellum is important in not only motor coordination, but also mediating 
timing and attention functions through frontal associations (Allen et al., 1997), and children with ADHD 
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have significantly smaller cerebellar hemispheres and smaller posterior-inferior vermal volumes (Mackie 
et al., 2007; Bledsoe et al., 2009; Cherkasova and Hechtman, 2009). Taken together, this evidence has 
resulted in the generation of the frontostriatal-cerebellar theory of ADHD (Krain and Castellanos, 2006), 
and provides another avenue by which we may characterize these High-Active mice. 
The second aim of this paper was to determine whether chronic, therapeutic doses of d-
amphetamine ameliorated hyperactivity in the High-Active lines. Toward this end, we observed that the 
low dose of 0.25 mg/kg amphetamine significantly reduced locomotor activity in our High-Active line 
whereas the same doses increased locomotor activity in the Control line (see Figure 2.5). The differential 
response to low dose amphetamine between our lines is most likely a correlated response to selection 
rather than a consequence of genetic drift (Table 2.2). Results establish the predictive validity of our 
model with respect to ameliorative effects of therapeutic doses of amphetamine on the hyperactive 
phenotype. Future studies will focus on evaluating the effect of daily 0.25 mg/kg amphetamine on other 
behavioral measures relevant to ADHD, such as impulsivity and inattention. 
The third aim of this paper was to determine whether chronic amphetamine influences neuronal 
activation of the dentate gyrus and number of newly divided cells, as previous results from our lab using 
the exact dosing regimen over the same developmental period found dose-dependent increases in 
neurogenesis in C57BL/6J mice (Dabe et al., 2013). However, in the current study, no changes in the 
number of new cells in the dentate gyrus were observed in response to amphetamine without adjusting 
for the effects of distance traveled. After adjusting for distance traveled, the higher doses, 0.5 and 2 
mg/kg, reduced numbers of BrdU+ cells. Although we did not perform a double label analysis to detect 
co-labeling between BrdU and a mature neuronal marker such as NeuN to confirm that the BrdU cells 
were in fact neurons, based on previous work in our lab, it is likely that a majority of these new cells 
were neurons (probably greater than 80%) (Clark et al., 2011). It is possible that the increase in 
neurogenesis from amphetamine observed in Dabe et al. (2013) is specific to the C57BL/6J genotype. 
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The High-Active and the Control lines in this study were derived from a cross of 8 divergent strains 
(including 3 subspecies) and the individuals within the lines are expected to display a large degree of 
genetic variation as supported by the low inbreeding coefficient estimated in Table 2.2. Hence, if the 
influence of amphetamine on neurogenesis is highly genotype-specific, then large individual genetic 
variation in our lines would be expected to obscure detection of a response characteristic of a single 
genotype such as C57BL/6J. 
Although group differences in neuroplasticity markers (c-Fos expression and BrdU positive cells) 
were not observed in response to amphetamine, significant line differences were detected. Mice from 
the High-Active lines displayed greater numbers of c-Fos and BrdU positive cells than mice from Control 
lines. The difference is likely due to the different levels of physical activity displayed by the animals and 
the strong phenotypic relationship between distance traveled and the outcome variables (Fig. 2.8.A-C). 
 We endeavored to measure the Morris Water Maze (MWM) because we hypothesized that the 
High-Active mice might display poor performance relative to Control lines due to their inherent 
inattention, and that the amphetamine might ameliorate some of this decline. The MWM is also a 
hippocampal dependent task, and we hypothesized that changes in the number of new cells in the 
hippocampus or neuronal activation between the groups might relate to performance. While previous 
literature has reported that d-amphetamine facilitates learning in the MWM (Brown et al., 2000), in the 
present study all animals learned the task over 5 days without any overall significant effect of 
amphetamine. A significant effect of line was detected, with High-Active mice performing worse than 
Control. Inspection of Figure 2.6 indicates that the difference was most apparent at the higher doses of 
amphetamine. Results suggest impaired performance in High-Active mice relative to Controls on day 2 is 
likely a correlated response to selection rather than a consequence of genetic drift (Table 2.2). The 
difference might reflect inattention or inherently reduced hippocampal function in High-Active mice. 
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Regardless of the cause, the water maze performance in High-Active mice was certainly not improved 
with amphetamine, and if anything, was impaired.   
Results from this study provide support for using the High-Active mice as a model for ADHD. 
High-Active mice performed significantly worse on the water maze and rotarod which could be related 
to their inattention or inability to focus on the task at hand. However, attributing their performance to 
inattention or any other cognitive construct would have to be evaluated empirically using operant tests 
such as serial reaction time or Go/No-go tasks (Bari and Robbins, 2013). Moreover, if the impaired 
performance was caused by inattention it certainly was not ameliorated with amphetamine as is 
typically observed in ADHD (see Fig. 2.6). On the other hand, amphetamine significantly ameliorated the 
hyperactivity in the High-Active line. Current studies are already in progress characterizing impulsive-like 
behavior in these High-Active mice, using the Go/No-go paradigm (Moschak and Mitchell, 2012). It will 
be interesting to observe whether impulsivity is affected by our continued selection for home cage 
hyperactivity, and the extent to which that impulsivity is ameliorated by d-amphetamine. Moreover, it 
will be important to evaluate whether the High-Active mice display any reduced dopamine function in 
prefrontal regions before continuing to evaluate this model in the context of ADHD (Arnsten, 2009).  
In conclusion, our High-Active mouse line provides a unique tool which may be used to evaluate 
the genetic and neurobiological mechanisms underlying hyperactivity and its correlated responses such 
as reduced body mass, reduced reproductive success, and locomotor response to amphetamine 
administration. Results support the continued development of the High-Active line as a model for ADHD. 
Future studies will compare attention, impulsivity-like behavior, cerebellar volume and various 
measures of dopamine function between the lines.  
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Tables and Figures 
 
Generation S (km/day) R (km/day) h
2
realized 
1 0.27 0.12 0.44 
2 0.36 0.25 0.69 
3 0.87 0.051 0.06 
4 0.56 0.22 0.39 
5 0.43 0
a 
0 
6 0.14 0.31 1
b
 
7 0.82 0
a 
0 
8 0.64 0.025 0.04 
9 0.53 0.5 0.94 
Avg. 0.51 0.16 0.40 
 
Table 2.1 Realized heritability (h
2
realized) estimates of home cage activity. 
a
The actual value was negative. 
b
The actual value was above 1.0. S refers to the selection differential while R refers to the response to 
selection. 
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Table 2.2. The magnitude and statistical significance of between-line differences in secondary traits 
expressed in standardized phenotypic SD units (Dy) and compared to 95% confidence intervals (95% CI) 
for Dy as computed from Equation 1 in the text. h
2
 references are as follows: Body Mass (Falconer, 1973; 
Table 5); Gen 10 Cohort Home Cage Activity and Wheel Running (Zombeck et al., 2011; Table 1 and 
Figure 6c); Open Field (DeFries et al., 1970); Rotarod (Belknap et al., 1993; Rustay et al., 2003); 
Amphetamine Response (Alexander et al., 1996); Morris Water Maze latency (Galsworthy et al., 2005; 
Table 4); Total number of new cells in dentate gyrus (Clark et al., 2011). 
a
Body Mass refers to Generation 
Secondary Trait Figure Sex High-Active line Control line p-value h
2
F n 95% CI Dy
Body mass (g)
a
2.2.C Male 23.48 (±0.44) 27.53 (±0.87) <0.0001 0.37 0.06217 24 1.00 -1.08
Female 18.58 (±0.29) 22.32 (±0.77) <0.0001 0.37 0.06217 24 1.00 -1.35
Gen 10 Cohort Home Cage 
Activity (km/day) 2.3.A Male 1.10 (±0.20) 0.31 (±0.05) 0.002 0.33 0.06217 24 0.98 1.68
Female 1.83 (±0.28) 0.34 (±0.05) <0.0001 0.33 0.06217 24 0.98 2.35
Wheel running (km/day) 2.3.B Male 8.34 (±0.73) 4.90 (±0.62) 0.002 0.39 0.06217 24 1.01 0.57
Female 9.79 (±1.40) 9.30 (±0.83) NS 0.39 0.06217 24 1.01 0.14
Open Field (m)
2.3.C Male 45.88 (±4.41) 27.14 (±2.72) 0.003 0.13 0.06217 24 0.87 0.55
Female 37.65 (±2.60) 29.12 (±4.01) NS 0.13 0.06217 24 0.87 0.80
Rotarod (s)
b
2.3.D Male 49.06 (±4.09) 50.54 (±3.55) NS 0.44 0.06217 24 1.03 -0.04
2.3.E Female 39.28 (±3.83) 58.56 (±8.95) 0.026 0.44 0.06217 24 1.03 -0.89
Response to 0.25 mg/kg 
Amphetamine (m/90 min)
c
Collapsed (test) 2.4.A+B Male -43.42 (±22.74) 61.82 (±26.29) 0.023 0.21 0.06217 22 0.95 -2.18
2.4.C+D Female -84.55 (±31.02) 27.84 (±17.47) 0.02 0.21 0.06217 22 0.95 -2.23
Response to 0.5 mg/kg 
Amphetamine (m/90 min)
c
Collapsed (test) 2.4.A+B Male -1.20 (±28.57) 16.24 (±7.50) NS 0.21 0.06217 22 0.95 -1.64
2.4.C+D Female -53.78 (±17.46) 27.42 (±8.89) 0.006 0.21 0.06217 22 0.95 -2.93
Response to 2 mg/kg 
Amphetamine (m/90 min)
c
Collapsed (test) 2.4.A+B Male 70.43 (±41.36) 64.94 (±21.31) NS 0.21 0.06217 22 0.95 0.09
2.4.C+D Female 58.13 (±58.16) 59.33 (±17.73) NS 0.21 0.06217 22 0.95 -0.02
Morris water maze latency 
(m) 2.6.A-D
Day 1
Collapsed 
(sex, dose) 10.64 (±0.64) 11.74 (±1.05) NS 0.24 0.06217 22 0.96 -0.28
Day 2
Collapsed 
(sex, dose) 9.36 (±0.92) 5.09 (±0.63) 0.001 0.24 0.06217 22 0.96 1.21
Day 3
Collapsed 
(sex, dose) 6.21 (±0.92) 3.50 (±0.53) 0.015 0.24 0.06217 22 0.96 0.80
Day 4
Collapsed 
(sex, dose) 5.48 (±0.81) 4.26 (±0.71) NS 0.24 0.06217 22 0.96 0.36
Day 5
Collapsed 
(sex, dose) 3.97 (±0.84) 3.50 (±0.52) NS 0.24 0.06217 22 0.96 0.15
Total number of new cells 
in dentate gyrus                            
(#  BrdU+ cells)
d
2.7.B Male 5313.02 (±421.51) 4173.35 (±588.72) NS 0.53 0.06217 22 1.10 0.27
Female 7592.58 (±758.05) 5787.87 (±684.44) 0.045 0.53 0.06127 22 1.10 0.59
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10. 
b
Rotarod refers to average latency of the 4 trials per day over three days. 
c
Locomotor response to 
amphetamine expressed as a difference score relative to the saline group of each sex and line. 
d
Total 
number of new cells in dentate gyrus refers to average total number of BrdU cells in the granule layer of 
the dentate gyrus collapsed across dose. Standard errors are shown in parentheses next to means for 
the secondary phenotypic traits under “High-Active line” and “Control line”. “P-value” refers to a pair-
wise comparison of the High-Active line versus the Control line. "F" refers to the inbreeding coefficient 
estimated from the entire pedigree. “n” refers to the number of families represented for the specific 
phenotypic trait that was analyzed. “95% CI” refers to the 95% confidence interval for Dy expected by 
genetic drift as calculated from Equation 1 in the text. “Dy” refers to the difference between lines in 
standardized phenotypic units. Dy values larger than the 95% CI are shown in bold and provide evidence 
that the secondary trait has evolved as a correlated response to selection for home cage activity. 
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Figure 2.1. Time-course for Experiment 2. Animals were administered twice daily i.p. injections of saline, 
0.25, 0.5, or 2 mg/kg d-amphetamine (n= 5 per sex/line/treatment = 80 total) for 49-51 days, starting 
from when the mice were 23 days old (Experimental day 1) and continuing until they were 73 days old 
(Experimental day 51). Mice also received 10 daily i.p. injections of BrdU (50 mg/kg) to label dividing 
cells on experimental days 1-10 (mouse age 23–32 days old). On Experimental days 16-18 and 40-42, 64 
mice/80 total were placed in specialized cages which allowed for video tracking of home cage locomotor 
behavior (Tests 1-4). Prior to the first locomotor activity session, mice were separated from group 
housing conditions and individually housed to allow for individual locomotor tracking. Mice then 
remained singly housed throughout the duration of the experiment. On Experimental days 43-48, 40 
mice/80 total were tested on the Morris water maze (MWM). On Experimental days 49-51, the same 64 
mice were placed in the specialized home cages to allow for video tracking one final time (Test 5), then 
staggered over the course of the next two days for systemic perfusions with 4% paraformaldehyde 
exactly 90 min. following the final injection for each mouse. 
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Figure 2.2. Home cage activity, reproductive success and body mass across generations. A) Data points 
represent the population means (±SE) from each generation for home cage activity (distance traveled on 
days 5 and 6 in km/day). Males and females are plotted separately. B) Every generation, 14 pairs of 
High-Active mice and 14 pairs of Control mice were paired to produce the next generation. The total 
number of successful pairings from each line for generation are represented here (14 max). C) Average 
body mass (±SE) at the time of home cage phenotyping, PND 60-66. Males and females are plotted 
separately.  
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Figure 2.3. Locomotor activity and motor performance in the High-Active and Control lines from 
Generation 10. Males and females are plotted separately (n=10 High-Active males, n= 9 Control males, 
n= 10 High-Active females, n=10 Control females). A) Average distance traveled in the home cage (±SE) 
on days 5 and 6 (km/day) for the same animals shown in B-E. B) Average distance traveled on a running 
wheel (±SE) over 5 days (km/day). C) Average distance traveled in the open field (±SE), across 2 daily 5-
minute open field tests (m/5 min). D and E) Average latency (±SE) to fall off the accelerating rotarod 
(sec) averaged across 4 sessions per day.  
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Figure 2.4. Locomotor activity following saline or amphetamine administration. A) Average (±SE) 
distance traveled in the home cage by Control males within a 90 min period following an i.p. injection of 
saline, 0.25. 0.5, or 2 mg/kg d-amphetamine across 5 separate test days (Tests 1 and 2 occurred on 
postnatal days 41 and 42; Tests 3 and 4 occurred on postnatal days 63 and 64; Test 5 occurred between 
postnatal days 71 and 73 just prior to sacrifice). Each test day is an average of morning and afternoon 
injections. B), C), and D) Same as A) for cohorts of High-Active males, Control females, and High-Active 
females, respectively. The same 64 mice underwent video tracking on all Tests 1-5 
(n=4/sex/line/treatment = 64 total).  
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Figure 2.5. Locomotor response to amphetamine. Average (±SE) locomotor response to 0.25, 0.5, and 2 
mg/kg amphetamine in the Control and High-Active lines. Response was calculated for each individual 
receiving amphetamine as the distance traveled 90 minutes after administration of amphetamine minus 
the average distance traveled by the saline group from the same sex and line. Hence negative values 
indicate a suppression of locomotor activity from amphetamine whereas positive values indicate 
stimulation. Results are shown collapsed across sex (n=8/line/treatment = 64 total). 
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Figure 2.6. Morris water maze acquisition in response to amphetamine. A) Average (±SE) path length (m) 
to reach the submerged, hidden platform on each day, 15 minutes after receiving an afternoon i.p. 
injection of saline (n=3 High-Active males, n=3 Control females, n=2 Control males, n=2 High-Active 
females; n=10 total). B), C), and D), Same as A) except for the administration of 0.25 mg/kg d-
amphetamine, 0.5 mg/kg d-amphetamine, or 2 mg/kg d-amphetamine, respectively.  
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Figure 2.7. Hippocampal activation and growth of new cells in response to amphetamine. A) Average 
(±SE) total number of c-Fos-positive cells in the dentate gyrus granule layer of the hippocampus. B) 
Same as A for BrdU-positive cells. 
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Figure 2.8. Correlations between cellular activation, growth of new cells in the dentate gyrus, and 
locomotion. A) Phenotypic correlation between total number of c-Fos+ cells and distance traveled (m) 
within the 90 minute period prior to euthanasia (n=4/sex/line/treatment = 64 total). B) Same as A for 
BrdU+ cells. C) Phenotypic correlation between total number of c-Fos+ cells and total number of BrdU+ 
cells for all mice, regardless of whether they underwent video tracking (n=5/sex/line/treatment = 80 
total).  
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Abstract 
ADHD is a major societal problem with increasing incidence and a stagnant track record for treatment 
advances. A lack of appropriate animal models has partly contributed to the incremental advance of this 
field. Hence, our goal was to generate a novel mouse model that could be useful for ADHD medication 
development. We reasoned that hyperactivity is a core feature of ADHD which could easily be bred into 
a population, but to what extent other hallmark features of ADHD would appear as correlated responses 
was unknown. Hence, starting from a heterogeneous population we applied within-family selection over 
16 generations to produce a High-Active line, while simultaneously maintaining an unselected line to 
serve as the Control. We discovered that the High-Active line demonstrate motor impulsivity in two 
different versions of the Go/No-go test which was ameliorated with a low dose of amphetamine, and 
further display hypoactivation of the prefrontal cortex and dysregulated cerebellar vermal activation. 
We conclude that the High-Active line represents a valid model for the Hyperactive-Impulsive subtype of 
ADHD which should be used in future studies to advance our understanding of etiology of ADHD and 
screen novel compounds for its treatment.  
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Introduction 
Despite the prevalence of Attention-Deficit/Hyperactivity Disorder (ADHD) in our society, and 
our readiness to dispense pharmaceutical interventions, much of the underlying etiology remains 
unknown. Core deficits include hyperactivity, inattention, and impaired action inhibition (Barkley, 1997, 
Nigg, 2001, Castellanos et al., 2006). U.S. prevalence rates among children and adults are substantial, 
and while many children in the U.S. (4.8%) are currently medicated for ADHD, little is known regarding 
the long-lasting impact of these medications on cognitive health in adulthood(Kessler et al., 2006, 
Zuvekas et al., 2006, Berman et al., 2009). 
ADHD is a multifactorial, highly heritable disorder, with twin studies estimating a mean 
heritability of 76 percent (Faraone et al., 2005). Despite high heritability estimates, the specific network 
of genes implicated in ADHD are not known (Neale et al., 2010). Candidate gene studies that place 
narrow focus on evaluating components of dopamine and norepinephrine signaling(Gizer et al., 2009, 
Elia et al., 2012) are associated with small odds ratios that some have argued may be false positives(Flint 
and Munafo, 2013). Overall, the genes currently associated with ADHD are estimated to account for a 
small fraction of the total genetic variation (Kuntsi et al., 2006, Elia and Devoto, 2007, Neale et al., 
2010). A novel approach is needed for a more complete understanding of the genetic underpinnings of 
ADHD. An improved understanding of the genetic basis of ADHD will lead to improved, targeted 
therapeutic approaches. 
Several animal models of ADHD currently exist but none of them were developed specifically for 
the purpose of modeling the multifactorial, genetic foundation of ADHD. Single-gene mutant rodent 
models of ADHD are critical for understanding the contribution of monoaminergic pathways on ADHD 
pathology and treatment response (Leo and Gainetdinov, 2013), yet they are unable to elucidate the 
broader network of genes mediating behavioral deficits associated with ADHD. Lesion-based models are 
limited since ADHD is known to involve dysregulation of multiple brain regions, such as the prefrontal 
74 
 
cortex (PFC), striatum, and cerebellum (Durston et al., 2011, Castellanos and Proal, 2012). Arguably the 
most well studied model of ADHD is the spontaneously hypertensive rat (SHR), which has shown 
hyperactivity, impulsivity, and inattention (Sagvolden, 2000). However, the SHR is limited in two 
important aspects: 1) the model was selectively bred for hypertension, therefore it is difficult to 
disassociate the effects of hypertension from hyperactivity, and 2) the SHR lacks an appropriate control 
strain to statistically determine whether phenotypic differences between the lines are related to 
hyperactivity or other factors. The commonly utilized control, the Wistar-Kyoto rat (WKR), often 
demonstrates activity levels below that of other rats, and has even been suggested as a model of 
depression (Drolet et al., 2002, Rittenhouse et al., 2002, van den Bergh et al., 2006, Ferguson et al., 
2007). Therefore, as most studies compare the SHR against only the WKR, it is difficult to determine 
whether the differences between the strains are related to hyperactivity/ADHD-related phenotypes, 
hypertension, depression, or any number of other features that differs between these two highly 
divergent strains.  
In the present work, we developed a line of mice specifically to model core features of ADHD 
along with an appropriate Control line for discovery-based research. In brief, we have been maintaining 
2 lines of mice, one that is bred for increased physical activity in their home cage each generation and 
the other which is randomly bred with respect to physical activity. We previously reported strong 
response to selection, correlated responses with other measures of physical activity and paradoxical 
locomotor responses to amphetamine (Majdak et al., 2014). Hallmark features of ADHD also include 
impulsivity and inattention. Further, evidence suggests that AHDH in humans is associated with a 
hypofunctioning prefrontal cortex and dysregulated cerebellar vermal functioning (Rubia et al., 1999, 
Zang et al., 2007, Durston et al., 2011). Hence, the goal of this study was to determine the extent to 
which the High-Active line recapitulates other core features of ADHD, including motor impulsivity across 
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2 versions of the Go/No-go task, alleviation of impulsive action via amphetamine, inattention on the Y-
maze, and the functionality of implicated brain regions such as the PFC and cerebellum.  
Materials and Methods  
Animals 
Mice from Generation 15 (Experiment 1) and Generation 16 (Experiments 2 & 3) of a selective 
breeding experiment for increased distance traveled in the home cage were used (Zombeck et al., 2011, 
Majdak et al., 2014). Our lab maintains two lines of genetically variable mice: a randomly bred, 
unselected (Control) line and a line selectively bred for increased distance traveled in the home cage 
(High-Active). Inbreeding is minimized via within-family selection. The starting population for each line 
was generated by systematically crossing 8 different inbred strains, chosen to maximize genetic 
variation (Collaborative Cross mice (Chesler et al., 2008)). Each generation at weaning on postnatal 
(PND) 21, mice are group-housed by sex. At approximately PND 60, mice are phenotyped for home cage 
activity. Mice are placed in custom-made acrylic home cages (18.5 cm x 33.5 cm x 16 cm) with clear 
plastic lids that allow continuous ceiling-mounted video tracking by TopScan (CleverSystems, Reston, VA, 
USA). Each cage individually houses 4 mice by sex, with an interaction zone constructed of wire mesh 
that allows for limited physical contact and interaction. The video coverage allows for continuous 
tracking of 64 individual mice over the span of 6 days. Well after an extended habituation period of 4 
days, the average distance traveled during days 5 and 6 is used as the selection criterion (Zombeck et al., 
2011, Majdak et al., 2014). 
General husbandry 
Rooms are kept controlled for temperature (21 ± 1°C) and photo-period (12:12 L:D; lights on at 
8:00 PM and off at 8:00 AM). All behavioral testing occurred during the dark cycle. Food (Harlan Teklad, 
7012) and water were provided ad libitum, except during operant training and testing. Mice were group 
housed by sex after weaning, individually phenotyped in custom-built plexiglass cages, and then 
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individually housed in standard shoebox cages. Corncob bedding (7097 Harlan Teklad, Madison, 
Wisconsin, USA) was provided in all cages. The Beckman Institute Animal Facility is AAALAC approved. 
All procedures were approved by the University of Illinois Institutional Animal Care and Use Committee 
and adhered to NIH guidelines. 
Apparatus for operant conditioning 
For Go/No-Go testing, 6 identical modular operant test chambers (12 x 9.5 x 8.25 in) for mice 
(Med Associates Inc., St. Albans, VT) were each housed within a standard MDF sound-attenuating 
cabinet (22 x 15 x 16 in). A house light (28 V DC, 100 mA) is installed opposite the nose poke holes. A 
tone generator (Sonalert, 2,900 Hz) is mounted next to the house light. Within the chamber are three 
nose-poke recesses. The left and right recesses have a yellow LED stimulus (cue light) directly within the 
hole. The center nose-poke recess has no light but is equipped with a lever to dispense a sucrose reward 
(10% w/v) via a 0.01 cc stainless steel cup. The grid floor of the chamber consisted of 24 stainless steel 
rods (0.13 inch diameter rods spaced at 0.31 inches) mounted in polycarbonate supports. A computer 
program written in MED-PC (Med Associates Inc.) controlled the output devices and recorded 
responses. 
General procedure for operant conditioning & variables of interest 
We followed the general procedure outlined by Mitchell and colleagues to compare Go/No-go 
impulsivity measures in multiple strains of mice, as this paradigm provided published heritability 
estimates (Gubner et al., 2010). Mice were food restricted for 3 days prior to Training Phase 1, and this 
food restriction continued throughout operant training and testing. After successfully completing 
training Phase 1 by achieving 30 correct “hits” (nose poke response to the Go cue light) in under 40 
minutes, for two consecutive days, mice progressed to Phase 2. In Phase 2, the cue was illuminated for 
only 10 seconds. After completing Phase 2 using the same criteria as Phase 1, mice are considered to 
have an established prepotent motor response (Gubner et al., 2010) (Fig. 3.1.A). Not all mice passed 
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these training phases, hence resulting in the unbalanced sample sizes listed for each subsequent 
experiment. Mice then underwent Go/No-go testing as outlined below. For all experiments, mice that 
failed to collect their earned sucrose reward during Go/No-go testing were excluded from analysis. 
Variables of interest from Go/No-go testing included hits (nose pokes in response to a Go cue light), 
false alarms (incorrect nose pokes in response to a No-go cue), the latency to make a hit or false alarm, 
precue responses (nose pokes during the last 3 seconds of the precue period), cue-side pokes (random 
poking in cue recess in absence of any cue, i.e. during the precue, reward, or darkened intertrial interval 
periods), and efficiency (total reinforcers earned/total number of nose pokes). 
Experiment 1: Evaluating two discrepant Go/No-go procedures 
Impulsivity was measured in High-Active and Control mice using two Go/No-go procedures that 
differed in the sensory cues used to elicit inhibition. In Version 1, testing was conducted over 10 daily 
sessions during which the Go cue was the nose poke cue light, and the No-go cue was a tone. This 
version closely resembles the published procedure across multiple strains (Gubner et al., 2010). In 
Version 2, Go/No-go testing was conducted over 20 daily sessions during which the Go cue is the nose 
poke cue light, while the No-go cue is the simultaneous presentation of the Go cue and a tone. This 
version is similar to previously published methods using concurrent light and tone to signal a No-go cue 
(McDonald et al., 1998, Loos et al., 2010), and was included because it demands a stronger level of 
behavioral inhibition than Version 1. In Version 1 the mouse must inhibit prepotent responding to a tone 
that was never paired with reward, but in Version 2 the mouse must inhibit their prepotent response to 
the light cue that was originally paired with reward when it co-occurs with a tone.  
A total of 22 High-Active (n=11 males and n=11 females) and 16 Control (n=8 males and n=8 
females) mice were phenotyped for home cage activity at PND 60-70. Individuals were from distinct 
families within each sex. Eight weeks after home cage phenotyping, mice (PND 116-126) were trained 
and then tested for Go/No-go behavior using Version 1 or Version 2 described above (Fig. 3.1.B). At the 
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start of training, 19 mice were assigned to Version 1, and 19 to Version 2. However, only the following 
mice made it through exclusion criteria for training and reward consumption: High-active mice (Version 
1: n = 7 mice [3 males, 4 females]; Version 2: n = 7 mice [4 males, 3 females]) and Control mice (Version 
1: n = 7 [4 males, 3 females]; Version 2: n = 7 mice [4 males, 3 females]).  
Experiment 2: Adolescent male amphetamine Go/No-go response  
Adolescent males were used to evaluate impulsivity and amphetamine response at a clinically 
relevant age, in order to validate the face validity of the High-Active model in the context of the 
preferentially affected sex (Gershon, 2002). A total of 20 High-Active and 19 Control male mice were 
phenotyped for home cage activity from PND 33-38. In total, these mice represented 11 families, and 
were born within 4 days of each other. As outlined in Fig. 3.1.C, immediately after home cage activity 
was recorded, mice began receiving daily intraperitoneal injections of 0.25 mg/kg d-amphetamine 
(Sigma A-5880; Lot # 065K1894) or saline vehicle. Food restriction occurred after 3 days of these 
injections. Following three days of food restriction, mice started operant training and completed Version 
1 of Go/No-go testing. On days when animals were being trained and tested on the Go/No-go task, 
injections occurred exactly 15 minutes prior to placement in the operant boxes. This schedule was 
implemented to ensure the mice were experiencing the same degree of psychoactive effects from 
amphetamine while performing the operant tasks. The injections continued every day throughout the 
duration of the study up until the day of euthanasia. Only the following mice successfully met criteria: 
male High-active mice (n = 5 receiving saline, and n = 7 receiving 0.25 mg/kg amphetamine) and Controls 
(n = 4 receiving saline, and n = 5 receiving 0.25 mg/kg amphetamine).  
 Experiment 3: Adult females tested on Y-maze, rotarod, Go/No-go amphetamine response and c-Fos 
Adult female High-Active (n=20) and Control (n=23) mice were used for this experiment because 
they display exaggerated levels of home cage hyperactivity relative to males, not only within our High-
Active and Control lines, but in all strains of mice of which we are aware (Clark et al., 2011). Mice were 
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phenotyped for home cage activity from PND 60-65. Individuals were from distinct families within each 
sex. Approximately 6 weeks later, mice were tested on the Y-maze (1 day) and rotarod (3 days). 
Following rotarod, mice began receiving daily injections of 0.25 mg/kg d-amphetamine or saline 
concurrent with food restriction, and after 3 days of acclimation to this schedule began training on 
Version 1 of Go/No-go (Fig. 3.1.D). On days when animals were being trained and tested on the Go/No-
go task, injections occurred exactly 15 minutes prior to placement in the operant boxes. Following the 
Go/No-go testing mice were euthanized for immunohistochemical detection of c-Fos in the infralimic 
and prelimbic cortices (PFC), and posterior cerebellar vermal lobules.  
Y-maze 
The Y-maze was used to measure spontaneous alternation behavior, which requires aspects of 
attention and working memory (Sarter et al., 1988, Hughes, 2004). The maze consisted of 3 identical 
arms (15 x 3 x 5 in) made of black Plexiglas. The top of the maze was not covered, and continuous 
ceiling-mounted video tracking by TopScan recorded arm entries. At the start of each trial, a mouse was 
placed in the center of the maze and allowed to freely explore for the entire 8-minute duration. The 
sequence in which the mouse entered the arms of the maze was recorded manually. An arm entry was 
defined as the entry of all four paws into the arm. An alternation was defined as consecutive entry into 
all three arms (without revisiting an arm). The total number of arm entries was also recorded.  
Rotarod 
Mice were placed on the stationary rotarod dowel (AccuRotor Rota Rod Tall Unit, 63cm fall 
height, 30mm diameter rotating dowel; Accuscan, Columbus, OH) which was then accelerated at 60 
rpm/min. The latency to fall (in seconds) was recorded. The procedure was repeated for 4 consecutive 
trials per day. If an animal fell off the rotarod rapidly due to inattention or slips, they were given an 
additional trial. The entire procedure was repeated for a total of 3 days. Average and maximum 
latencies across the 4 trials per day were analyzed. 
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Go/No-go 
The following mice successfully completed the operant training: High-active mice (n = 8 
receiving saline, and n = 10 receiving 0.25 mg/kg amphetamine) and Controls (n = 4 receiving saline, and 
n = 9 receiving 0.25 mg/kg amphetamine).  
c-Fos immunohistochemistry and image analysis  
The purpose of the immunohistochemical analysis was to measure activation of the PFC (pre- 
and infra-limbic cortices) and the posterior cerebellar vermis of High-Active and Control mice, both at 
baseline (saline) and in response to low-dose (0.25 mg/kg) amphetamine. These regions were analyzed 
to provide construct validity for the High-Active line, as the PFC and cerebellum are influenced by 
amphetamine and have also been shown to be correlated with ADHD (Castellanos et al., 2006, Durston 
et al., 2011). Only mice that successfully completed the operant training were analyzed for c-Fos (see 
Go/No-go section above). Mice were euthanized exactly 90 minutes following their final injection of 
either saline or 0.25 mg/kg amphetamine. Briefly, mice were anesthetized with 100 mg/kg sodium 
pentobarbital via intraperitoneal injection, and then perfused transcardially with ice-cold saline. Brains 
were immediately dissected. The left hemisphere and intact cerebellum were placed in 4% 
paraformaldehyde in phosphate buffer solution (PBS) overnight, and then transferred to 30% sucrose 
solution with sodium azide at 4°C.  
A cryostat was used to section the left hemispheres into 40 µm coronal sections and cerebellum 
into 40 µm sagittal sections that were then stored in tissue cryoprotectant at -20° C. 
Immunohistochemical detection of c-Fos was performed as previous described (Clark et al., 2011). 
Primary c-Fos antibody concentrations were 1:3000 for PFC, and 1:500 for cerebellum (Santa Cruz, sc-
52). A 1:6 series was stained for PFC (i.e., series of sections throughout the rostrocaudal extent with 240 
μm separating each section) while a 1:5 series (200 μm separating each section) was stained for 
cerebellar vermis. A bright field microscope 10x objective (total magnification 100X) interfaced to 
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computer via AxioCam camera was used to photograph the prelimbic and infralimbic cortices (from 
Bregma, anterior +1.98 mm to +1.54 mm) (Paxinos and Franklin, 2004). Prelimibic and infralimbic 
cortical regions were traced using anatomical relationship to the emerging corpus callosum (see Fig 
3.7.A) and the total number of c-Fos positive cells within the field was hand counted. For the 
cerebellum, the granule layer of posterior vermal lobules VI and VII (from Bregma, lateral -0.04 mm to 
+1.44 mm) (Paxinos and Franklin, 2004) were outlined (see Fig. 3.7.B) and c-Fos cells were counted using 
an automated threshold set in ImageJ. 
Statistical analysis 
Data were analyzed using SAS (version 9.3) statistical software. In all analyses, P ≤ 0.05 was 
considered to be statistically significant, and P ≤ 0.10 was considered a trend.  
Home cage activity: Home cage distance traveled on days 5 and 6 was compared between High-Active 
and Control lines using an unpaired t-test for each experiment separately. Only data from individuals 
that completed the operant training are analyzed and represented. Data were collapsed across sex for 
Experiment 1.  
Operant training: Mice were trained to respond (Go) to a cue light by poking their nose in the hole 
containing a light up to a certain criterion (see General Procedure for Operant Conditioning). Average 
latency to respond on the last 4 days of training up to the point when criterion was reached was 
analyzed by repeated measures ANOVA with line, sex (Experiment 1), version (Experiment 1), treatment 
(Experiments 2 & 3), and day (within subjects) as factors. 
Go/No-go: Measures of performance across all days of Go/No-go testing (number of hits, false alarms, 
latency to nose poke, precue pokes, cue-side pokes, and efficiency) were averaged for each mouse, and 
were analyzed with sex, line, and version as factors (3-way ANOVA for Experiment 1) and treatment and 
line as factors (2-way ANOVA for Experiments 2 and 3). Precue responses and cue-side pokes were log 
transformed to improve homogeneity of variance between groups. 
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Y-maze, rotarod, and c-Fos: In Experiment 3, number of Y-maze arm entries and alternations were 
analyzed by unpaired t-tests comparing High-Active to Control. Average and maximum latency to fall 
from the rotarod were analyzed using a repeated-measures ANOVA with line and day (within subjects). 
The average number of c-Fos positive cells (cerebellar vermis lobules VI and VII data were log 
transformed to improve homogeneity of variance between groups) were analyzed by two-way ANOVA, 
with treatment and line as factors. One individual was removed from analysis of all brain regions due to 
poor staining.  
Genetic drift: To determine whether the phenotypic differences between the lines were likely caused by 
selection as opposed to drift, variance expected from genetic drift was calculated for each trait following 
previous work (Majdak et al., 2014). Briefly, in order to calculate standardized phenotypic differences 
between the lines (Dy), Control trait means were subtracted from High-Active trait means, and divided 
by the pooled estimates of the standard deviation for that line’s trait. This Dy value was then compared 
to the 95% confidence interval for genetic drift, which was estimated using our inbreeding coefficient 
(“F”) generated by ASReml-R version 2.0(Konarzewski et al., 2005), heritability (“h
2
”) values obtained 
from the literature, and the number of families used in the phenotypic measurement (“n”). The absolute 
values of Dy that fall out the confidence interval are likely correlated responses to selection as opposed 
to genetic drift. 
Results  
Home cage activity 
As expected, High-Active mice were significantly more active than Controls in each experiment 
(Fig. 3.2; Experiment 1: t26=16.7, P=0.0004; Experiment 2: t19=9.8, P=0.006; Experiment 3: t29=7.05, 
P=0.013). Neither sex nor the interaction between line and sex were significant in Experiment 1.  
Training performance 
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In all three experiments, High-Active mice displayed significantly faster latencies to nose-poke in 
response to the cue light. However, this difference dissipated toward the end of the training session as 
the latencies for Control mice dropped to similar levels as High-Active mice, indicating both groups 
displayed a similar prepotent motor response prior to Go/No-go testing (see Figs. 3.3.A-B). In 
Experiment 1, this was indicated by significant effect of line (F1,22=14.3; P=0.001), significant effect of day 
(F3,66=30.99; P<0.0001), and a significant interaction between day and line (F3,66=4.78; P=0.005). As 
expected, no training difference was detected between Go/No-go Version 1 and Version 2, nor were 
there any interactions with the other factors, confirming that the mice were similarly trained going into 
the Go/No-go testing. Post-hoc Tukey tests indicated High-Active mice were significantly faster to 
respond than Controls on Day 1 (P<0.0001), but not on the other days. Experiments 2 and 3 followed a 
similar training pattern, wherein line differences were nonexistent just prior to Go/No-go testing 
(Experiment 2: day effect F3,87=24.2; P<0.0001 and day by line interaction F3,87=4.61; P=0.005; 
Experiment 3: day effect F3,96=51.6; P<0.0001 and day by treatment trend F3,96=2.49; P=0.065; data not 
shown). 
Experiment 1: Evaluating two discrepent Go/No-go procedures 
Hits and false alarms 
Out of 30 possible hits during a Go/No-go session, High-Active mice on average, demonstrated 
significantly more hits than Controls (F1,18=9.2; P=0.007; collapsed hits across versions for Fig. 3.3.C-D). 
No effect of Go/No-go version was detected. In addition, High-Active mice made significantly more false 
alarms errors than Controls in both versions of the task (F1,18=18.0; P=0.0005; Fig. 3.3.C-D). As expected, 
number of false alarms was much greater for Version 2 than Version 1 of the Go/No-go test (F1,18=115.9; 
P<0.0001), indicating mice had difficulty acquiring the meaning of the No-go cue in Version 2. The 
increased number of hits and false alarms in the High-Active line relative to the Control line was 
significantly greater than would be expected from drift alone (Table 3.1).  
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Latency to nose poke 
High-Active mice responded significantly more quickly to the Go cue than Controls (F1,18=6.7; P=0.019; 
collapsed hits across versions for Fig.3.3.E-F). No difference in version or interaction between version 
and line was detected. In addition, High-Active mice mistakenly responded significantly more quickly to 
the No-go tone cue than Controls (F1,18=10.9; P=0.004; Fig. 3.3.E-F). As expected, the latency to make an 
error and respond to the No-go cue was much longer for Version 1 than 2, since Version 2 was a more 
difficult task (F1,18=10.9; P=0.004; Fig.3.3.F). Decreased latency to commit a false alarm is likely a 
correlated response to selection for increased home cage activity rather than genetic drift for both 
versions, while latency to perform a hit did not survive the test for drift (Table 3.1).  
Additional measures of operant responding 
Additional measures of operant responding (precue responding, cue-side pokes, and efficiency) 
did not reach statistical significance between the lines (data not shown). 
Experiment 2: Adolescent male amphetamine Go/No-go response  
Hits and false alarms 
0.25 mg/kg d-amphetamine had opposite effects on hits in adolescent High-Active mice as 
compared to adolescent Controls (Fig. 3.4.A). This was indicated by a significant main effect of line 
(F1,17=11.9; P=0.003), as overall High-Active mice made more hits than Controls, no main effect of 
treatment (saline versus amphetamine), and a significant interaction between line and treatment 
(F1,17=7.01; P=0.017). In High-Active mice, amphetamine tended to decrease hits (P=0.07), whereas in 
Control mice it tended to increase number of hits (P=0.08). Hits, and the ability of amphetamine to 
attenuate High-Active hits, are likely correlated responses to selection rather than a result of genetic 
drift (Table 3.1).  
Adolescent High-Active males also displayed significantly greater number of false alarms than 
Controls (F1, 17=8.80; P=0.009; Fig. 3.4.B). Amphetamine tended to reduce number of false alarms across 
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lines (F1, 17=3.18; P=0.092), and the magnitude of the reduction tended to be greater in High-Active mice 
than Controls (P=0.04). While increased false alarms in the High-Active line are correlated to selection 
for hyperactivity, differences in response to amphetamine for number of false alarms between High-
Active and Control lines did not survive the test for genetic drift (Table 3.1). 
Latency to nose poke 
Amphetamine had an opposite effect on latency to respond to the Go cue in High-Active mice as 
compared to Controls (Fig. 3.4.C). In High-Active mice, amphetamine tended to increase latency to 
respond, whereas in Control mice it decreased latency to respond. This was indicated by a trending main 
effect of line (F1, 17=3.6; P=0.076), no effect of treatment, but a significant interaction between 
treatment and line (F1, 17=5.2; P=0.035). Amphetamine tended to increase latency to mistakenly respond 
to the No-go cue, i.e., false alarms, in both lines (Fig. 3.4.D). However the effect was of greater 
magnitude in the High-Active Iine than Control line. This was indicated by a trend for an effect of 
amphetamine (F1, 17=4.0; P=0.062) and a significant main effect of line (F1, 17=9.3; P=0.010). Differential 
responses to amphetamine in High-Active versus Control lines survived the test for genetic drift for hit 
latencies but not false alarm latencies (Table 3.1).  
Additional measures of operant responding 
Additional measures of operant responding (precue responding, cue-side pokes, and efficiency) 
did not reach statistical significance between the lines (data not shown). 
Experiment 3: Adult females tested on y-maze, rotarod, Go/No-go amphetamine response and c-Fos 
Y-maze 
High-Active mice displayed significantly more arm entries than Control mice throughout the 
duration of the Y-maze (F1, 41=18.12, P=0.0001; Fig. 3.5.A). Specifically, High-Active mice averaged 64 arm 
entries while Control mice averaged 42 entries. When all arm entries during the entire eight minute 
trials were analyzed, the percentage of alternation was similar between the High-Active (53%) and 
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Control mice (57%) (F1, 41=1.75, P=0.193; Fig. 3.5.B). However, when only considering the first 20 arm 
entries, High-Active mice showed a trend in engaging in less spontaneous alternation behavior than 
Control mice. High-Active mice averaged 51% spontaneous alternation and Control mice averaged 60% 
(F1,41=3.35, P=0.075; Fig. 3.5.B). The difference in number of arm entries between High-Active and 
Control mice likely arose as a correlated response to selection for hyperactivity (Table 3.1). 
Rotarod 
All mice learned the rotarod task as indicated by a main effect of day for both average latency to 
fall (F2, 82=12.45, P<0.0001; Fig. 3.5.C) and maximum latency (F2, 82=10.54, P<0.0001; Fig. 3.5.D). However, 
High-Active mice performed significantly worse than Controls. This was indicated by a significant main 
effect of line (average latency, F1, 41=6.40, P=0.015; maximum latency F1, 41=6.24, P=0.017), and 
interaction between line and day (average latency, F2, 82=3.41, P=0.038; maximum latency, F2,82=2.41, 
P=0.097). Post-hoc tests indicate lines differ on day 2 (maximum latency, P=0.088), and day 3 (average 
latency, p=0.015; maximum latency, P=0.074). The difference in average latency to fall from the rotarod 
(across all 3 days) between High-Active and Control mice did not survive the test for genetic drift (Table 
3.1).  
Hits and false alarms 
Significantly more hits were made by High-Active mice in response to a Go cue (F1, 27=4.24; 
P=0.049), yet there was only a trend for an effect of dose (F1, 27=2.83; P=0.10) and no interaction of line 
and dose (Fig. 3.6.A). The dose trend is due to amphetamine non-significantly increasing hits in Control 
mice (F1, 17=7.77; P=0.013) whereas it had no effect in High-Active. Likewise, more false alarms were 
committed by High-Active mice (F1, 27=8.64; P=0.007), and while there was no effect of dose, there was a 
significant interaction of line and dose (F1, 27=4.46; P=0.044; Fig. 3.6.B). This is because amphetamine 
increased the number of false alarms in Control mice (F1, 17=16.61; P=0.001) without affecting High-
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Active mice. The high number of false alarms committed by High-Active mice is likely due to selection for 
home cage hyperactivity (Table 3.1). 
Latency to nose poke 
Latency to nose poke did not reach statistical significance between the lines (data not shown). 
Additional measures of operant responding 
Impulsive precue responding, defined as nose pokes within the final 3 seconds of the precue 
period, was significantly increased in High-Active mice (F1, 27=11.88; P=0.002), and while there was no 
main effect of dose, there was a significant interaction between line and dose (F1, 27=8.73; P=0.006; Fig 
3.6.C). This is because amphetamine tended to reduce precue responses (i.e., enhanced impulse 
restraint) in High-Active mice whereas it tended to increase precue responses in Control mice (P=0.055). 
Moreover, High-Active mice made significantly more nose pokes on the cue-side hole while it was not 
illuminated (F1, 27=14.33; P=0.0008), and while there was no main effect of dose, there was a significant 
interaction between line and dose (F1, 27=5.85; P=0.023; Fig. 3.6.D). Post-hoc Tukey tests indicated 
amphetamine tended to reduce cue-side pokes in High-Active mice whereas it increased it in Controls 
(P=0.094); these data reflect the capacity of amphetamine to reduce random prepotent responding in 
hyperactive mice. The efficiency measure (providing minimal responses for maximal reward) indicated 
that High-Active mice were responding less efficiently for rewards (F1, 27=9.19; P=0.005), and while there 
was no effect a dose, there was a significant interaction between line and dose (F1, 27=13.05; P=0.001) 
(Fig. 3.6.E). Amphetamine reduced efficiency in Control mice (P=0.006) whereas it increased efficiency in 
High-Active mice (P=0.05).  
Immunohistochemical analysis 
Amphetamine increased the total number of c-Fos positive cells in the infralimbic and prelimbic 
cortices by appromiately 43% in Control mice whereas amphetamine had no significant effect in High 
Active mice (Fig. 3.7.A). This was indicated by a significant effect of line (F1, 31=6.42; P=0.017) and a trend 
88 
 
for an interaction between line and dose (F1, 31=2.888; P=0.10). Posthoc tests indicated that the Control 
line given amphetamine displayed more c-Fos cells than the other groups (each pairwise comparison 
P<0.05). Amphetamine had an opposite effect on the number of c-Fos positive cells in the granular layer 
of cerebellar vermis lobules VI and VII in High-Active versus Control mice. This was indicated by a 
significant interaction between line and dose (F1, 28=4.15; P=0.043). In Control mice, amphetamine 
increased c-Fos whereas in High-Active mice it decreased c-Fos, as indicated in Figure 3.7.B. Main effects 
of line and dose were not significant, nor were any posthoc tests. 
Discussion 
The main finding of the study is that 16 generations of selection for increased physical activity in 
the home cage results in increased motor impulsivity in the High-Active line relative to the Control line, 
suggesting that hyperactivity and impulsivity are inevitably entangled traits influenced by similar suites 
of genes in our lines (Table 3.1). This result was confirmed using two different versions of the Go/No-go 
test of motor impulsivity (Experiment 1) in adolescents and adults (Experiments 2 and 3), and in both 
males and females. Supporting the predictive validity of the High-Active model is the finding that 
amphetamine, widely used as a therapeutic for ADHD, ameliorates not only home cage hyperactivity 
(Majdak et al., 2014) but also motor impulsivity. Moreover, High-Active mice displayed marginal 
impairment on the Y-maze spontaneous alternation task of attention, and demonstrated significant 
impairment in the accelerating rotarod task which requires motor coordination, motor learning, and 
intact cerebellar function. High-Active mice also displayed altered cellular activation in the cerebellar 
vermis and PFC in response to low therapeutic amphetamine administration, consistent with human 
literature implicating altered functionality in these regions associated with ADHD (Solanto, 2002). We 
conclude that the High-Active line, when used in conjunction with the concurrently bred Control line, 
represents a valuable model for exploring the etiology of the Hyperactive-Impulsive subtype of ADHD, 
and as a platform for new medication development.  
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The High-Active line demonstrates that hyperactivity and impulsivity are genetically entangled 
traits. Excessive motor impulsivity in the High-Active line was demonstrated in two separate assays, 
across distinct sensory cues employed to elicit behavioral inhibition (Gubner et al., 2010, Loos et al., 
2010). In both cases, a central measure of impulsivity (false alarms) suggest High-Active impulsivity is 
unlikely due to genetic drift, and is more likely a correlated response to selection for hyperactivity, as 
reflected in Table 3.1. False alarms, or the mistaken “go” response to a No-go cue, indicate an impaired 
ability to withhold a prepotent, impulsive motor response in order to obtain a reward (Gubner et al., 
2010). Furthermore, the duration of that withholding behavior is shortened in High-Active mice relative 
to Controls, and this deficient control over withholding impulsive behavior is also a correlated response 
to selection for hyperactivity (Table 3.1). Hits, or correct responses to the Go cue, are commonly 
evaluated in the context of Go/No-go paradigms. It is important to emphasize that hits are not a 
measure of impulsivity; hits are simply the developed prepotent motor response, and reflect activity or 
vigilance of the mice to respond to cues in the operant chambers. In the context of false alarms, hit 
measurements enables evaluation of the degree to which mice discriminate between Go and No-go 
cues. In Version 1, there is a clear differential response to a Go versus a No-go cue (Fig. 3.3.C), while 
Version 2 presents a more challenging task wherein go and no-go cues elicit similar levels of responding 
(Fig. 3.3.D). The latency of the mice to withhold the impulsive nose poke also underscores the 
discriminatory capacity of the cues; mice clearly inhibit responding to No-go cues in Version 1 (Fig. 
3.3.C), and if a mistake is committed, it occurs after a longer period of maintained inhibition as 
compared to a correct hit (Fig. 3.3.E). While both versions of the Go/No-go task ultimately indicated 
higher measures of impulsive false alarms in High-Active mice, Version 1 cues elicited clearly 
discriminatory behaviors, and therefore allow us to more clearly parse out capacity for impulse control. 
Furthermore, Version 1 adheres to parameters established for 15 strains of mice in Go/No-go testing 
(Gubner et al., 2010) and is therefore ideal for this highly heterogeneous population. Version 1 was 
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subsequently utilized in assessing motor impulsivity in a translationally relevant cohort (Experiment 2, 
adolescent males; Fig. 3.4.B) and our most extreme hyperactive population (Experiment 3, adult 
females; Fig. 3.6.B). In all cohorts, the High-Active line demonstrated increased motor impulsivity 
relative to Controls. 
Although these data clearly establish that the hyperactivity and impulsivity measures collected 
are genetically correlated traits in our lines, the specific genes that relate to both traits are not known, 
nor are the mechanisms for how those genes exert their influence on hyperactivity and impulsivity 
understood. One possibility is that the association between impulsivity and hyperactivity is a trivial 
consequence of the method used to assess motor impulsivity; there may exist a linear relationship in 
which hyperactivity directly translates into excessive cue poking, and therefore increases non-specific 
operant responding (as seen in Fig. 3.6.D). Indeed, previous rodent studies have positively correlated 
open field activity and impulsive lever pressing across 6 strains of mice (McKerchar et al., 2005), and 
further correlated open field activity and impulsive escape behavior (Cabib et al., 2002). Moreover, the 
SHR model of ADHD has demonstrated that reducing hyperactivity via d-amphetamine administration 
also reduces impulsive lever pressing (Sagvolden and Xu, 2008). If there existed an established strategy 
to measure motor impulsivity independent of locomotor activity, then this hypothesis would predict 
High-Active mice would not display impulsive motor behavior. The other possibility is that certain genes 
are common to both hyperactivity and impulsivity, so the genetic changes which cause hyperactivity 
inevitably deteriorate impulse control as well. This “common genes” hypothesis of entangled impulsivity 
and hyperactivity is embraced in clinical literature; many heritability studies only seek to parse out the 
genetic constructs underlying the “Hyperactive-Impulsive” subtype from the “Inattentive” subtype 
(Willcutt et al., 2000, McLoughlin et al., 2007, Toplak et al., 2009). Clinical diagnostic categories confirm 
the validity of this approach; there exists no separate diagnoses for “Hyperactive” versus “Impulsive” 
subtypes of ADHD in the DSM-V (APA, 2013). This hypothesis posits that the relation between 
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impulsivity and hyperactivity is not trivially dependent on locomotion, and if there were a reliable 
method for testing motor impulsivity independent of locomotion, then High-Active mice would still 
display increased motor impulsivity relative to Controls.  
Multiple clinical and animal model studies corroborate the present High-Active impulsivity data 
to support the hypothesis that impulsivity and hyperactivity are distinct yet related constructs. A study 
conducted by Wilkinson and colleagues supports this hypothesis by demonstrating genetic hyperactivity 
and impulsivity are indeed not trivially locomotor-dependent in mice (Isles et al., 2004). Multiple inbred 
lines of mice displayed co-varying levels of activity and impulsive choice on a delayed-reinforcement 
paradigm, yet this phenomenon was not attributed to generalized activity, largely due to the absence of 
systemic effects within motor performance (Isles et al., 2004). Another study demonstrates that activity 
levels (exploration in novel open field) and impulsivity (precue responding in the five-choice serial 
reaction time task) are not correlated and further purports that these traits may be mediated by 
disparate genetic influences, based on the systemic analysis of 12 different inbred mouse strains (Loos 
et al., 2009). Pharmacological evidence has also implicated differential bases for motor impulsivity and 
hyperactivity; different doses of amphetamine uniformly increases locomotor activity while producing a 
complex dose response pattern on impulsivity in young male mice, indicating distinct neural 
mechanisms mediate hyperactivity and impulsivity (Isles et al., 2003). In the present study, while 
hyperactivity and false alarms do co-vary, we do not observe differential non-specific cue-side 
responding between the lines in Experiments 1 and 2 (data not shown). Furthermore, latency to nose 
poke on the last day of training for all cohorts did not significantly differ between lines, suggesting 
aspects of nose poking acquisition are not broadly attributed to hyperactivity (Figs. 3.3.A-B). 
Interestingly, however, non-specific nose poking line differences (Fig. 3.6.D) arose in our cohort of 
extremely hyperactive adult females (Fig. 3.2.C). Activity levels exist along a continuum, and this 
observation lends credence to the hypothesis that perhaps extreme hyperactivity may obfuscate the 
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shared genetic underpinnings of both hyperactivity and impulsivity via those aforementioned trivial 
locomotor confounds which increase non-specific responding. In this way, increased non-specific 
responding of the High-Active line may artificially deflate the efficiency scores (reinforced 
responses/total responses; Fig. 3.6.E), and reflect more closely a combination of hyperactivity within the 
chamber as well as those genetic factors influencing impulsivity. These data further provide evidence of 
a more complex relationship between hyperactivity and impulsivity; the increased hyperactivity 
between High-Active cohorts used in Experiment 2 and 3 (Figs. 3.2.B-C) did not result in increased in 
impulsive action (i.e., false alarms) between the cohorts (Figs. 3.4.B & 3.6.B) as would be expected if 
hyperactivity produced impulsive behavior. Taken together, these data imply a non-linear relationship 
between hyperactivity and impulsivity in the High-Active line. 
The significance of the translational potential of the High-Active line in modeling ADHD is 
validated by robust evidence that low-dose amphetamine reversed hyperactivity and impulsivity, both 
core symptoms of ADHD. In particular, data from the translationally relevant cohort of High-Active 
adolescent males provide strong predictive validity for the model. High-Active adolescent males reduce 
impulsivity in response to 0.25 mg/kg d-amphetamine (Fig. 3.4.B), which also improved their impulsive 
action restraint capacity as evidenced by increasing latency to commit an error (Fig. 3.4.D). As would be 
expected from clinical and animal literature on the differential effects of psychostimulants (Davids et al., 
2002, Solanto, 2002), Control adolescent males remained minimally affected by amphetamine 
administration in these domains of motor impulsivity (Figs. 3.4.B & D). Yet, correct prepotent 
responding itself is paradoxically influenced by amphetamine in High-Active and Control mice (Figs. 
3.4.A & C), indicating low-dose amphetamine modulates conditioned motor behavior in both lines to a 
common, middle ground. Taken together, these data suggest amphetamine has a specific capacity to 
ameliorate impulsive behavior in the High-Active cohort of adolescent males. However, the application 
of the same low dose of amphetamine which successfully ameliorated impulsive action in the High-
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Active adolescent cohort was insufficient to significantly reduce impulsivity in the High-Active adult 
cohort (Fig. 3.6.B). While 0.25 mg/kg d-amphetamine was effective in a less hyperactive population (Fig. 
3.4.B), the extreme hyperactivity of the adult females may necessitate a higher dose to combat 
hyperactive/impulsive behavior. These results demonstrating that amphetamine ameliorates impulsive 
motor behaviors in the High-Active mice, while having either no effect or a detrimental effect in 
Controls, is consistent with a large literature on the rate-dependent effects of psychostimulant drugs 
(Leander and McMillan, 1974, Solanto, 1998, Cirulli and Laviola, 2000). This literature establishes that 
across multiple strains and individuals, those subjects which display high baseline responses, e.g., 
hyperactivity, impulsivity, will tend to display reductions in these responses from amphetamine, while 
hypoactive or marginally active subjects with appropriate impulse control will tend to increase these 
behaviors in response to amphetamine (Solanto, 1998, Covey et al., 2013). Our data suggest that the 
same stimulant dose which ameliorates High-Active responding, also enhances the activity of low 
Control responders (Fig. 3.4.A); thus we provide evidence that the amphetamine dose titrates both ends 
of the behavioral continuum toward an established middle ground. While this is not an explanation of 
the underlying mechanism by which this amphetamine-induced responding occurs, it remains a 
consistent observation in the High-Active line. 
Unequal neural activation within the prelimbic and infralimbic cortices (PFC) in response to low-
dose amphetamine provides further construct validity for this model of genetic hyperactivity-
impulsivity. The PFC is consistently identified as a region of critical dysfunction in the etiology of ADHD; 
lesioning the PFC recapitulates the hyperactivity, impulsivity, and inattention of ADHD (Faraone and 
Biederman, 1998, Zhang et al., 2001, Arnsten, 2006), and hypofrontality, or weakened PFC functioning, 
is commonly identified in ADHD imaging studies (Rubia et al., 1999, Zang et al., 2007). We therefore 
hypothesized that the degree of neuronal activation in the PFC would reflect measures of impulsive 
action, but the data indicate this relationship is more complex based on the genetic differences between 
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the lines. High-Active mice show decreased neural PFC activation relative to Controls, and this finding is 
driven by the reduced sensitivity of the High-Active PFC to low-dose amphetamine (Fig. 3.7.A). Altered 
functionality or expression of amphetamine targets (dopamine or norepinephrine transporters) in the 
High-Active PFC is a likely rationale to explain its minimal response to amphetamine (Gizer et al., 2009, 
Leo and Gainetdinov, 2013). The role of the PFC and psychostimulants in impulse control (Sokolowski 
and Salamone, 1994, Solanto, 1998) is supported by these data; the altered High-Active PFC did not 
respond to amphetamine (Fig. 3.7.A) and amphetamine did not significantly ameliorate High-Active 
motor impulsivity (Fig. 3.6.B). Yet in the Control line, amphetamine-enhanced PFC activation (Fig. 3.7.A) 
and impulsivity (Fig. 3.6.B) do co-vary. Taken together, the present data suggest genetic alterations in 
dopamine/norepinephrine-related functionality in the High-Active PFC that are not present in the 
Control PFC, keeping in line with the hypothesis that altered monoaminergic transmission plays a central 
role in ADHD pathogenesis (Sagvolden and Xu, 2008, Gizer et al., 2009, Leo and Gainetdinov, 2013). This 
pharmacological evidence of differential neurobiology within a region critical for attention and impulse 
control provides construct validity for the model. 
Differential regulation of the cerebellum by low-dose amphetamine in the High-Active and 
Control lines further supports the validity of the High-Active model of ADHD. The dysregulation of the 
cerebellar vermis has become broadly accepted a potential etiological component of ADHD in clinical 
imaging studies (Mulder et al., 2008, Durston et al., 2011). Firstly, in an effort to assess the gross 
cerebellar functionality of our High-Active and Control lines, we employed a cerebellar-dependent 
accelerating rotarod task (Goddyn et al., 2006). As hypothesized, the High-Active mice demonstrate 
deficits in the motor coordination required to successfully manage the task (Figs. 3.5.C-D), suggesting 
underlying neural dysfunction of the region. Therefore, post-mortem immunohistochemical analysis of 
the activation of the granular layer of posterior vermal lobules VI and VII in response to saline or 0.25 
mg/kg amphetamine was undertaken to determine whether hypo-activation correlated with this poor 
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rotarod performance. Contrary to our hypothesis, High-Active mice show increased activation of this 
region relative to Controls, an effect which is reversed by exposure to amphetamine (Fig. 3.7.B). 
Previous work has confirmed the projection of dopaminergic ventral tegmental area fibers onto the 
granule layer of the cerebellar cortex (Ikai et al., 1992); therefore it is possible aberrant baseline 
dopamine signaling increases baseline activation of vermal lobules VI and VII in the High-Active line, 
which is corrected by the action of amphetamine on neural substrates which project to vermal granular 
layer. The increased c-Fos expression in Controls exposed to amphetamine is expected, based on 
previous studies which have demonstrated acute d-amphetamine increases c-Fos expression in 
posterior lobules in rodents (Klitenick et al., 1995). Taken together, the paradoxical effect of 
amphetamine on vermal activation implicates dopaminergic and noradrenergic dysfunction of upstream 
projections in the High-Active line. 
Ultimately, the High-Active line represents a useful model for exploring the etiology of the 
“predominantly Hyperactive-Impulsive” subtype of ADHD. High-Active mice demonstrate significant 
home cage hyperactivity and motor impulsivity, yet do not demonstrate significant inattention relative 
to Controls, as evidenced by spontaneous alternation behavior in the Y-maze (Fig. 3.5.B) and vigilance 
for hits in the Go/No-go task (Figs. 3.3.C-D & 3.4.A). Certainly no rodent model perfectly manifests the 
multifaceted presentation of ADHD, but we propose the High-Active line demonstrates evidence of face, 
construct, and predictive validity which makes it suitable for testing hypotheses regarding the 
Hyperactive-Impulsive subtype of ADHD. Selective breeding has generated a heterogeneous population 
reflective of human genetic complexity, and in this way provides the truly unique opportunity to 1) 
evaluate whether candidate genes currently associated with ADHD are also correlated with 
hyperactivity-impulsivity in the High-Active model, and/or 2) uncover novel gene pathways underlying 
hyperactive-impulsive behavior. The identification of such novel genes may provide new targets for 
candidate gene studies in clinical populations. Furthermore, the specific behavioral and pharmacological 
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contributions of any novel genes may be elucidated using transgenic rodent modeling (Gainetdinov, 
2008). The High-Active model has also been validated with low-dose amphetamine, and is therefore 
suitable for testing novel compounds to ameliorate ADHD. Lastly, the concurrent breeding of the Control 
and High-Active lines from the same Collaborative Cross founder population allows for powerful, 
statistically valid comparisons of any behavior, drug response, or genetics which may differ between the 
two lines.  
This High-Active model offers the possibility to explore previously untestable hypotheses 
regarding the etiology of ADHD, the inheritance of related behavioral traits, and the efficacy of novel 
treatments that may more specifically address core behavioral deficits. The High-Active line is a 
powerful tool for identifying novel genes and pathways underlying the inevitable entangling of 
hyperactivity and impulsivity. Using approaches such as RNA sequencing, we may identify up- and down-
regulated transcripts in regions of interest which will allow a better understanding of which gene 
products are being dynamically regulated under hyperactive conditions. In addition to uncovering novel 
genes, the High-Active line may also serve as an innovative translational tool for uncovering specific 
subsets of behaviors, or endophenotypes, tightly correlated to the broader behavioral deficits of ADHD 
(Slaats-Willemse et al., 2003, Rommelse et al., 2008). The identification of an endophenotype, or 
heritable trait which consistently reflects a facet of a behavior and its underlying genes, would be of 
significant clinical relevance (Castellanos and Tannock, 2002, Gainetdinov, 2010). Finally, one of the 
most significant advantages of this model will be as a platform for testing novel therapeutic 
interventions to ameliorate the behavioral deficits associated with ADHD. Home cage hyperactivity is 
easily and reliably measured in this model, and the establishment of the Go/No-go parameters for this 
line provides the construct for evaluating drug efficacy on multiple aspects of motor impulsivity. 
Combining the High-Active line’s potential for uncovering novel genetic pathways with the emergent 
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fields of personalized medicine and genome editing will critically broaden our understanding and 
treatment of ADHD. 
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Tables and Figures 
 
Table 3.1. Evaluation of secondary traits as correlated responses to selection for home cage 
hyperactivity. Mean values (±SEM) of each line (“Control” and “High-Active”) are further analyzed to 
determine whether line differences are likely attributable to selective breeding for hyperactivity, rather 
than another genetic phenomenon such as drift. The statistical significance of line differences are 
expressed in standardized phenotypic units which are then compared to its 95% confidence interval in 
order to ascertain whether the trait is correlated to selective breeding for hyperactivity. “FA” denotes 
false alarms for Version 1 (V1) or Version 2 (V2); “AMPH on” refers to the influence of 0.25 mg/kg d-
amphetamine administered via i.p. injection 15 minutes before placement in the operant chamber on 
the trait. Amphetamine influence on a trait was calculated by subtracting the average saline response 
Trait Figure High-Active line Control line p-value h
2
F n 95% CI Dy
Home Cage Activity 3.2.A 0.92 (±0.10) 0.44 (±0.06) 0.0004 0.33 0.06217 12 1.26 1.54
Home Cage Activity 3.2.B 0.72 (±0.11) 0.31 (±0.04) 0.006 0.33 0.06217 11 1.31 1.38
Home Cage Activity 3.2.C 1.36 ( ±0.25) 0.53 (±0.11) 0.013 0.33 0.06217 13 1.22 0.97
Hits 3.3.C-D 28.2 (±0.44) 23.7 (±1.37) 0.007 0.4 0.06217 12 1.29 1.30
Hits latency 3.3.E-F 1.53 (±0.12) 2.24 (±0.22) 0.007 0.18 0.06217 12 1.21 -1.17
FA (V1) 3.3.C 16.5 (±1.39) 9.59 (±1.50) 0.005 0.17 0.06217 12 1.20 1.82
FA (V2) 3.3.D 28.3 (±0.38) 24.8 (±1.40) 0.020 0.17 0.06217 11 1.25 1.63
FA latency (V1) 3.3.E 3.43 (±0.14) 4.16 (±0.12) 0.002 0.06 0.06217 12 1.16 -2.06
FA latency (V2) 3.3.F 1.39 (±0.09) 1.91 (±0.26) 0.053 0.06 0.06217 11 1.21 -1.27
Hits 3.4.A 20.5 (±0.82) 13.0 (±0.50) 0.003 0.4 0.06217 11 1.33 4.92
AMPH on Hits 3.4.A -3.10 (±1.2) 3.42 (±1.59) 0.008 0.21 0.06217 11 1.26 -1.93
FA 3.4.B 8.22 (±0.50) 5.30 (±0.64) 0.009 0.17 0.06217 11 1.25 2.44
AMPH on FA 3.4.B -2.08 (±0.8) -0.46 (±0.5) NS 0.21 0.06217 11 1.26 -0.88
Hits latency 3.4.C 2.94 (±0.12) 3.72 (±0.08) 0.001 0.18 0.06217 11 1.25 -3.53
AMPH on Hits latency 3.4.C 0.36 (±0.15) -0.49 (±0.3) 0.017 0.21 0.06217 11 1.26 1.66
FA latency 3.4.D 4.25 (±0.05) 4.53 (±0.08) 0.010 0.06 0.06217 11 1.21 -2.03
AMPH on FA latency 3.4.D 0.22 (±0.08) 0.07 (±0.04) NS 0.21 0.06217 11 1.26 0.84
Y-maze arm entries 3.5.A 63.8 (±4.18) 42.0 (±3.12) 0.0001 0.39 0.06217 18 1.11 1.30
Rotarod latency (s) 3.5.C 31.7 (±2.06) 43.3 (±3.90) 0.015 0.44 0.06217 18 1.13 -0.77
Hits 3.6.A 19.8 (±2.10) 12.6 (±3.47) 0.049 0.4 0.06217 13 1.25 1.15
AMPH on Hits 3.6.A 0.43 (±1.28) 6.42 (±1.77) 0.013 0.21 0.06217 13 1.18 -2.80
FA 3.6.B 9.45 (±1.59) 3.20 (±0.78) 0.007 0.17 0.06217 13 1.16 1.62
AMPH on FA 3.6.B -1.35 (±1.1) 3.87 (±0.51) 0.001 0.21 0.06217 13 1.18 -0.68
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from each individual amphetamine response and comparing line means. “P-value” refers to a standard 
pair-wise comparison of the High-Active versus Control line trait. Heritability (“h
2
”) references were used 
for analyses of home cage activity (Zombeck et al., 2011), operant measures (hits, false alarms, hits  or 
“go” latency, false alarms or “no-go” latency) (Gubner et al., 2010), Y-maze arm entries (Smolen et al., 
1994), and an average of the three days of rotarod (Belknap et al., 1993, Rustay et al., 2003). “Hits” and 
“Hits latency” data reflected in the Experiment 1 cohort are collapsed across Versions 1 and 2, as the Go 
signal was identical in both. "F" refers to the inbreeding coefficient estimated from the pedigree. “n” 
refers to the number of families represented in the analyzed trait.  “95% CI” refers to the 95% 
confidence interval for Dy expected by genetic drift (Majdak et al., 2014). “Dy” refers to the difference 
between lines in standardized phenotypic SD units. Dy absolute values exceeding the 95% CI are shown 
in bold, and provide evidence that the secondary trait has evolved as a correlated response to selection 
for hyperactivity in the home cage. 
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Figure 3.1. Experimental schematics. A) This schematic represents the context in which all cues are 
presented. First, the house light is illuminated at the onset of the variable precue period. A correct 
response (nose poke for Go cue, withholding nose poke for No-go cue) dispenses a small sucrose reward 
(an incorrect response bypasses the reward period). Lastly, the house light is extinguished for 10 
seconds. In Training Phase 1, sixty 30-second Go cues (lights) are presented, but 30 nose pokes in 
response to the cue light in under 40 minutes for two consecutive days advances the mouse to Training 
Phase 2, in which the cue light is illuminated for only 10 seconds (reinforcing the prepotent motor 
response). The same 30 hits/40 minutes criterion advances mice to Go/No-go testing, in which thirty 5-
second Go cues are randomly interspersed with thirty 5-second No-go cues. While both versions of 
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Go/No-go testing had the same Go cue (light), in Version 1 (V.1) mice underwent 10 days of testing with 
a tone No-go cue, while in Version 2 (V.2) mice underwent 20 days of testing with a concurrent tone + 
light No-go cue. Version 1 was implemented for subsequent Experiments 2 and 3. B) In Experiment 1, 
disparate Go/No-go methods assessed impulsivity across paradigms. Adult male and female mice were 
phenotyped and food restricted throughout training and testing. At Go/No-go testing, paradigms 
diverge between Versions 1 and 2 as outlined in 1a. C) Experiment 2 utilized adolescent males which 
were phenotyped, acclimated to daily i.p. injections of saline or 0.25 mg/kg d-amphetamine over 3 days, 
and food restricted over an additional 3 days. Mice received injections administered 15 minutes prior to 
placement in the operant chamber. D) Experiment 3 utilized the most hyperactive cohort of mice (adult 
females) which were first assessed on the Y-maze and accelerating rotarod, before concurrently 
acclimating to food restriction and saline or 0.25 mg/kg d-amphetamine i.p injections over 3 days. Food 
restrictions and injections 15 minutes prior to operant chamber placement continued throughout 
training and testing.  
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Figure 3.2. Distance traveled in the home cage setting. Data represent the average distance traveled in 
the home cage (km/day ±SEM) across days 5 and 6 of a six-day test (i.e. phenotype). These data reflect 
only those Control and High-Active mice which completed operant training and Go/No-go testing. 
Asterisks represent statistically significant line differences (P<0.05) A) Phenotype of adult male and 
female mice used in Experiment 1. B) Phenotype of adolescent males used in Experiment 2. C) 
Phenotype of adult female mice used in Experiment 3. 
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Figure 3.3. Experiment 1: Evaluating High-Active and Control performance in two discrepant Go/No-go 
procedures. White bars/circles represent Control mice while dark bars/circles represent High-Active 
mice. Version 1 means (No-go cue = tone) are shown in the left panel, while Version 2 means (No-go cue 
= tone + light) are in the right panel. Asterisks represent statistically significant line differences (P<0.05) 
while hashtags represent a trend (P<0.10). A & B). Data represent the mean latency in seconds (±SEM) 
for the Version 1 and Version 2 cohorts to respond to the presentation of a Go cue (light) during the last 
four days of their training before commencing Go/No-go testing. Both versions employed an identical 
Go cue. C) The average number of hits (correct nose poke in response to a light) and false alarms 
(incorrect nose pokes in response to a tone) (±SEM) over 10 days of Go/No-go testing in Version 1. A 
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maximum of 30 hits and 30 false alarms is possible. D)  The average number of hits (correct nose poke in 
response to a light) and false alarms (incorrect nose pokes in response to a tone + light) (±SEM) over 20 
days of Go/No-go testing in Version 2. A maximum of 30 hits and 30 false alarms is possible. E) The 
average latency in seconds to make a hit or a false alarm across 10 days of Go/No-go testing in Version 
1. A maximum latency of 5 seconds is possible. F) The average latency in seconds to make a hit or a false 
alarm across 20 days of Go/No-go testing in Version 2. A maximum latency of 5 seconds is possible. 
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Figure 3.4. Experiment 2: Adolescent male response to low-dose amphetamine in Go/No-go testing. 
White bars indicate saline-exposed mice while dark bars represent 0.25 mg/kg amphetamine-exposed 
mice. Intraperitoneal injections were administered 15 minutes before performing Go/No-go testing. 
Bars with a different letters are significantly different from each other (P<0.05). All data reflect the 10 
day average across Go/No-go testing. A) The average number of hits (correct nose poke in response to a 
light) (±SEM) in response to i.p. injections of either saline or 0.25 mg/kg d-amphetamine. B) The average 
number of false alarms (incorrect nose pokes in response to a tone) (±SEM) in response to i.p. injections 
of either saline or 0.25 mg/kg amphetamine. C) The average latency in seconds (±SEM) to respond to the 
presentation of a Go cue (light) when exposed to saline or 0.25 mg/kg amphetamine. D) The average 
latency in seconds (±SEM) to (incorrectly) respond to a No-go cue (tone) when exposed to saline or 0.25 
mg/kg amphetamine.  
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Figure 3.5. Experiment 3: Adult female performance in the Y-maze and accelerating rotarod. White 
bars/circles represent Control mice while dark bars/circles represent High-Active mice. Asterisks 
represent statistically significant line differences (P<0.05) while hashtags represent a trend (P<0.10). A) 
The average number of arm entries (±SEM) made during an 8 minute Y-maze free exploration by adult 
female High-Active and Control mice. B) The average percentage of spontaneous alternation behavior 
(±SEM) made by adult female High-Active and Control mice during their first 20 arm entries choices 
(“First 20”) and across the entire 8 minute trial (“Total”). A spontaneous alternation was defined as 
consecutive entries into all three arms without revisiting an arm. C) The average latency in seconds 
(±SEM) to fall off an accelerating rotarod dowel. Each mouse performed 4 consecutive trials per day, 
which were averaged together, across 3 days. D) The maximum latency in seconds (±SEM) to fall off an 
accelerating rotarod dowel. The best trial (i.e., longest latency to fall) of the 4 daily trials completed by 
each mouse was used to generate averages across the 3 days. 
107 
 
 
Figure 3.6. Experiment 3: Adult female response to low-dose amphetamine in Go/No-go. White bars 
indicate saline-exposed mice while dark bars represent 0.25 mg/kg amphetamine-exposed mice. 
Intraperitoneal injections were administered 15 minutes before performing Go/No-go testing. Bars with 
a different letters are significantly different from each other. All data reflect the 10 day average across 
Go/No-go testing. A) The average number of hits (correct nose poke in response to a Go cue light) 
(±SEM) performed by High-Active and Control mice across Go/No-go testing. B) The average number of 
false alarms (incorrect nose pokes in response to a No-go tone cue) (±SEM) performed by High-Active 
and Control mice across Go/No-go testing. C) The average number of precue responses (±SEM), defined 
as nose pokes made in the 3 seconds prior to the cue presentation, across Go/No-go testing. D) The 
average number of nose pokes (±SEM) made in the nose poke recess which contains the cue light, in the 
absence of any cue presentation, across Go/No-go testing. E) The average percent efficiency (total 
number of reinforcers obtained for correct responding/total number of nose pokes made x 100), across 
Go/No-go testing.  
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Figure 3.7. Experiment 3: Adult female response to low-dose amphetamine in regional neural activation. 
White bars indicate saline-exposed mice while dark bars represent 0.25 mg/kg amphetamine-exposed 
mice. Bars with a different letters are significantly different from each other. Intraperitoneal injections 
were administered 90 minutes before sacrifice in order to obtain sufficient c-fos activation for 
immunohistochemical analyses. Representative images are shown; tiled, composite images are taken 
under 50x magnification, while inset images are taken at 100x magnification. Light blue tracings denote 
regions of interest outlined, and arrows indicate c-fos punctae. A) The total number of c-Fos positive 
(activated) cells in the prefrontal cortex, i.e. the combined prelimbic (PrL) and infralimbic (IL) cortices, of 
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High-Active and Control mice exposed to either saline or 0.25 mg/kg d-amphetamine. B) The total 
number of c-Fos positive (activated) cells in the granular cell layer of cerebellar vermis lobules VI and VII 
of High-Active and Control mice exposed to either saline or 0.25 mg/kg d-amphetamine. 
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Abstract 
Early environmental conditions are increasingly appreciated as critical in shaping behavior and cognition. 
Evidence suggests that stressful rearing environments can have an enduring impact on behaviors in 
adulthood, but few studies have explored the possibility that rearing environment could exacerbate 
genetic hyperactivity disorders. Uncovering a strong environmental influence on the transmission of 
hyperactivity could provide novel avenues for translational research. Recently we developed a 
selectively bred High-Active line of mice to model ADHD, providing a unique resource to address the 
question of environmental transmission. The High-Active line demonstrates transgenerational 
hyperactivity, but the influence of the postnatal environment (i.e. maternal care provided by dams) on 
hyperactivity had not been systemically quantified. This study employed a cross-fostering method to 
simultaneously address 1) whether High-Active and Control pups are provided with similar levels of care 
in the early environment, and 2) whether any differences in rearing environment influence hyperactive 
behavior. High-Active dams demonstrated extreme impairment in all measures of maternal competence 
relative to Controls, which reduced survival rates and significantly reduced the body mass of offspring in 
early life and at weaning. While the deteriorated perinatal environment provided by High-Active dams 
was ultimately sufficient to depress Control activity, the hyperactivity of High-Active offspring remained 
unaffected by fostering condition. These data not only confirm the power of raw genetics to influence 
hyperactivity across generations, but also provide evidence that early rearing environments may not 
have a significant impact on the extreme end of hyperactive phenotypes. 
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Introduction 
The power of environment to influence complex behavioral phenotypes has generated great 
interest over the past several decades (Heim and Binder, 2012). In addition to the established influence 
of genetics (via mutations, protein synthesis, development) on phenotype, maternal environment (via 
histone modification, DNA methylation) may also disrupt the trajectory of normal behavioral and 
psychological development in individuals predisposed to disease states. Multiple studies have 
demonstrated significant associations between adversive perinatal environments and the manifestation 
of clinical disorders later in life (Levine, 2005, Dudley et al., 2011, Maguire et al., 2015). Modeling these 
parameters in animals have largely corroborated such results; exposure to early life stressors such as 
maternal separation or neglect heightens stress reactivity, aggression, and other features of clinical 
disorders such as depression and schizophrenia (Carlyle et al., 2012, Nishi et al., 2014, Pena et al., 2014, 
Bian et al., 2015). Accumulating evidence not only suggests that early life environment affects relevant 
genes via epigenetic modifications which may serve as biomarkers for susceptible populations (Mehta et 
al., 2013, Uddin et al., 2013), but furthermore that environmentally-induced behavioral deficits may be 
transmitted to subsequent generations (Franklin et al., 2010, Zhu et al., 2014, Babenko et al., 2015). 
Determining the relative contribution of genes versus environment to the manifestation of a specific 
behavior is of critical importance for not only elucidating its etiology, but also guiding ongoing 
endeavors to identify relevant trait-specific biomarkers. 
Over the past decade, our lab has maintained a line of mice selectively bred for an extreme 
hyperactivity phenotype which has shown promise as a model of Attention-deficit/Hyperactivity 
disorder (ADHD) in recent generations (Zombeck et al., 2011, Majdak et al., 2014). ADHD demonstrates 
exceptionally high heritability estimates in the range of 70-90% (Faraone et al., 2005, McLoughlin et al., 
2007), therefore we propagated a highly genetically variable line of mice for hyperactive behavior across 
multiple generations to recapitulate that facet of the disorder. Additional studies have further validated 
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the High-Active model by demonstrating that their hyperactivity is paradoxically ameliorated by low-
dose amphetamine, a psychostimulant commonly used to treat ADHD (Majdak et al., 2014). Recently, 
however, evaluating the High-Active line in light of its potential relevance to ADHD prompted reflection 
on a fundamental, yet unverified, assumption of the model itself; we assume that hyperactivity is driven 
purely through genetic factors. It is possible that some of the hyperactive phenotype is transmitted to 
offspring through extremely hyperactive dams creating a chaotic, stressful early rearing environment 
(Son et al., 2007, Kwak et al., 2009). This alternative explanation for the propagation of hyperactivity has 
never been systemically explored in our line, despite circumstantial evidence for its possibility; across 
multiple generations, the High-Active line shows impaired reproductive success (Majdak et al., 2014) 
which has anecdotally been ascribed to High-Active dams providing poor maternal care by engaging in 
trampling and/or cannibalization behavior. Thus, in order to understand the transmission of 
hyperactivity in the High-Active line it is critical to 1) assess the quality of High-Active versus Control 
rearing environments, and 2) determine whether these environments influence the hyperactive 
phenotype. Evidence of a substantial environmental influence on hyperactivity would support studies 
suggesting aversive environments exacerbate ADHD-like behaviors (Son et al., 2007, Nigg et al., 2010), 
while a predominantly genetic component to hyperactivity, minimally influenced by environment, would 
more closely support the construct validity of the High-Active line to model a disorder as highly 
influenced by genetics as ADHD (Faraone et al., 2005).  
In order to parse out the contributions of environment and genetics on home cage activity 
levels, we employed a cross-foster design to simultaneously address both aforementioned questions. 
Dams underwent maternal care observations and performed pup retrieval tasks with their assigned 
litters, which were comprised of a mixture of pups from both lines. Using this approach we were able to 
determine whether High-Active dams create an aversive rearing environment relative to Control dams, 
and furthermore whether those environmental conditions exacerbate or ameliorate the hyperactive 
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behavior of High-Active pups in adulthood. Both objectives are of critical importance, not only in 
understanding the transmission of hyperactivity in our model, but also in providing direct tangible 
evidence for or against the idea that perinatal environment affects hyperactivity in adulthood. Either 
outcome, that rearing environment does or does not influence hyperactivity, advances our 
understanding of the relative influence of genetic versus environmental factors that contribute to 
variation in physical activity. 
Materials and Methods 
Animals 
Selective breeding and general husbandry 
Our lab maintains two lines of outbred mice; a randomly bred, unselected Control line and a 
High-Active line selectively bred for increased distance traveled in the home cage (Zombeck et al., 2011, 
Majdak et al., 2014). The starting population for each line was generated from the highly genetically 
variable Collaborative Cross mice (Chesler et al., 2008). At approximately postnatal day (PND) 60, mice 
of each line are phenotyped individually for home cage activity. Custom-made acrylic home cages (18.5 x 
33.5 x 16 cm) with clear plastic lids allow for continuous video tracking by TopScan software 
(CleverSystems, Reston, VA, USA). Each cage individually houses 4 mice, with a wire mesh interaction 
zone that allows for limited physical contact. This video coverage allows for simultaneous tracking of a 
maximum of 64 individual mice over a 6-day test. After an extended habituation period of 4 days, the 
average distance traveled during days 5 and 6 is used as the selection criterion for the High-Active line. 
Controls are randomly bred with respect to distance traveled in the home cage. Selective pressure was 
not applied to the High-Active line in Generations 13 and 14 (Fig. 4.2C) due to a lack of resources and 
personnel; during these two generations, no mice were phenotyped and therefore the High-Active 
breeding protocol following that of the Control line (mice from different families were bred randomly 
within each line). 
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Rooms are kept controlled for temperature (21 ± 1°C) and photo-period (12:12 light:dark; lights 
on at 7:30 PM and off at 7:30 AM). Food and water are provided ad libitum (Harlan Teklad 7004 for 
breeders in addition to 2g peanut butter daily while paired; Harlan Teklad 7012 for offspring). Corncob 
bedding (Harlan Teklad 7097, Madison, Wisconsin, USA) was provided in all standard shoebox cages. The 
Beckman Institute Animal Facility is AAALAC approved. All procedures were approved by the University 
of Illinois Institutional Animal Care and Use Committee and adhered to NIH guidelines. 
Generation 18 breeders 
Male and nulliparous female mice from Generation 18 of the High-Active line (n=50/sex for 25 
High-Active pairs) and Control line (n=50/sex for 25 Control pairs) were used. Mice were approximately 
3 months at time of pairing, and represent 10 families from the Control line and 9 families from the 
High-Active line. Pairs were placed in standard clear shoebox cages, in order to non-invasively conduct 
behavioral observations following parturition. The pairs were left undisturbed, except for routine cage 
maintenance or peanut butter feeding. After 18 days, and prior to any litter births, males were removed 
from the cage. 
Generation 19 offspring 
Cross-fostering occurred on PND 0 among litters born within 24 hours of each other. A dam and 
her litter were removed from the study if no other litters were born within the same 24 hour time 
window. Typically, half of each litter was given to a different dam of the same line, and the other half 
was given to a dam of the opposite line. In no case did a pup remained with its original mother. In the 
event that only 2 litters were born on a day, dams simply swapped litters. Therefore, depending on the 
number of litters born on a particular day, each dam fostered approximately 4-8 pups, from between 1-
3 different families, from either one or both lines. Before cross-fostering, all pups were tattooed with 
green animal ink (Ketchum Manufacturing Inc., Canada) on either the left or right hind paw, in order to 
easily identify original lineage at weaning age. All offspring were born within two weeks of each other. 
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Maternal care 
Pup-retrieval test 
Pup retrieval was used to quantify the level of maternal competence displayed by the dams 
(adapted from Girard and colleagues (Girard et al., 2002). Pup-retrieval tests were performed 2-5 hours 
into the dark cycle, one trial per day, from PND 3-6 (Fig. 4.1.A). Prior to each trial, the presence or 
absence of a nest (defined as a majority of bedding formed into a nest within one quadrant of the cage) 
was noted. The dam was temporarily removed from the cage, while her pups were gently placed in a 
pile in the opposite corner of the nest. The dam was immediately reintroduced to the empty nest, and a 
clear Plexiglas sheet was placed over the cage to prevent escape and distraction. Each trial lasted a 
maximum of 10 minutes, but the trial was stopped if a dam did not retrieve the first pup by the 5 minute 
mark. A video camera recorded the movements of the dam, and blinded video files were analyzed using 
the JWatcher program (JWatcher 1.0, Macquarie University, Sydney, Australia). Failures to retrieve were 
noted, and these dams were removed from subsequent analyses. Latency to retrieve each pup was 
recorded, in addition to a number of non-maternal behaviors such as approaching a pup and 
investigating it for one or more seconds without retrieval, digging by using paws and/or snout to 
displace bedding material in a directed fashion for one or more seconds, and trampling over one or 
more pups. Lower latency to retrieve pups and fewer non-maternal behaviors indicate better maternal 
care. Pup weights and survival rates were measured on the last retrieval test conducted on PND 6. 
Maternal care observations 
On PND 8, maternal observations were made approximately 1-3 hours into both the dark and 
light cycle (twice per day), while on PND 14 observations were made approximately 1-3 hours into the 
dark cycle only (Fig. 4.1.A). Following the protocol from Girard and colleagues (Girard et al., 2002) a scan 
sampling technique was used as a non-invasive way to assess maternal care. An observer first watched a 
dam for 9 seconds in order to establish context for her behavior, and on the 10
th
 second the action of 
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the dam was recorded. Behaviors were broadly classified as maternal versus non-maternal in nature. 
Maternal behaviors included nursing, resting with pups, nest building, grooming pups, and carrying 
pups. Non-maternal behaviors included resting alone, grooming self, feeding, drinking, digging, climbing, 
walking or running, jumping, and inactivity. Importantly, “resting with pups” included both resting 
nearby the litter and passive nursing wherein the dam was asleep; “nursing” refers to an active process 
with an awake dam assuming the classic arched-back posturing. For each dam, 24 behavioral 
observations were made over the span of approximately 45 minutes.  
Cross-fostered phenotype 
On PND 21, pups were weighed, ear tagged, and weaned into groups of 4 by sex. During 
weaning, tattoos were used to compile information regarding genetic lineage. A total of eight groups (2 
lines x 2 foster lines x 2 sexes) were generated. 158 pups comprised those eight groups (Fig. 4.1.B): High-
Active pups raised by High-Active dams (males=29, females=22), Control pups raised by High-Active 
dams (males=22, females=21), High-Active pups raised by Control dams (males=20, females=16), and 
Control pups raised by Control dams (males=13, females=15). During adulthood at PND 60, mice were 
phenotyped as detailed above. 
Statistical analysis  
Data were analyzed with SAS (version 9.3) and R (3.0.2) statistical software. In all analyses, 
P≤0.05 was considered to be statistically significant, and P≤0.10 was considered a trend.  
Transgenerational analysis: Reproductive success, defined as the percentage of pairings resulting in 
offspring which propagated the lines, was analyzed using a Fisher’s exact test. Body mass and home 
cage activity were analyzed per generation by 2-way analysis of variance (ANOVA), with sex and line 
(High-Active and Control) as factors. 
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Dam characteristics: Parental phenotype was analyzed using a two-way ANOVA with line and sex as 
factors. Litter sizes generated by each dam were compared using a student’s t-test. Cannibalization 
events were analyzed using a Fischer’s exact test.  
Pup retrieval: The presence or absence of a nest across each day of pup retrieval testing was analyzed 
using Fischer’s exact test. Student’s t-tests were used to analyze all pup retrieval data, except for latency 
to retrieve pups across four days (repeated-measures ANOVA with line as between-subjects factor and 
day as the within-subjects factor). Post-hoc Tukey tests were used to determine significant line 
differences in retrieval time at each day. 
Maternal care observations:  Collapsed maternal observations were analyzed via a student’s t-test, while 
the frequency of maternal and non-maternal behaviors represented in the pie charts were analyzed 
using a Fischer’s exact test. 
Cross-fostered phenotype: Cross-fostered phenotype data were first log transformed to improve 
homogeneity of variance, and then analyzed using a three-way ANOVA with sex, line, and foster-
condition as factors. A t-test was used to compare the means of Control pups raised under either High-
Active or Control conditions. 
Body mass as a correlated response: To determine whether the body mass differences between High-
Active and Control lines are likely caused by selection, variance expected from genetic drift was 
calculated by following previously established methods (Majdak et al., 2014). Briefly, in order to 
calculate standardized phenotypic differences between the lines (Dy), Control mass means were 
subtracted from High-Active mass means, and divided by the pooled estimates of the standard 
deviation. This Dy value was then compared to the 95% confidence interval for genetic drift, which was 
estimated using our inbreeding coefficient (“F”) generated by ASReml-R version 2.035, heritability (“h
2
”) 
values obtained from Swallow and colleagues (Swallow et al., 1999), and the number of families used in 
123 
 
the phenotypic measurement (“n”). Absolute Dy values outside of the confidence interval indicate that 
body mass is likely a correlated response to selection for hyperactivity. 
Results 
Transgenerational demographics 
The High-Active mice demonstrate a trend for reduced reproductive success as compared to the 
Control line (Fig. 4.2.A); on average across all generations, 87% of paired Control mice produce offspring 
surviving to propagate future generations, while only 66% of High-Active mice successfully reproduce 
(Fischer’s exact test, P=0.053). The likely rationale for the only marginal significance of this effect is 
driven by the improved reproductive success of Generations 16-18 following relaxed selection for 
hyperactive behavior in Generations 13-14. Weaning body mass (PND 21) does not differ consistently 
between the lines, yet in adulthood High-Active mice have significantly lower body mass across 
generations as compared to Control mice of the same sex, which becomes evident in Generation 5 (Fig. 
4.2.B). The High-Active line continues to respond to selection across 18 generations (Table 4.1), with 
females demonstrating higher levels of activity relative to males in both lines (Fig. 4.2.C).  
Dam demographics 
As expected, High-Active mice demonstrated hyperactivity relative to Controls (F1,72=120.95; 
P<0.0001), and dams exhibited higher activity levels relative to sires (F1,72=4.14; P=0.046; Fig. 4.3.A). 
High-Active and Control dams gave birth to litters of similar size (t36=0.84, P=0.36; Fig. 4.3.B), yet High-
Active dams cannibalized more pups than Control dams after the first week (Fischer’s exact test, 
P<0.0001; Fig 4.3.C). Importantly, dams did not preferentially cannibalize pups of a specific line (data not 
shown).  
Pup-retrieval test 
Prior to pup retrieval testing on each of the four days, the presence of absence of a nest was 
noted for each dam. Overall, in 99% of observations Control mice constructed nests while in only 86% of 
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observations High-Active dams constructed nests for their pups (Fischer’s exact test, P=0.006; Fig 4.4.A). 
Furthermore, High-Active mice were significantly less likely to even complete the retrieval task relative 
to Controls (t6=49.0; P=0.004; Fig 4.4.B); i.e., significantly more High-Active dams did not pick up their 
first pup within the first 5 minutes, nor completed returning all pups to the nest in the allotted 10 
minute trial. Analyses of those dams which did perform the task over 4 days indicate main effects of day 
(F3,65=3.10; P=0.033; Fig 4.4.C) and a trend for line, suggesting High-Active dams retrieve pups more 
slowly (F1,33=3.97; P=0.055; Fig 4.4.C). No interaction between line and day was detected. A Tukey post 
hoc test for Day 4 indicated a significant difference in average retrieval latencies for High-Active versus 
Control dams (P=0.032). Indeed, the total time to retrieve all pups on Day 4, when dams should be most 
experienced and efficient with the task, is significantly higher in High-Active relative to Control dams 
(t35=5.48; P=0.025; Fig 4.4.D).  
Behaviors other than the expected retrievals were observed in both lines of mice and hence 
quantified. High-Active dams trampled pups more than Controls (t35=5.0; P=0.032; Fig 4.4.E) and made 
significantly more approaches to distressed pups without retrieving them (t35=5.56; P=0.024; Fig 4.4.F). 
Furthermore, there is a trend of High-Active dams performing more digging/tunneling throughout the 
home cage compared to Control dams (t35=4.1; P=0.051; Fig 4.4.G). 
Maternal care observations 
The number of maternal behaviors demonstrated by the dams was assessed at 3 different time 
points, on PND 8 (during the dark and light cycle), and PND 14 (during the dark cycle). The first 
observation on PND 8 during the active phase (dark cycle) showed significantly fewer maternal 
behaviors being performed by High-Active dams relative to Controls (t35=17.7; P=0.0002; Fig 4.5.A). 
Observations 12 hours later into their inactive phase (light cycle) held this pattern, albeit as a trend for 
reduced maternal behaviors performed by High-Active mice (t35=3.15; P=0.085; Fig 4.5.B). One week 
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later, on PND 14 during the active phase, High-Active dams still performed fewer routine maternal care 
behaviors for their pups, similar to the PND 8 time point (t35=10.1; P=0.0031; Fig 4.5.C).  
The frequency of key behaviors (e.g. nursing, resting with pups, trampling) represented in the 
pie charts significantly differ between High-Active and Control dams at each observation period 
(Fischer’s exact test, P<0.05). Only low frequency behaviors (occurring at a rate of 3% or less) did not 
demonstrate significant line differences (e.g. carrying pup, feeding, time spent inactive). 
Cross-fostered phenotype 
Genetic line had the strongest impact on the levels of activity displayed by Control and High-
Active mice (F1,150=242.8; P<0.0001; Fig. 4.6.C). Fostering environment showed a trend for an effect on 
activity (F1,150=2.8; P=0.098), driven by the reduced activity of Control pups raised by High-Active dams 
(P=0.025). There was no significant interaction of line and fostering environment. Females 
demonstrated increased levels of home cage activity relative to males (F1,150=7.1; P=0.008), but sex did 
not interact with any other main effects (Figs. 4.6.A-B). 
Body mass as a correlated response to selection 
Cross-fostering provides context and insight as to whether genetic hyperactivity disorders are 
associated with increased or decreased body mass (Table 4.2). The use of the High-Active line to 
correlate body mass and hyperactivity circumvents some issues identified in clinical studies, such as the 
confounding influence of socioeconomic status (van Egmond-Frohlich et al., 2012).  
Firstly body mass means were compared using standard t-test analyses. Generation 18 High-
Active mice were smaller at PND 21 weaning (F1,72=34.7; P<0.0001), and no sex differences were 
detected (Table 4.2). During adulthood (PND 60-65) High-Active mice overall maintain a smaller body 
mass (F1,72=24.8; P<0.0001) with males of both High-Active and Control lines heavier than females 
(F1,72=80.9; P<0.0001). The interaction between sex and line was not significant.  
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At birth (PND 0), Generation 19 High-Active and Control pups did not differ in body mass 
(t36=2.7; P=0.11), yet 6 days of High-Active fostering significantly reduced the body mass (t35=4.6; 
P=0.04) of those pups which survived High-Active rearing conditions (Fig. 4.3.C). At weaning (PND 21), 
the dominant influence on body mass was fostering condition (F1,178=6.8; P=0.010), with line of origin 
only marginally influencing body mass (F1,178=3.6; P=0.061). Females had a smaller body mass relative to 
males (F1,178=6.3; P=0.013) but this effect did not interact with any other main effects. However, by 
adulthood (PND 60-65) mice of High-Active origin demonstrated a reduced body mass (F1,152=4.4; 
P=0.04) which is not influenced by foster condition. Females displayed smaller body masses relative to 
males (F1,152=122.3; P<0.0001), with High-Active mice tending to demonstrate a smaller sex difference 
than Controls (interaction of line and sex F1,152=3.3; P=0.07); on average, High-Active males are 4.8 
grams heavier than High-Active females, while Control males are 6.6 grams heavier than Control 
females. 
Table 4.2 indicates that the reduced body mass of High-Active males from Generation 18 is likely 
associated with selection for hyperactivity, but drift cannot be ruled out for the smaller body mass of 
High-Active females. Generation 19 cross-fostered pups further clarify this observation. Comparisons 
were made between High-Active and Control lines both raised by Control dams (“HA:CON” and 
“CON:CON”; Table 2), thereby removing the impact of environment on mass. While pairwise 
comparisons between High-Active and Control males (raised Control) at PND 21 and 60 indicate 
significant body mass differences (P=0.003 and P=0.03, respectively), these differences do not survive 
the test for drift. These data suggest that severely adverse rearing conditions reduce body mass in 
hyperactive mice. 
Discussion 
This study makes use of a novel genetic model of ADHD to provide converging evidence for the role 
of environment versus raw genetics on the transmission of locomotor hyperactivity. The High-Active line 
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displays impaired maternal competence as evidenced by poor performance in the pup-retrieval task as 
well as during maternal care observations. The grossly deteriorated maternal care provided by High-
Active dams was sufficient to reduce survival rates of pups, as well as the body mass of surviving pups 
during both early life and weaning. Yet ultimately this environment did not influence the hyperactivity of 
High-Active offspring. Alternatively, these aversive conditions significantly depressed the locomotor 
activity of Control offspring. The finding that home cage hyperactivity is entirely genetically mediated 
not only resolves a significant question in the breeding of the High-Active model, but also within genetic 
hyperactivity literature; early perinatal environment is insufficient to impact the trajectory of highly 
heritable hyperactivity phenotypes. 
Breeding for hyperactivity in the home cage produces secondary deficits in maternal competence. 
While there is no evidence for reduced fertility (Fig. 4.3.B), it is clear High-Active dams provide a hostile 
early environment which results in significantly more pup deaths (Fig. 4.3.C) and ultimately contributes 
to reduced reproductive success (Fig. 4.2.A). This harsh environment includes a baseline reduction of 
brood nest building (Fig. 4.4.A) and impaired maternal competence during both light and dark cycles 
(Fig. 4.5.A-C). High-Active dams are less motivated to retrieve pups (Fig. 4.4.B) despite recognizing their 
distress (Fig. 4.4.F), and those dams which do complete the task tend to be slower (Figs. 4.4.C-D). 
Instead of tempering hyperactive behavior and engaging in instinctual pup retrievals, High-Active dams 
manifest hyperactivity via trampling and digging behaviors (Figs. 4.4.E & G). Such digging or burying 
behavior has been suggested to reflect an obsessive/compulsive-like tendency for repetitive movement 
that is unrelated to anxiety or the construction of a new nest (Thomas et al., 2009). Unobtrusive home 
cage observations confirmed the neglectful and injurious High-Active dam behavior; less nursing and 
more trampling were recorded across multiple sessions prior to weaning on PND 21 (Fig. 4.5). The only 
period of reprieve for pups under High-Active care is during the light cycle (inactive phase), during which 
time pups take advantage of dam inactivity and nurse passively (Fig. 4.5.B). Impaired dark cycle maternal 
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care and passive nursing during the light cycle is also observed in lines of rats bred for exaggerated 
novelty-induced locomotion (Clinton et al., 2010). The impaired maternal competence of the High-Active 
line effectively reduces the sampling pool used to estimate activity means per generation and therefore 
also reduces the potential for a strong selection differential during breeding; ultimately the data indicate 
that impoverished maternal care may set a selection limit for hyperactivity.  
The severity of maternal impairment of the High-Active line is unique, as selective breeding for 
increased levels of physical activity do not necessarily beget secondary deficits in maternal care. Pup 
retrieval and maternal observation protocols used in this study were adapted from analyses of replicate 
lines of mice bred for high levels of wheel running. In those studies, no differences in pup retrieval or 
maternal observations were identified between Control and High-Runner lines (Girard et al., 2002). 
However High-Runner dams were not given access to wheels in this study, in keeping with standard 
breeding protocol of the High-Runner lines. Therefore it is possible that wheel access might reduce the 
quantity, if not necessarily the quality, of maternal care. Furthermore, dams of the hyperactive SHR 
model show evidence of enhanced maternal care relative to controls; SHR dams spend more time with 
pups and engage in a higher frequency of nursing and licking behavior compared to WKY controls 
(Cierpial et al., 1987). Even dams from a line of mice bred for inter-male aggression are not deficient in 
maternal care; dams from the aggressive line displayed less trampling and higher pup retrieval rates 
compared to non-aggressive lines (Lagerspetz and Wuorinen, 1965, Sandnabba, 1996). The extent of 
impairment in maternal competence of the High-Active line is truly unique to selective breeding for 
home cage hyperactivity. 
The High-Active foster environment may therefore be considered a severe rodent model of abuse or 
neglect in early life. To our knowledge, no pre-weanling rodents have been exposed to conditions as 
extreme as those consistently maintained by High-Active dams. The extent of physical harm from a 
behavior such as repeated trampling (Fig. 4.4.E) is unexplored in rodent literature. The reduced nursing 
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and time spent with pups (Fig. 4.5.A-C) leading to pup death may be interpreted as maternal neglect. 
One model of naturally-occurring maternal neglect arises from selective breeding for maternal 
aggression, yet these neglectful dams, defined as litters lost by PND 5, do not engage in trampling or 
cannibalization behavior (Gammie et al., 2008). Another interpretation is that High-Active behavior 
reflects maternal separation procedures used to induce early life stress. However, most maternal 
separation protocols tend to be less severe relative to the observed High-Active conditions. Maternal 
separations range from a few hours per day over one or more days, and still produce significant effects 
on stress reactivity, locomotor behavior, and regional brain activation (Nishi et al., 2014). Compounding 
any potential (unmeasured) effects on pups are those induced by the lack of a well-constructed nest 
(Fig. 4.4.A). Nest building is considered an ethologically-relevant “activity of daily living” for healthy 
rodents (Jirkof, 2014) which is positively correlated to fitness (Bult and Lynch, 1996). Increasing activity 
levels via pharmacological treatment or selective breeding also reduces nest building behavior (Carter et 
al., 2000, Pathak et al., 2015). However, failure to build sleeping nests differs from the failure of 
pregnant dams to build brooding nests. Intentionally restricting access to nesting or bedding material on 
PNDs 2-9 not only stresses the dam but also reduces pup body weight, decreases the licking/grooming 
experienced by pups, and alters pup hypothalamic-pituitary-adrenal responsivity (Ivy et al., 2008, Rice et 
al., 2008, Naninck et al., 2015). Taken together, the level of maternal neglect experienced by pups raised 
in High-Active conditions is well beyond published behaviors or stress techniques employed in rodent 
studies. The fact that Control or High-Active pups survive these conditions at all may be due to the 
heterosis of the lines. 
Given both the exceptionally aversive rearing environment and simultaneous strength of genetic 
predisposition to hyperactivity, the intractability of High-Active home cage behavior to environment was 
not only remarkable but difficult to predict (Fig. 4.6.A-C). Previous studies have demonstrated that early 
life stress may elicit depressive-like behavior (Bian et al., 2015), which was observed in the activity levels 
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of Control pups raised by High-Active dams (Fig. 4.6.C). Yet the response of a line selectively bred for 
extreme habituated hyperactivity was wholly unexplored. Some SHR studies have been conducted on 
the subject of environment and hyperactivity, but are limited to assessing environmental enrichment 
interventions during post-weaning periods (Pamplona et al., 2009, Botanas et al., 2016), not negative 
experiences in early life. Two previous cross-fostering studies of SHRs provide tentative hypotheses for 
the outcome of the present study (Howells et al., 2009, Gauthier et al., 2015). In both cases, cross-
fostering SHR pups to either WKY or Sprague-Dawley control dams did not influence activity levels, 
consistent with our findings. Yet these studies preclude foresight of our outcome, due to the fact that 1) 
WKY maternal care is not an improvement over SHR maternal care (Cierpial et al., 1987), and 2) these 
studies employ a different definition of hyperactivity. Our selective breeding protocol defines 
hyperactivity as an average activity level over several days in a home cage setting, well after an 
extended habituated period (Zombeck et al., 2011, Majdak et al., 2014); SHR hyperactivity in these 
studies was defined as activity across one fifteen-minute open field test (Howells et al., 2009) or activity 
during a ten-minute social-interaction test (Gauthier et al., 2015). Therefore the present study not only 
corroborates previous findings in a related model of genetic hyperactivity, but also expands on them by 
first quantifying the vast differences in maternal behavior of both High-Active and Control dams, and 
then measuring the habituated hyperactivity of large samples of both male and female cross-fostered 
pups. 
The inclusion of males and females uncovered sex-specific effects of body mass as it correlates 
to selection for hyperactivity. Twin and adoption studies indicate a strong genetic component to body 
mass index (Stunkard et al., 1990, Maes et al., 1997), and analyses of High-Active mice from generation 
10 suggested decreased body mass is correlated with hyperactivity (Majdak et al., 2014). In Generation 
18, male High-Active mice show reduced body mass which survives the test for drift, but decreased body 
mass in females does not (Table 4.2). Male mice selectively bred for increased wheel-running behavior 
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also demonstrate a negative association with body mass, but females do not (Swallow et al., 1999). 
However, raising both lines under Control dams eradicates the significant selection-related differences 
at PNDs 21 and 60, suggesting that rearing environment is the primary factor reducing the body mass of 
High-Active male mice (Table 4.2). This data is further supported by the finding that a standard 
comparison of PND 21 body masses (High-Active males raised High-Active and Control males raised 
Control) does survive the test for drift (data not shown). It may be that a lack of appropriate nest 
building contributes to this decrease in body weight (Fig. 4.4.A), as previous studies have demonstrated 
that limiting nesting material between PNDs 2-9 significantly reduces pup weight gain (Naninck et al., 
2015). Taken together, these data suggest that fostering condition affects growth and development of 
pups; therefore, future studies using the High-Active line should exercise precaution and cross-foster 
both lines to Control dams prior to behavioral testing in cognitive and behavioral domains outside of 
gross locomotor activity (Colorado et al., 2006, Nishi et al., 2014).These body mass findings also have 
implications for the High-Active line as a developmental model of ADHD. Smaller body masses at birth 
are observed in ADHD populations (Lahti et al., 2006, Linnet et al., 2006), but there was only a 
marginally non-significant reduction of High-Active pup weight at birth (Table 4.2). Line differences 
appeared at PND 6, likely in response to the poor care afforded by High-Active dams. The finding that 
body mass is not significantly associated with genetic hyperactivity (after removing the rearing 
confound) supports studies that show ADHD not associated with weight (van Egmond-Frohlich et al., 
2012) but not others which find a positive correlation between ADHD and weight gain (Waring and 
Lapane, 2008, Hanc et al., 2015). 
Ultimately these findings inform the construct validity and utility of the High-Active line to 
model the hyperactivity associated with ADHD. Keeping in line with published etiological studies of 
ADHD (Levy et al., 1997, Faraone et al., 2005) this cross-fostering experiment unambiguously supports 
the conclusion that genetics mediate hyperactive behavior in the High-Active line (Fig. 4.6.C; Table 4.1). 
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This finding confirms the construct validity of the High-Active model to recapitulate genetic 
hyperactivity-associated disorders. Furthermore, the dysregulation of monoaminergic 
neurotransmission is a recurring theme not only in ADHD literature and animal modeling of increased 
physical activity (Rhodes and Garland, 2003, Arnsten, 2006, Sagvolden and Xu, 2008, Gainetdinov, 2010) 
but also in the field of maternal stress and neglect (Son et al., 2007, Gammie et al., 2008). The 
convergence of both innate hyperactivity and maternal neglect in the High-Active line strongly 
implicates monoaminergic dysregulation in this model. This confluence of traits is rarely observed to 
such an extent in other animal models, but is found in the well-studied dopamine transporter knockout 
(DAT-KO) mouse model of ADHD (Spielewoy et al., 2000, Gainetdinov, 2010). High-Active mice and DAT-
KO dams share key traits; both lines are fertile, demonstrate hyperactivity, therapeutic responsivity to 
psychostimulant administration, and are also significantly impaired on the pup retrieval task (Spielewoy 
et al., 2000, Gainetdinov, 2010, Majdak et al., 2014). Moreover both DAT-KO and High-Active dams are 
less likely to retrieve displaced pups; if pups are retrieved, they demonstrate a longer latency to 
complete the task and are more likely to become preoccupied with grooming and digging behaviors 
during retrieval tests (Spielewoy et al., 2000). Taken together these data suggest that High-Active 
maternal behavior is on par with the behavior of mice exposed to strong chemical disruptions of 
dopamine. However, current literature suggests that such extreme disruptions of genes related to a 
single pathway are unlikely to accurately reflect clinical populations (Neale et al., 2010, Flint and 
Munafo, 2013). Nevertheless, the interpretation that extreme monoamine dysfunction mediates 
disparate facets of High-Active behavior suggests the line may be well-suited for exploring a theoretical 
extreme of the ADHD continuum. Ultimately the High-Active line can be used to identify exaggerated 
variants in gene networks underlying hyperactive behavior which may provide novel targets for 
biomarkers of populations displaying hyperactivity in habituated environments. 
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In conclusion, the High-Active model serves as a unique platform to address important 
questions regarding the transmission of hyperactive behavior. High-Active dams largely neglect their 
pups, creating a rearing environment which ranges from stressful to lethal. Exposure to this 
environment is ultimately sufficient to significantly depress the locomotor activity of the robust, 
heterogeneous Control line. Yet this powerful environmental effect was not observed in High-Active 
locomotor activity. The discovery that the High-Active line itself is predominantly influenced by genetic 
factors, despite the severity of its early rearing environment which effectively reduces body mass and 
survival rates, validates the power of raw genetics in mediating hyperactivity. Moreover this finding that 
hyperactivity is unaffected by environment provides construct validity for the High-Active line in 
modeling a highly heritable disorder such as ADHD (Faraone et al., 2005, McLoughlin et al., 2007). Taken 
together, these data suggest that future endeavors to identify biomarkers for extreme genetic 
hyperactivity-associated disorders may benefit from focusing on genetic, as opposed to epigenetic, 
targets.  
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Tables and Figures 
Generation S (km/day) R (km/day) h
2
 
1 0.27 0.12 0.44 
2 0.36 0.25 0.69 
3 0.87 0.05 0.06 
4 0.56 0.22 0.39 
5 0.43 0
a
 0
a
 
6 0.14 0.31 1
b
 
7 0.82 0
a
 0
a
 
8 0.64 0.025 0.04 
9 0.53 0.5 0.94 
10 0.79 0
a
 0
a
 
11 1.0 0.33 0.33 
12 0.97 - - 
13 - - - 
14 - - - 
15 0.50 0.22 0.44 
16 0.13 0
a
 0 
17 0.71 0.46 0.64 
18 0.47 1
b
 1
b
 
Avg. 0.57 0.23 0.40 
 
Table 4.1. Realized heritability (h
2
realized) estimates of home cage activity. “S” is the selection 
differential (average phenotype of a generation’s most active mice used as breeders minus average 
phenotype of that generation), and “R” is response to selection (average phenotype of next generation 
minus average phenotype of current generation). Realized heritability (h
2
) is calculated as R/S. Only 
breeding pairs which successfully produced pups contributing to the next generation were used in 
generating the selection differential and therefore h
2
. Generations 13 and 14 were not phenotyped and 
therefore heritability estimates could not be produced. Superscript 
a
 indicates the actual value was 
negative, while superscript 
b
 indicates the actual value was above 1.0. The response to selection for 
Generation 18 was estimated using only High-Active mice raised under High-Active conditions, keeping 
in line with calculations for all previous generations. 
  
135 
 
 
Table 4.2. Body mass across the lifespan and its correlation with selection for home cage hyperactivity. 
Mean values (±SEM) of each line (“Control” and “High-Active”) are analyzed to determine whether line 
body mass differences may be attributed to selective breeding for hyperactivity. The statistical 
significance of line differences is expressed in standardized phenotypic units, which are compared to 
their 95% confidence interval; absolute values which fall outside of this interval indicate the difference is 
a correlated genetic response. “M”=male, “F”= female, “MF”=collapsed by sex, "HA"=High-Active, 
"CON"=Control; abbreviations separated by a colon indicate mice of a genetic line raised by a line (e.g., 
HA:CON indicates High-Active mice raised by Control dams). "P-value” refers to a standard pair-wise 
comparison of the High-Active versus Control (for Generation 19 PND 21 and 60 weights, lines raised by 
Control dams are compared); heritability (“h
2
”) references were used for analyses of body mass at PNDs 
21 and 60 (as the heritability estimate was calculated at PND 49 (Swallow et al., 1999), we considered its 
application to PNDs 0 and 6 inappropriate); "F" refers to the inbreeding coefficient; “n” refers to the 
number of families represented in the cohort; “95% CI” refers to the 95% confidence interval for Dy 
expected by genetic drift; “Dy” refers to the difference between lines in standardized phenotypic SD 
units, and those values in bold are considered correlated responses to selection. 
  
Cohort PND Sex P-value h
2
F n 95% CI Dy
Gen 18 21 M 0.0001 0.31 0.06 19 1.05 -1.73
F 0.001 0.31 0.06 19 1.05 -1.01
Gen 18 60 M 0.0001 0.31 0.06 19 1.05 -1.24
F 0.01 0.31 0.06 19 1.05 -1.04
Gen 19 0 MF 0.11 - - - - -
Gen 19 6 MF 0.04 - - - - -
HA:HA HA:CON CON:CON CON:HA
Gen 19 21 M 14.1 (±0.3)14.4 (±0.3)15.7 (±0.3)14.7 (±0.5) 0.003 0.31 0.06 37 0.84 -0.79
F 13.5 (±0.4)14.2 (±0.3)14.3 (±0.4)14.1 (±0.4) NS 0.31 0.06 37 0.84 -0.04
Gen 19 60 M 26.3 (±0.5)24.9 (±0.6)27.5 (±1.1)27.7 (±0.9) 0.03 0.31 0.06 37 0.84 -0.78
F 20.6 (±0.6)21.1 (±0.6)20.6 (±0.8)21.4 (±0.9) NS 0.31 0.06 37 0.84 -0.17
4.38 (±0.18) 4.88 (±0.14)
22.7 (±0.5) 28.7 (±1.6)
19.5 (±0.5) 23.1 (±1.0)
1.54 (±0.06) 1.68 (±0.06)
High-Active line Control line
10.3 (±0.5) 14.7 (±0.6)
11.4 (±0.5) 14.2 (±0.7)
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Figure 4.1. Timeline and cross-fostering procedure. A) On PND 0, all High-Active and Control pups were 
cross-fostered to new dams of the same or opposite line (Control vs High-Active). Pup retrieval tests 
began on the pups’ PND 3 and continued for four consecutive days until PND 6, after which body mass 
and pup death rates were recorded. Each pup retrieval procedure lasted a maximum of 10 minutes and 
was conducted 2-3 hours into the dark cycle (active phase).  Dams and litters were left undisturbed for 
one day, and the following day (PND 8) underwent unobtrusive behavioral observations in their home 
cage environment. A total of 24 observations of dam behavior were recorded at each session over the 
span of 45 minutes, approximately 2-3 hours into the dark cycle (active phase) and again 12 hours later 
during the light cycle (inactive phase). One week later, dams were again observed in the home cage 2-3 
hours into the dark cycle. Offspring were weaned at PND 21, and phenotyped for locomotor activity in 
the home cage from PNDs 60-65, as is protocol for the breeding of the High-Active and Control lines. B) 
This schematic represents the procedure implemented for cross-fostering pups. Of the 50 Generation 18 
pairs made (25 Control, 25 High-Active), 18 Control dams and 20 High-Active dams gave birth to a total 
of 158 Generation 19 pups. All pups immediately received a small green tattoo on either the left or right 
back paw to indicate genetic origin, and were crossed to a new dam on PND 0 (i.e., no pup remained 
with its birth mother). All offspring used in this experiment were born within 2 weeks of each other. 
Total group n’s are represented on the right as “pup” raised by “dam” (e.g., CC indicates Control pups 
raised by Control dams). 
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Figure 4.2. Transgenerational reproductive success, body mass, and phenotypic home cage activity. A) 
Each data point reflects the percentage of paired mice each generation which successfully contributed 
offspring to propagate the lines. Typically 14 High-Active and 14 Control pairs are made during each 
breeding cycle. B) Average body mass in grams (±SEM) at PNDs 21 (weaning) and 60 (adulthood 
phenotyping) are represented for each generation. During Generations 13 and 14, mice were not 
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phenotyped, therefore adulthood body mass was not recorded (as indicated by the boxed “relaxed 
selective pressure”). C) Data reflect the average locomotor activity in the home cage in km/day (±SEM) 
of hundreds of adult High-Active and Control mice across 18 generations. Mice undergo distance 
tracking in the home cage for six consecutive days; the 24-hour activity levels on days 5 and 6 of a six-
day test are averaged to assess the phenotype. As mentioned above, relaxed selective pressure 
precluded the collection of activity data for Generations 13 and 14. 
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Figure 4.3. Generation 18 parental demographics. A) Data represent the average locomotor activity in 
the home cage in km/day (±SEM) of Generation 18 parents on days 5 and 6 of a six-day test. These 
phenotypic data reflect the raw genetic pressure contributed by dams and sires to their offspring. B) 
Data represent the average number of pups (±SEM) birthed by dams of the Control and High-Active 
lines. C) Data reflect the total number of pups cannibalized by PND 6. One Control dam cannibalized 1 
pup, while five High-Active dams cannibalized a total of 21 pups. 
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Figure 4.4. Pup retrieval testing. A) The percentage (±SEM) of dams with nests constructed in the home 
cage across the four days of pup retrieval tests. B) The average number of Control vs High-Active dams 
(±SEM) which failed to retrieve pups across the four days. These dams were removed from all 
subsequent pup retrieval analyses. C) The average latency in seconds (±SEM) for dams to retrieve a 
displaced pup from the corner and return it to the nest across the four days of retrieval sessions. D) On 
the final day of pup retrieval testing (Day 4), the total time in minutes (±SEM) for dams to return all pups 
back into the nest. Litter sizes were not significantly different between Control and High-Active dams. E) 
Average number of trampling events (±SEM) during pup retrieval across all four days. A trampling event 
was defined as the dam running over one or more pups. F) Average number of approaches without 
retrieving pups (±SEM) across all four days. Approaches were defined as a dam investigating a distressed 
pup with its nose for one or more seconds, but not returning it to the nest. G) Average number of 
digging events (±SEM) performed during pup retrieval across all four days. A digging event was defined 
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as focused bedding displacement for one or more seconds. H) Video still from an example pup retrieval 
session. The dam on the left is a Control (“CON”) dam, while the dam on the right is a High-Active (“HA”) 
dam (labeled for illustrative purposes; behavioral scoring was blinded to the line of the dam). The left 
picture is a frame less than 1 second after the reintroduction of the dam to the empty nest, while the 
right picture is a frame 2 minutes into the pup retrieval test. Note the quality of the nest constructed 
and the active nursing posturing of the Control dam after successfully retrieving all pups, contrasted to 
the sparse nest constructed by the High-Active dam and her failure to retrieve pups by the same time 
point. 
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Figure 4.5. Maternal and non-maternal dam behaviors. A total of 24 observations were made during 
each session, and dam activities were classified broadly into maternal vs non-maternal behaviors. Bar 
graph data represents the average number of maternally-related behaviors performed by Control versus 
High-Active dams (±SEM). Pie charts detail the total sum of activities performed by Control vs High-
Active dams. Activities performed less than 1% of the time were not labeled with a percentage in pie 
charts. A) Maternal and non-maternal behavior recorded for dams 2-3 hours into the dark cycle (active 
phase) on pups’ PND 8. B) Maternal and non-maternal behavior recorded for dams 2-3 hours into the 
light cycle (inactive phase) on pups’ PND 8. C) Maternal and non-maternal behavior recorded for dams 
2-3 hours into the dark cycle (active phase) on pups’ PND 14. 
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Figure 4.6. Environmental impact on phenotypic home cage activity. Data represent the average home 
cage locomotor activity in km/day (±SEM) of Generation 19 cross-fostered offspring during adulthood. 
A) Phenotype of female mice. B) Phenotype of male mice. C) Phenotype of all mice collapsed across sex. 
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FUTURE DIRECTIONS 
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Since the inception of this selective breeding experiment in 2008 the High-Active line has 
developed into a robustly validated model with potential to meaningfully advance ADHD-related 
research.  High-Active mice demonstrate significant face validity for Hyperactive-Impulsive ADHD, as 
they are hyperactive in a habituated environment (Figs. 2.2.A and 4.2.C) and demonstrate motor 
impulsivity across disparate Go/No-go paradigms (Figs. 3.3.C-F) while showing only mild evidence of 
inattention (Fig. 3.5.B). These hyperactive-impulsive traits are observed in males and females, 
adolescence and adulthood, and across multiple generations. The High-Active line also demonstrates 
construct validity, as it is a genetically variable line selectively bred specifically for hyperactivity in which 
motor impulsivity appeared as a correlated response to selection (Table 3.1); the line effectively 
recapitulates the heritability associated with ADHD (Tables 2.1, 4.1; Fig. 4.6.C). Furthermore, molecular 
evidence to date suggests the High-Active line shows dysregulated prefrontal cortex activation (Fig. 
3.7.A) and altered cerebellar vermis activation (Fig. 3.7.B) which is implicated in clinical pathophysiology 
(Arnsten, 2006, Durston et al., 2011), while behavioral maternal care data implicate strongly 
dysregulated DA neurotransmission (Figs. 4.4.A-G, 4.5.A-C; (Spielewoy et al., 2000, Gainetdinov, 2010)). 
Finally, the predictive validity of the High-Active line is also established as both hyperactivity and 
impulsivity are paradoxically calmed by low-dose amphetamine (Figs. 2.5, 3.4.B & D) and furthermore 
the PFC and cerebellum of High-Active versus Control mice respond differentially to low-dose 
amphetamine (Fig.3.7.A-B). Several important future experiments should be undertaken in order to 
maximize the potential of this novel, validated ADHD model. 
The most obvious avenue of fruitful pursuit will be in making use of the High-Active line for its 
intended purpose, i.e. elucidating the genetic underpinnings of ADHD. This may be accomplished via the 
unbiased identification of chromosomal regions and/or specific genes associated with genetic 
hyperactivity. Across 20 generations, we have collected tissue samples for each phenotyped animal in 
every generation, resulting in a cache of approximately 3,000 samples which may potentially be used for 
150 
 
quantitative trait locus (QTL) analysis. Quantitative trait mapping is a statistical approach used to 
identify regions of chromosomes associated with a quantitative trait (phenotype). A genomic linkage 
map of polymorphic marker loci is used to identify alleles which differ between lines or individuals. The 
frequency of allelic variations may be evaluated in the context of behavioral data, which in this case 
would be the phenotypic variation in activity levels among High-Active individuals and between the 
High-Active and Controls lines (Falconer and Mackay, 1996). These mouse QTLs may then be used to 
identify syntenic regions of the human genome and either corroborate currently identified QTLs in 
clinical populations (Mill et al., 2005) or provide avenues for exploratory genomic research. However, an 
important caveat regarding this approach in the High-Active line is that any QTLs identified may be false 
positives resulting from linkage disequilibrium, a phenomenon wherein certain alleles appear together 
more frequently than would be predicted by independent assortment. Therefore it would be difficult to 
parse out which alleles are causal to the hyperactive phenotype and which are simply inherited along 
with those causal alleles. Ultimately a successful behavioral QTL (bQTL) mapping of the High-Active line 
would still only yield a chromosomal region that potentially contains many genes influencing 
hyperactivity. The exact genes within the bQTL which mediate the phenotype will need to be resolved. 
RNA-sequencing of relevant regions such as the prefrontal cortex, striatum, or cerebellum, can identify 
gene transcripts which are up- or down-regulated in response to selection for hyperactivity; by 
comparing the expression patterns of High-Active and Control mice with a genetic marker data set we 
may generate a regional expression QTL (eQTL) map for High-Active mice. An eQTL is a locus which 
affects the mRNA expression levels of other genes.  Genes which demonstrate overlap, i.e. those genes 
which are identified in both eQTLs and bQTLs, are likely important in mediating the hyperactive behavior 
of the High-Active line. 
One particularly interesting question to consider during this foray into the genetic basis of 
hyperactivity is whether we may identify any differences in males versus females. In the High-Active line, 
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females tend to demonstrate higher levels of hyperactivity than males (Figs. 2.2.A, 2.3.A, and 4.2.C). The 
enhanced activity of females relative to males is characteristic of rodent ethology; across many strains 
females demonstrate higher levels of home cage activity (Clark et al., 2011). Yet within clinical 
populations males are more frequently diagnosed with ADHD compared to females, at a rate of 3:1 
(Willcutt, 2012). Despite this imbalance in diagnostic prevalence, there do exist females with the 
disorder but they remain chronically understudied in both clinical and basic science research (Gaub and 
Carlson, 1997, Rucklidge, 2008). While some consider the enhanced male:female ratio to be a cultural 
artifact arising from selection bias or a lack of measurement invariance (Gershon, 2002) others discount 
this possibility and posit instead that females may require a higher “genetic load” to manifest ADHD 
symptoms (Hawi et al., 2005, Arnett et al., 2015, Taylor et al., 2016). As a validated ADHD model with 
extremely hyperactive females, our High-Active line is uniquely situated to assess the genetic 
underpinnings and features of female genetic hyperactivity. 
In addition to identifying individual genes related to ADHD, we may use bioinformatics tools to 
both broaden our understanding of the signaling pathways underlying hyperactivity and also identify 
novel therapeutic compounds. Accomplishing both of these aims could begin with an RNA-sequencing 
experiment performed on High-Active and Control tissue from either the striatum, prefrontal cortex, or 
cerebellum, as these regions are strongly associated with ADHD-related motor deficits and are also 
highly influenced by current ADHD medications (Arnsten, 2006, del Campo et al., 2011). In order to 
identify molecular pathways related to hyperactive behavior, the differentially expressed genes 
identified by RNA-seq can be processed by the NIAID bioinformatics annotation tool DAVID which 
organizes genes into broader biological systems (Huang et al., 2007). This approach may provide insight 
into molecular pathways underlying hyperactive behavior and can also be used to design proof-of-
concept pharmacological experiments in which certain pathways are agonized or antagonized to 
influence hyperactivity or impulsivity. In addition we may also use the list of differentially expressed 
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genes from our RNA-sequencing experiment to identify novel treatment compounds. This objective can 
be accomplished by using LINCS (Library of Integrated Network-Based Cellular Signatures). Since 2006 
LINCS has been used to test novel therapeutic interventions within many different fields of research 
including cancer, obesity, and immunity (Lamb et al., 2006, Sirota et al., 2011, Qu and Rajpal, 2012, de 
Jong et al., 2016). By entering in those genes most up- and down-regulated in the High-Active line into 
Lincscloud (http://apps.lincscloud.org), the program can compare patterns of gene expression produced 
by selection to patterns of gene expression produced in response to chemical and genetic perturbation. 
LINCS effectively screens through 60,000+ RNA-seq data sets (from approximately 4000 compounds 
applied to 15+ cell types) to determine which compounds mirror transcript regulation patterns and 
which show the opposite transcript regulation patterns.  In order to quantify the degree to which each 
compound elicits similar or dissimilar expression patterns, LINCS generates a “connectivity score” for 
each compound. A connectivity score of positive 1 indicates the treatment will likely recapitulate the 
expression pattern induced by selection for hyperactivity, while a connectivity score of negative 1 
indicates treatment will likely produce the opposite patterns; in this way LINCS generates a list of 
thousands of compounds ranked from -1 to +1. For the purposes of identifying a novel treatment which 
may reduce hyperactive behavior, compounds with a highly negative connectivity score should 
evaluated in terms of hypothesized mechanism and feasibility of implementation.  Many of the 
compounds in the LINCS database are already in clinical use; therefore open-label exploration of 
compounds of interest is feasible. In fact guanfacine has a similar story; it was already approved to treat 
hypertension before being explored as a medication for ADHD (Hunt et al., 1995). LINCS will be an 
excellent resource for facilitating translational insight into which novel therapeutic compounds may 
more specifically target deficits associated with ADHD.  
Furthermore the field of ADHD research would benefit significantly from identifying an 
endophenotype that consistently and accurately predicts hyperactive behavior in order to refine the 
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diagnosis of ADHD.  Currently, physician-administered scales and parent/teacher questionnaires are the 
methods whereby a diagnosis of ADHD is conferred (APA, 2013), as it is often difficult to assess the 
extent of hyperactive-impulsive behavior in a novel environment (i.e. the doctor’s office). These 
diagnostic criteria are very subjective, therefore a non-invasive and objective measure tightly correlated 
to hyperactivity would greatly aid in the accuracy of ADHD diagnostics. An endophenotype is a heritable 
trait thought to consistently reflect a facet of a behavioral disorder; this intermediate phenotypic trait is 
theoretically more closely and consistently related to a subset of genes which partially mediate that 
facet of the overall phenotype (Castellanos and Tannock, 2002). Therefore, discovery of an ADHD 
endophenotype (whether neuroanatomical, chemical, behavioral, or cognitive) would not only improve 
diagnostic accuracy but could also guide etiological research. Clinical ADHD research focuses on 
endophenotype candidates such as poor response inhibition, impaired working memory, risky decision-
making, abnormal temporal processing, etc. (Casey et al., 1997, Castellanos and Tannock, 2002, Slaats-
Willemse et al., 2003, Drechsler et al., 2008, Rommelse et al., 2008). The High-Active line may aid in 
these endeavors but will be of greatest use in evaluating those endophenotypes which are highly 
translatable between humans and mice. Such translatable endophenotypes include inhibitory control 
(Schachar et al., 1995, Barkley, 1997, Goos et al., 2009, Uebel et al., 2010), reaction time variability 
(Pinto et al., 2016), and intrasubject-intertrial variability in performance (Castellanos and Tannock, 
2002). These behaviors can be readily measured in both rodent and human populations. A cognitive 
impulsivity task (e.g. delayed discounting) or another type of motor impulsivity task (e.g. stop signal 
reaction time task) may elicit line differences in reaction variability or impulse control that reliably 
correlate with hyperactive behavior and serve as a useful endophenotype in clinically Hyperactive-
Impulsive patients.  
We have approached a pivotal and truly exciting chapter in not only the evolution of the High-
Active model but also within the broader field of ADHD research. With the behavioral and 
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pharmacological validity of the model firmly established, the High-Active line may be used to answer any 
number of questions related to genetic hyperactivity that are currently debated due to clinical 
heterogeneity, small sample sizes, and evolving definitions of ADHD; can chronic exposure to 
psychostimulant treatment alter reward sensitivity in individuals with ADHD to make them more 
predisposed to stimulant abuse later in life? (Luman et al., 2010); do circadian phase delays exacerbate 
ADHD deficits and might chronobiological treatments for ADHD be efficacious? (Rybak et al., 2006, 
Owens et al., 2013, Arns and Kenemans, 2014); can manipulation of the gut microbiome and/or immune 
response attenuate ADHD-associated deficits? (de Theije et al., 2014, Petra et al., 2015, de Jong et al., 
2016). The stage is set to explore the molecular and genetic basis of this poorly understood, highly 
complex behavioral disorder that affects so many millions of individuals worldwide. Coupled with the 
rapidly evolving fields of genomics and personalized medicine, we are poised to use the High-Active line 
to parse out the etiologic components of ADHD, discover relevant endophenotypes which may be used 
to refine diagnostic criteria, and innovate advances in its treatment.  
 
  
155 
 
References 
APA, 2013. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub. 
Arnett, A. B., Pennington, B. F., Willcutt, E. G., DeFries, J. C. and Olson, R. K., 2015. Sex differences in 
ADHD symptom severity. J Child Psychol Psychiatry. 56, 632-639. 
Arns, M. and Kenemans, J. L., 2014. Neurofeedback in ADHD and insomnia: vigilance stabilization 
through sleep spindles and circadian networks. Neurosci Biobehav Rev. 44, 183-194. 
Arnsten, A. F., 2006. Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology. 31, 2376-
2383. 
Barkley, R. A., 1997. Behavioral inhibition, sustained attention, and executive functions: constructing a 
unifying theory of ADHD. Psychol Bull. 121, 65-94. 
Casey, B. J., Castellanos, F. X., Giedd, J. N., Marsh, W. L., Hamburger, S. D., Schubert, A. B., Vauss, Y. C., 
Vaituzis, A. C., Dickstein, D. P., Sarfatti, S. E. and Rapoport, J. L., 1997. Implication of right 
frontostriatal circuitry in response inhibition and attention-deficit/hyperactivity disorder. J Am 
Acad Child Adolesc Psychiatry. 36, 374-383. 
Castellanos, F. X. and Tannock, R., 2002. Neuroscience of attention-deficit/hyperactivity disorder: the 
search for endophenotypes. Nat Rev Neurosci. 3, 617-628. 
Clark, P. J., Kohman, R. A., Miller, D. S., Bhattacharya, T. K., Brzezinska, W. J. and Rhodes, J. S., 2011. 
Genetic influences on exercise-induced adult hippocampal neurogenesis across 12 divergent 
mouse strains. Genes Brain Behav. 10, 345-353. 
de Jong, S., Newhouse, S. J., Patel, H., Lee, S., Dempster, D., Curtis, C., Paya-Cano, J., Murphy, D., Wilson, 
C. E., Horder, J., Mendez, M. A., Asherson, P., Rivera, M., Costello, H., Maltezos, S., Whitwell, S., 
Pitts, M., Tye, C., Ashwood, K. L., Bolton, P., Curran, S., McGuffin, P., Dobson, R. and Breen, G., 
2016. Immune signatures and disorder-specific patterns in a cross-disorder gene expression 
analysis. Br J Psychiatry. 
de Theije, C. G., Bavelaar, B. M., Lopes da Silva, S., Korte, S. M., Olivier, B., Garssen, J. and Kraneveld, A. 
D., 2014. Food allergy and food-based therapies in neurodevelopmental disorders. Pediatr 
Allergy Immunol. 25, 218-226. 
del Campo, N., Chamberlain, S. R., Sahakian, B. J. and Robbins, T. W., 2011. The roles of dopamine and 
noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. 
Biol Psychiatry. 69, e145-e157. 
Drechsler, R., Rizzo, P. and Steinhausen, H. C., 2008. Decision-making on an explicit risk-taking task in 
preadolescents with attention-deficit/hyperactivity disorder. J Neural Transm (Vienna). 115, 
201-209. 
Durston, S., van Belle, J. and de Zeeuw, P., 2011. Differentiating frontostriatal and fronto-cerebellar 
circuits in attention-deficit/hyperactivity disorder. Biol Psychiatry. 69, 1178-1184. 
Falconer, D. S. and Mackay, T. F., 1996. Introduction to quantitative genetics. Harlow: Longman Group 
Ltd. 
Gainetdinov, R. R., 2010. Strengths and limitations of genetic models of ADHD. Atten Defic Hyperact 
Disord. 2, 21-30. 
Gaub, M. and Carlson, C. L., 1997. Gender differences in ADHD: a meta-analysis and critical review. J Am 
Acad Child Adolesc Psychiatry. 36, 1036-1045. 
Gershon, J., 2002. A meta-analytic review of gender differences in ADHD. J Atten Disord. 5, 143-154. 
Goos, L. M., Crosbie, J., Payne, S. and Schachar, R., 2009. Validation and extension of the 
endophenotype model in ADHD patterns of inheritance in a family study of inhibitory control. 
Am J Psychiatry. 166, 711-717. 
156 
 
Hawi, Z., Segurado, R., Conroy, J., Sheehan, K., Lowe, N., Kirley, A., Shields, D., Fitzgerald, M., Gallagher, 
L. and Gill, M., 2005. Preferential transmission of paternal alleles at risk genes in attention-
deficit/hyperactivity disorder. Am J Hum Genet. 77, 958-965. 
Huang, D. W., Sherman, B. T., Tan, Q., Collins, J. R., Alvord, W. G., Roayaei, J., Stephens, R., Baseler, M. 
W., Lane, H. C. and Lempicki, R. A., 2007. The DAVID Gene Functional Classification Tool: a novel 
biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 8, 
R183. 
Hunt, R. D., Arnsten, A. F. and Asbell, M. D., 1995. An open trial of guanfacine in the treatment of 
attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 34, 50-54. 
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J. P., 
Subramanian, A., Ross, K. N., Reich, M., Hieronymus, H., Wei, G., Armstrong, S. A., Haggarty, S. J., 
Clemons, P. A., Wei, R., Carr, S. A., Lander, E. S. and Golub, T. R., 2006. The Connectivity Map: 
using gene-expression signatures to connect small molecules, genes, and disease. Science. 313, 
1929-1935. 
Luman, M., Tripp, G. and Scheres, A., 2010. Identifying the neurobiology of altered reinforcement 
sensitivity in ADHD: a review and research agenda. Neurosci Biobehav Rev. 34, 744-754. 
Mill, J., Xu, X., Ronald, A., Curran, S., Price, T., Knight, J., Craig, I., Sham, P., Plomin, R. and Asherson, P., 
2005. Quantitative trait locus analysis of candidate gene alleles associated with attention deficit 
hyperactivity disorder (ADHD) in five genes: DRD4, DAT1, DRD5, SNAP-25, and 5HT1B. Am J Med 
Genet B Neuropsychiatr Genet. 133B, 68-73. 
Owens, J., Gruber, R., Brown, T., Corkum, P., Cortese, S., O'Brien, L., Stein, M. and Weiss, M., 2013. 
Future research directions in sleep and ADHD: report of a consensus working group. J Atten 
Disord. 17, 550-564. 
Petra, A. I., Panagiotidou, S., Hatziagelaki, E., Stewart, J. M., Conti, P. and Theoharides, T. C., 2015. Gut-
Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune 
Dysregulation. Clin Ther. 37, 984-995. 
Pinto, R., Asherson, P., Ilott, N., Cheung, C. H. and Kuntsi, J., 2016. Testing for the mediating role of 
endophenotypes using molecular genetic data in a twin study of ADHD traits. Am J Med Genet B 
Neuropsychiatr Genet. 
Qu, X. A. and Rajpal, D. K., 2012. Applications of Connectivity Map in drug discovery and development. 
Drug Discov Today. 17, 1289-1298. 
Rommelse, N. N., Altink, M. E., Oosterlaan, J., Beem, L., Buschgens, C. J., Buitelaar, J. and Sergeant, J. A., 
2008. Speed, variability, and timing of motor output in ADHD: which measures are useful for 
endophenotypic research? Behav Genet. 38, 121-132. 
Rucklidge, J. J., 2008. Gender differences in ADHD: implications for psychosocial treatments. Expert Rev 
Neurother. 8, 643-655. 
Rybak, Y. E., McNeely, H. E., Mackenzie, B. E., Jain, U. R. and Levitan, R. D., 2006. An open trial of light 
therapy in adult attention-deficit/hyperactivity disorder. J Clin Psychiatry. 67, 1527-1535. 
Schachar, R., Tannock, R., Marriott, M. and Logan, G., 1995. Deficient inhibitory control in attention 
deficit hyperactivity disorder. J Abnorm Child Psychol. 23, 411-437. 
Sirota, M., Dudley, J. T., Kim, J., Chiang, A. P., Morgan, A. A., Sweet-Cordero, A., Sage, J. and Butte, A. J., 
2011. Discovery and preclinical validation of drug indications using compendia of public gene 
expression data. Sci Transl Med. 3, 96ra77. 
Slaats-Willemse, D., Swaab-Barneveld, H., De Sonneville, L., Van Der Meulen, E. and Buitelaar, J., 2003. 
Deficient response inhibition as a cognitive endophenotype of ADHD. Journal of the American 
Academy of Child & Adolescent Psychiatry. 42, 1242-1248. 
157 
 
Spielewoy, C., Roubert, C., Hamon, M., Nosten-Bertrand, M., Betancur, C. and Giros, B., 2000. 
Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter 
knockout mice. Behav Pharmacol. 11, 279-290. 
Taylor, M. J., Lichtenstein, P., Larsson, H., Anckarsater, H., Greven, C. U. and Ronald, A., 2016. Is There a 
Female Protective Effect Against Attention-Deficit/Hyperactivity Disorder? Evidence From Two 
Representative Twin Samples. J Am Acad Child Adolesc Psychiatry. 55, 504-512 e502. 
Uebel, H., Albrecht, B., Asherson, P., Borger, N. A., Butler, L., Chen, W., Christiansen, H., Heise, A., Kuntsi, 
J., Schafer, U., Andreou, P., Manor, I., Marco, R., Miranda, A., Mulligan, A., Oades, R. D., van der 
Meere, J., Faraone, S. V., Rothenberger, A. and Banaschewski, T., 2010. Performance variability, 
impulsivity errors and the impact of incentives as gender-independent endophenotypes for 
ADHD. J Child Psychol Psychiatry. 51, 210-218. 
Willcutt, E. G., 2012. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic 
review. Neurotherapeutics. 9, 490-499. 
 
 
 
